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Objectives:  The objectives of this study were to assess the clinical utility of 
extended femur DXA scan software in the identification of incomplete atypical 
femoral fractures in a routine clinical population; to assess the short term in-vivo 
precision of extended femur scans; and to investigate of the incidence of 
atypical femoral fractures between 2008 – 2018 within NHS Grampian, to 
provide a context for DXA scan findings. 
 
Method:  A short term precision study was undertaken using the GE Lunar 
extended femur DXA scanning software, with 30 participants exposed to 
duplicate extended femur scans.  From this, analysis was undertaken to assess 
and compare beaking index measurements and bone mineral density 
measurements from the software. 
Audits of scan acquisition, assessment and software stability were undertaken 
in order to assess the scan software and staff compliance with training, the 
service was routinely scanning the extended femur in all patients over 20 years 
of age.  The images acquired were used to assess the utility of the software in 
identifying and measuring the endosteal femoral cortex, in contrast to the visual 
assessment of the same areas by experienced members of staff.   
A retrospective review of patients within NHS Grampian identified as having 
femoral fractures over a ten year period was carried out in order to identify the 
incidence of those suffering atypical femoral fractures within this healthcare 
service.   
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Results:  The visual assessment of the femoral cortex was found to be more 
effective and efficient than the scan software alone in identifying abnormalities, 
in line with the findings of previous studies comparing automated analysis with 
visual assessment.  There was no identified difference in bone mineral density 
precision errors at the hip precision using the extended femur scanning 
software compared to standard hip measurements in the 30 patients included in 
the study, but there were some discrepancies in duplicated beaking index 
measurements in part thought to be caused by slight differences in positioning 
for scans.  Least significant change was measured as 5.68% at femoral neck 
and 3.96% for total hip across the study, well within the parameters of ISCD 
accepted figures of 6.9% for femoral neck measurements and 5% for total hip. 
A negative predictive value of 100% was found when using the software in a 
clinical setting for six months, with a positive predictive value of 0.01% and an 
accuracy rate of 82.07%.  Around 20% of patients scanned were found to have 
peaks ≥1mm on extended femur DXA scan automated analysis, however these 
were found to have an entirely normal appearance on visual inspection of 
images acquired.  Audits of scan positioning, analysis and assessment of 
extended femur scans identified several positioning anomalies which were 
addressed when identified. 
 
Of the 7102 patients reviewed with femoral fractures over a period of ten years, 
13 (0.18%) were identified as suffering atypical femoral fracture, with one of 
those patients having bilateral AFF.  All the patients suffering AFF were also 




Discussion:  Measurement of bone mineral density (BMD) by DXA is routinely 
used to diagnose osteoporosis and monitor treatment response. When 
comparing scans it is important to distinguish between real changes in BMD as 
opposed to changes related to the measurement process itself i.e. the precision 
of measurements.  There is no published evidence of this type of beaking index 
precision study having been undertaken, indeed studies performed on extended 
femur scanning have all utilised slightly different methodology, making direct 
comparison impossible. 
Atypical femoral fracture is a rare but recognised complication of osteoporosis 
treatment and the use of extended femur scan software demonstrates a 
promising ability to identify and assess incomplete AFF in conjunction with 
routine bone mineral density measurement, identifying abnormal thickening or 
peaks in the lateral femoral cortex aided by automated software measurements 
of beaking index.  However, in light of the study findings, visual assessment of 
the femoral cortex must also be undertaken by the operator to ensure false 
positives are eliminated from further investigation. It would be highly unlikely in 
the context of current literature that 20% of a general population would exhibit 
signs of iAFF on extended femur scanning. 
 
Conclusion:   
The extended femur scan acquisition and automated analysis was found to 
expose the patient population to a slightly higher radiation exposure.  The 
automated analysis was not acceptable as a stand alone assessment of the 
femoral cortex, visual assessment was essential in tandem to ensure software 
anomalies were not reported as suspicious peaks, the investigation of which 
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would place pressures on imaging services and also un-necessary anxiety to 
patients. 
Patient positioning as per the GE Lunar scan handbook is highlighted as 
important in terms of reproducibility of scans and also for accurately measuring 
the femoral cortex.  For patients and clinicians there is reassurance that 
although such abnormalities are rare, affecting 0.18% of the local population, 
abnormalities will be identified by the software and highlighted by the reporting 
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This section presents an overview of osteoporosis, the use of DXA scanning in 
the diagnosis, monitoring and management of the condition and the use of new 
extended femur DXA scanning software. 
 
1.1 Motivation for the study. 
 
Atypical femoral fractures (AFFs) have been associated with the long term use 
of bisphosphonate drugs used to treat osteoporosis and were first described in 
the seminal paper as being atraumatic and occurring in the presence of long 
term Alendronate therapy [1].  Numerous subsequent studies have 
demonstrated similar findings, highlighting the significant morbidity associated 
with these types of fractures [2-5].  However, prior to complete fractures, there 
are often warning signs.  Patients may report persistent groin, thigh or hip pain 
and on imaging “beaking” can be visualised on the lateral aspect of the femur.  
These early features provide the potential for opportunistic screening for AFF 
using dual energy x-ray absorptiometry (DXA) as a low dose imaging technique 
where patients will be scanned routinely, as a means of monitoring their 
response to treatment and assessment for drug treatment holidays.   
Incomplete AFFs have been identified on imaging through thickening of the 




Figure 1.1 Radiographs of the right femur with lateral peak identified. 
 
Dual-energy x-ray absorptiometry (DXA) is widely recognised as the gold-
standard imaging modality for the measurement of bone mineral density (BMD) 
for the diagnosis, management and treatment response of osteoporosis 
medications [6].   
New DXA scanning software has been developed by manufacturers General 
Electric (GE) Lunar, which is compatible with scanners and software already 
used in a clinical setting, presenting the ability to routinely scan and assess the 
full length of the femur and highlight cortical changes.  The motivation for this 
study is the evaluation and assessment, in routine clinical use, of the extended 
femur scanning software developed by GE, designed to be used as part of 




1.2 Femur and bone biology. 
 
This section outlines the structure of the femur, bone biology and the relevance 
of muscle insertion points with regard to DXA scanning and peaks seen on 
extended femur scans.  
 
1.2.1 Bone biology and osteoporosis. 
Bone is an active tissue within the body that is constantly remodelling in 
response to mechanical stresses and strains.  Osteocytes, osteoclasts and 
osteoblasts all work together in the bone remodelling process, with osteocytes 
sending signals to osteoblasts and osteoclasts on the bone surface [7].  Micro-
architectural defects within the bone structure lead to increased risk of fracture 
owing to increased fragility of the bone.  Other factors influencing bone strength 
are the shape, size and mineralisation of the bones.  A continuous process of 
bone remodelling occurs throughout life, with mature bone resorption closely 
coupled with new bone deposition and ossification, which maintains bone 
strength, density and integrity.  When this process becomes imbalanced, 
through age, illness or medication, it leads to net loss of bone, degradation of 
bone microarchitecture, and ultimately a higher fracture risk, potentially leading 
to osteoporosis.  These changes take place at a cellular level within the bone 
structure [7-10]. 
Bone formation occurs in five stages, as demonstrated in figure 1.2.  In this 
cycle the stimulation and differentiation of preosteclasts to osteoclasts occurs, 
they then begin to digest mature bone cells.  Following this, there is an end to 
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the resorption process and osteoblasts begin to create new bone, when cells 
rest on the bone surface [11]. 
 
Figure 1.2 Bone remodelling process. 
 
Osteoblasts, bone-forming cells that take charge of the bone turnover cycle, are 
found in the periosteum within the ossification centres of juvenile bone, the ends 
of diaphyseal bone and at the site of fractures.  Osteoblasts produce and 
secrete bone matrix, primarily composed of calcium phosphate and collagen.  
This reaction is in response to mechanical stress and also to growth factors, 
which stimulate osteoblasts to form bone.  Osteoblasts release high levels of 
alkaline phosphatase and osteocalcin, and the amounts of these proteins in 
circulation is a reflection of bone formation rates [7].  
 
Osteoclasts, primarily responsible for the process of bone resorption, are 
essential for bone remodelling and changes in bone shaping of the mature 
skeleton.  Osteoclasts work at the surface of the bones, attaching to osteons, 
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on an ongoing process of resorption, producing and excreting enzymes that 
dissolve bone.  During this process, collagen is broken down to amino acids, 
calcium, magnesium and phosphate to be used elsewhere in the body [7, 8, 12].   
Several hormones have been identified as having a major influence on bone 
turnover, namely oestrogen, testosterone, calcitonin and parathyroid hormones, 
with oestrogen thought to have the most direct influence on bone health and 
turnover.  These hormones trigger a complex reaction within the bone cells, 
prompting increased activity within osteoblast cells, which affects the 
communication between osteoblasts and osteoclasts [10].  This has the effect of 
stimulating bone turnover.  Both oestrogens and androgens inhibit osteoclast 
regeneration, with oestrogens inducing osteoclast apoptosis while, in contrast, 
glucocorticoids prolong the life span of osteoclasts [10, 13, 14].  The rapid 
decrease in oestrogen levels at menopause causes an equally rapid loss of 
trabecular bone in women, while in men the bone loss trajectory is much slower 
and steadier decline.  A visual representation of bone density trajectory through 




Figure 1.3 Bone density trajectory through life, split by sex (adapted from [10]) 
 
Osteocytes are mature osteoblastic cells which become trapped within newly 
laid down bone, evenly distributed within the bone matrix.  Osteocytes are the 
most abundant and long living cells in the bone, becoming responsible for the 
maintenance and monitoring of bone tissue health.  This is in response to cues 
both hormonal and mechanical, and is possible due to their location and 
numbers.  Osteocytes are also responsible for the regulation of osteoclasts and 
osteoblasts, and detectors of microdamage within bone which has been 
induced by fatigue.  Signals are sent to osteoclasts, whereby remodelling of the 
damaged bone is induced.  Osteocytes also monitor and respond to changes in 
hormone circulation, adjusting rates of bone formation and resorption as 





















1.2.2 Structure of the femur. 
The diaphysis, or shaft, of femur is composed of cortical bone.  This type of 
bone is responsible for around 80% of the skeletal system and has great 
resistance to bending and torsion.  In this type of bone, osteocytes and 
extracellular matrix are tightly packed and combine in a concentric fashion 
known as a Haversian system, or osteon.  Central canals carry blood vessels, 
nerve fibres and connective tissues.  The blood flow nourishes these bone cells 
via gaps between osteocytes.  These canals extend longitudinally through the 
bone tissue, connected by Volkmann’s canals running transversely.  The 
transverse canals carry larger nerves and blood vessels, which the blood 
vessels and nerves in the smaller longitudinal canals use to connect with the 
surface of the bone [7, 8].   
As the skeletal system ages, cortical bone becomes more porous, reducing in 
strength while gaining surface area.  This is most relevant in the case of long 
bones such as the femur, where increased porosity near the periosteal surface 
causes a greater loss of strength.  Cortical bone also supports bending at the 
distal end of the neck of femur [7-9].   
 
1.2.3 Femoral muscle insertions and their influence on DXA scanning. 
The femur is the insertion point for numerous muscles which facilitate 
movement of the hip and leg.  A major muscle at the distal femur is the gluteus 
maximus, which has an insertion point within the pelvis and another on the 
gluteal tuberosity at the head of the linea aspera, a bony prominence running 
down the posterior aspect of the femur.  The origins of the gluteus maximus can 
be visualised on an over-rotated DXA scan image and has the potential to lead 
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to false positive peaks when using extended femur scan software.  One study 
found that prominent gluteus maximus insertion coupled with the over-rotation 
internally of the femur brings the linea aspera into relief against the lateral 
cortex of the femur, something which could be mistaken for an abnormality on 
DXA imaging.  However, in this case, abnormality was ruled out using 
computed tomography (CT) imaging, where the positioning and location of the 
suspicious area was found to be posteriolateral rather than lateral and 
demonstrated the insertion of the gluteus maximus tendon to the femur at the 
linea aspera [15].  These abnormalities are labelled as tug lesions and have a 
smoother contour with no break in the periosteum, which is in contrast to true 
beaking [16].  Such peaks are identified at approximately 120 mm from the tip of 
the greater trochanter, as measured and identified automatically by the scan 
software, demonstrated in figure 1.4.  Those that can be identified as beaking 
will have a lucent line in the centre of the peak, indicating micro fracture, and 
will generally be identified by DXA scanning software as a sharp peak on the 




Figure 1.4 False positive beaking on an extended femur DXA scan, highlighting 




This section seeks to cover the definition of osteoporosis, the use of bone 
strengthening medication to treat osteoporosis and monitoring of the 
aforementioned therapy.  An understanding of bone turnover and the effects of 
this with the use bone strengthening medication is essential to appreciate its 
benefits and balance risks and side effects.  
 
1.3.1 Osteoporosis and bone. 
Osteoporosis can be literally translated as porous bones, leading to structural 
deterioration of the bone coupled with a reduction in bone density, increasing the 
risk of fracture [17].  With untreated osteoporosis, the quantity and quality of the 
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bone deteriorates and becomes more vulnerable to fracture at much lower forces 
than would normally be expected.   
Primary osteoporosis is considered as a condition with non-modifiable risk 
factors, these conditions are predetermined, such as parental history of 
osteoporosis or hip fracture, age, gender, ethnicity, menopause prior to age 45 
years and genetic susceptibility.  Secondary osteoporosis is classified as 
osteoporosis caused by external factors, and therefore interventions can be 
used to alleviate risk.  This includes lifestyle choices of excessive alcohol 
consumption, smoking, low body weight/BMI, inactivity and low bone mineral 
density, as well as other drugs and diseases known to affect bone metabolism.   
 
Osteoporosis is the most likely cause of low trauma fractures in both men and 
women aged 80 years or older, and are classified as those fractures occurring 
as a result of a fall from standing height or less, of the femoral neck (hip), 
lumbar and thoracic vertebrae and distal forearm.  In the age range of patients 
between 65 – 79 years, a femoral fracture at any site was an indicator of 
increased osteoporosis risk [18].  Previous fracture confers an increased risk of 
subsequent fracture, significantly increasing the risk of a hip fracture in both 
sexes, not allowing for independent risk factors such as lifestyle choices or 
medications [19].  A local fracture liaison service identifies these patients from 
imaging reports and invites those aged between 50 and 75 years to attend for 
DXA scanning, with a view to reducing subsequent fractures and allowing timely 




1.3.2 Osteoporosis treatments. 
The use of bisphosphonate drugs to intervene in the process of bone loss 
through osteoclast suppression has been documented from the 1960's [20]. 
Such therapy also benefits conditions where bone turnover is imbalanced; 
hormone-induced bone loss – oestrogen and androgen deprivation [21, 22], 
glucocorticoid use [23], post transplant [24] and paralysis/spinal cord injury 
affecting weight bearing ability [25]. 
The World Health Organisation (WHO) define osteoporosis in men and 
postmenopausal women when the T score, acquired using DXA scanning of the 
femoral neck, is -2.5 standard deviations or more below the average 
measurement given for a young, healthy female [26].  It has been cited 
previously in a large scale meta analysis study [27] that there is over two times 
increased risk of hip and vertebral fracture for each decrease in standard 
deviation bone mineral density (BMD).  Although these study cohorts were 
predominantly women, the authors felt the results translated equally well to the 
male population.  These scan results are used as a guide to discussion and 
decision making in conjunction with the patient regarding treatment of 
osteoporosis, based on individual overall risk of fracture, as supported by the 
current NICE, SIGN and National Osteoporosis Guideline Group (NOGG) 
guidelines [28-30].  The guidelines do have slight variation in advice to UK 
healthcare professionals, with SIGN recommending the use of Q fracture to 
assess fracture risk, (NOGG) recommend the use of FRAX and assessment 
with either tool suggested by NICE.  Recommended scan intervals for 
assessment of treatment are also dependent on the guideline utilised, with 
SIGN suggesting a three year scan interval for assessment of treatment[29], 
NOGG recommend treatment review at three years following the use of 
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intravenous Zoledronate and five years of oral bisphosphonate therapy [30], 
and NICE advocating reassessment of BMD following three to five years of 
bisphosphonate treatment [28].  These guidelines reflect the interpretations of 
the available evidence, and despite minor differences, the care and treatment of 
those with osteoporosis transcends specific guidelines, and is recognised as a 
world wide problem. 
Anti-resorptive, or bisphosphonate drugs are used to treat low bone density and 
osteoporosis, and are the group of drugs most commonly used for the treatment 
of osteoporosis, taken over an extended period of time to aid the strengthening 
of the structure of bone tissue.  Osteoporosis treatments are designed to 
strengthen the internal structure of the bone, inhibiting osteoclast function, 
which in turn inhibits bone resorption, leading to net gain in bone density.  
Most commonly prescribed are nitrogen containing bisphosphonates: 
Alendronate, Risedronate, Zoledronate, Ibandronate and Pamidronate.  
Alendronate and Risedronate preparations are the most commonly prescribed 
osteoporosis drugs, designed to be consumed orally, and most commonly taken 
on a weekly basis to minimise inconvenience to patients.   
Alendronate therapy is highlighted as the most commonly prescribed 
bisphosphonate, and therefore most likely to be associated with atypical femoral 
fracture [31-33].  It is approved for treatment of postmenopausal osteoporosis in 
women, glucocorticoid - induced osteoporosis and osteoporosis in men.  
Risedronate works on the same basis as Alendronate therapy, approved for 
treatment of osteoporosis in postmenopausal women to reduce the risk of hip 
and vertebral fracture, and in men.  It is also indicated in the treatment of 
glucocorticoid - induced osteoporosis.  Ibandronate is taken monthly as an oral 
preparation or a three monthly injection as a means to treat osteoporosis in 
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postmenopausal women with an increased fracture risk.  With these therapies, 
a duration of five years is recommended, with continuation to ten years 
recommended in patients taking glucocorticoids ≥7.5mg per day, previous 
fracture history, or low trauma fracture whilst on treatment and age ≥75 years 
[34].  The drawbacks of bisphosphonate treatment can be related to poor 
compliance due to the nature of the prescription, intolerance due to short term 
and almost immediate reported side effects – stomach pain, oesophagitis and 
reflux, bone, joint and muscle pain, headache, uveitis and scleritis, bowel upset 
[35].  One study attributed 47.5% of non-persistence to adverse side effects, 
40% to inadequate health literacy and just over 10% related to cost of 
prescription [36].  Zoledronate has a greater skeletal uptake, and a longer 
duration of action, but does have longer lasting flu-like side effects, potentially of 
several days when compared with bisphosphonate tablets, which are more 
likely to cause heartburn type symptoms which may last for several hours [37].  
This may be more tolerable to patients as the Zoledronate infusion is annual 
and side effects ameliorated by the annual nature, and diminishing severity of 
potential side effects with each infusion given [38]. 
There is an increased risk of rebound vertebral fracture on discontinuing 
Denosumab, unless bisphosphonate therapy is initiated on cessation of therapy 
[39].  The risk increases at 3 months post cessation of therapy, with BMD at 12 
months dropping to back to pre treatment baseline if no concomitant therapy is 
taken [40].  This is speculated to be as a result of BMD dropping by around 5% 
at both hips and lumbar spine, something which can be mitigated with the use 
of bisphosphonate medication.  One study suggested that around 10% of 
patients studied suffered at least one fracture in the first year post Denosumab 
therapy, with all but one patient suffering from one or more vertebral fractures.  
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None of these patients were prescribed bisphosphonate therapy until after the 
fracture event [41].  Denosumab is known to have side effects related to 
hypocalcaemia, osteonecrosis of the jaw and skin/infection issues such as 
eczema and cellulitis.   
Bisphosphonates work through the suppression of bone turnover by inhibiting 
the breakdown of hydroxyapatite, a mineral salt composed of phosphate and 
calcium, which is a key component of normal bone, providing rigidity and 
toughness to bones.  Bisphosphonate drugs bind to hydroxyapatite crystals, as 
they have a high affinity to bone.  Osteoclast apoptosis is encouraged by 
bisphosphonates, which in turn decreases bone resorption.  This allows a 
relative increase in osteoblast activity, which gradually translates to increased 
bone mineral density.  It is suggested that maximum suppression of bone 
resorption occurs at around three months following commencement of therapy 
[42], although a measurable change in BMD takes many more months [43].  
Release of drugs from the bone is dependent on turnover rates and may remain 
in the bones for years following cessation of therapy.  The renal system 
excretes any bisphosphonate released by the bone, but bisphosphonate is 
recycled within the bone [44].  Binding of bisphosphonates to the bone matrix 
occurs at different rates, Zoledronate is best, followed by Alendronate then 
Risedronate.   
The action of Denosumab differs from bisphosphonate drugs, as it works by 
interfering with the receptor activator of nuclear factor kappa β ligand known as 
RANK-L system [45].  It does not attach to bone tissue, but rather binds to 
RANK-L in the circulation.  Denosumab is a human monoclonal antibody, 
binding RANK L, preventing it from activating RANK, which is its receptor on the 
surface of the osteoclast.  During this process, osteoclast activity is regulated by 
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RANK-L, produced by osteoblasts and osteocytes, which affects osteoclast 
survival rates, formation and function, as demonstrated in figure 1.5.  As a 
consequence of this, resorption of bone slows and growth factors are released, 
which increases osteoblast numbers and activity.  Osteoclasts also directly 
regulate osteoblasts via cell to cell contact and secreting additional factors [45].  
 
 
Figure 1.5. The action of Denosumab within bone. Figure removed by author of 
this thesis for copyright reasons 
 
Denosumab has a rapid onset and offset of action, having a half-life of 
anywhere from 25-32 days [46], and has been shown to increase cortical bone 
mass at a greater rate than Alendronate, with no plateau in BMD gains after an 














1.4 Hip fractures 
Hip fractures typically occur as a consequence of falls in the older individual, 
affecting around 65,000 people in the United Kingdom (UK), at a cost of 
approximately one billion pounds per year, expected to rise to £1.5 billion by 
2025 [49, 50].  The mean age of patients suffering typical hip fracture has been 
quoted as 76.5 years in some research [51, 52], although another study found 
the average age to be significantly higher at 82 years [53], and the National 
Institute for Health and Care Excellence (NICE) state the average age of to be 
77 years [54].  Patients typically present with the affected leg externally rotated, 
with apparent discrepancy in the length of the leg [55].   
The treatment options for hip fracture are dependent on the fracture location, as 
identified by the NICE hip fracture quality standards [49, 54] and Scottish 
Intercollegiate Guidelines Network (SIGN) guidelines [56].  Displaced fractures 
located within the capsule of the hip (intracapsular fractures) are treated with 
cemented hemiarthroplasty, with the option to have a full hip replacement if 
clinically justified.  Fractures at or above the level of the lesser trochanter 
should be treated by hip screw or other external bone fixator, in preference to 
intramedullary nailing.   
 
1.4.1 Morbidity and mortality of hip fracture. 
According to the works of Schnell [57], patients who suffer a hip fracture are 
75% more likely to be female, with a mean age of just under 85 years.  The 
relative risk of mortality and ageing associated with hip fracture increases by 
around 4% per year, with around half of patients requiring greater levels of care, 
whether that is with assisted living or requiring admission to a care facility.  
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Long term limitations in mobility, self care and activities of daily living following 
hip fracture, along with quality of life are suggested as main reasons for 
requiring assistance [53].  The risk of mortality is below two percent in patients 
under the age of 70, but is over 25% in patients over 90 [57].  The cost of all UK 
hip fractures was estimated at around £1 billion in 2011, covering medical care 
only with around 30% of all hip fracture patients dying within the first 12 months 
post fracture [49].  A caveat is mentioned within the same document however, 
that many of the patients not surviving one year post hip fracture died of 
associated health conditions, not primarily as a consequence of fracture.  All 
guidelines advocate fracture assessment of affected patients, with those under 
75 years generally referred for DXA scanning and those over 75 years to be 
discharged with bone strengthening medication [28, 29].  
 
1.4.2 Population demographics. 
It is estimated that by 2043, the population of Scotland aged 65 years will 
increase by over 23%, exceeding  633,000, with all age groups over 65 years 
identified as broadly increasing in numbers over the same timescale, as 
demonstrated in figure 1.6 [58, 59].  The life expectancy of average male is 
given as 80.6 years and female 83.8 years [60].  The United Kingdom (UK) 
national prediction for the growth in the population of over 65’s by 2069 is 
around 8.2 million, with populations in each area of the UK increasing steadily 
due to extended life expectancy.  With an ageing population comes an 
increased risk of fracture, this is the focus of osteoporosis therapy; to reduce 
fracture risks.  One in two women and one in five men will suffer from a fragility 
fracture in their lifetime (National Osteoporosis Society 2015).  The costs of hip 
fracture care in hospital alone amounts to over £14,000 per patient in the first 
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year post fracture [61].  Following this, 9.4% of patients will die within the first 30 
days, 31.2% will not survive the first year, almost 20% of patients will be 
admitted to a care facility, and for patients who suffer a second hip fracture this 
figure rises to 40% by one year post fracture [61].  
 
 
Figure 1.6 Population prediction pyramid of Scotland 1981 – 2043, 
demonstrating an increase in the over 65 population.  Fiogure removed by 
author of this thesis for copyright reasons. 
 
A forecasted 29% increase in hip fractures within the same age group [59] 
suggests the incidence and therefore the cost of osteoporosis and hip fractures 
to the National Health Service (NHS) is likely to increase significantly.  Hip 
fractures are debilitating, and impact hugely on the quality of life in the long term 
for the patient – women are three times more likely to fracture a hip than men, 
with mortality rates at one year post hip fracture between 22% and 29% [62].  
Around 20% of hip fracture patients will require admission to long term care 










Almost 50% of total fracture cost to the NHS in the UK can be attributed to hip 
fracture, at over £2000 million [64].  Men are more likely to fracture at a younger 
age than women, 79 years compared to 82.7 years, and are more likely to die 
within a year [62].  These statistics are broadly comparable across the western 
world and therefore transferrable to healthcare services in these areas. 
 
1.5 Osteoporosis risk factors. 
 
1.5.1 Diabetes Mellitus. 
Association between diabetes mellitus (DM) and fractures, including AFF,  
appear to be linked to microvascular bone damage [65].  There is agreement 
across research that there is a significant increase in fracture risk in patients 
diagnosed with diabetes mellitus (type 1 and 2) [65, 66].  Diabetes mellitus, both 
type 1 (T1DM) and type 2 (T2DM) have implications for BMD and fracture risk, 
specifically linked to subtrochanteric and diaphyseal fractures, with Caucasian 
women found to be at three times higher risk of these fractures if diabetic [67].  
No data was collected on the diabetic status of the patient group scanned, but 
around 7% of the population of the UK are thought to suffer from diabetes [68].   
In one study, observers found it difficult to separate T1DM and T2DM, as insulin 
dependence factored in both groups [69].  It was observed that one in 15 T1DM 
patients would be likely to suffer a hip fracture by the age of 65 years [69], and 
to be on average five years younger than T2DM hip fracture sufferers [70].  
Measurement of BMD at lumbar spine in T1DM is likely to be lower than age-
matched contemporaries [65, 71], while in T2DM patients BMD is likely to be 
higher than age matched controls, but with increased fracture risk [65, 72].  This 
is posited to be as a consequence of microvascular bone damage [66], perhaps 
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linked to peripheral neuropathy [66, 70], although this suggestion was refuted in 
another study [71].  An artificially elevated BMD, thought to explained by micro 
architectural abnormalities, appears to underestimate the fracture risk in T2DM 
patients [65], while there also appears to be a link between low Vitamin D status 
and T2DM [65, 66].  Assertions are also made that thiazolidinedione 
medications used to manage T2DM can increase risk, where metformin and 
sulfonylates reduce fracture rate and maintain or improve bone mineral density 
[66].   
No indication was found to suggest any issues with healing or non union of 
surgically repaired hip fractures, but T2DM patients required on average four 
days longer inpatient hospital care [70].  It has been suggested that diabetes is 
a strong risk factor for AFF by several authors [51, 73-77] and further research 
is indicated to understand the specific reasons behind this.  
 
1.5.2 Thyroid.   
There is a general acceptance in the literature that undiagnosed/untreated 
hyperthyroid leads to two fold acceleration on bone loss, increasing fracture risk 
[78, 79].  It is speculated this is as a result of calcium malabsorption, eventually 
leading to an increase in bone resorption [80].  A history of hyperthyroidism has 
been indicated as an independent risk factor for both hip and vertebral fracture 
[79], and even with treatment, BMD and fracture risk may never return to a 
normal range [78].  The findings of one study suggest that those with 
hypothyroid may also be at increased risk of fracture, hypothesising that there is 
an increased risk of osteoporosis and related fractures, especially in the 60-79 
years age group [81].  Thyroid hormone requirement decreases with age, 
therefore poorly monitored and balanced thyroxine prescription potentially leads 
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to increased risk of thyroxine induced hyperthyroidism [81].  This is in 
contradiction to another study, which found no evidence of detriment to BMD at 
any site with thyroxine therapy, however this information was gathered over a 
one year period of treatment [82].  A possibility was mooted of reduced BMD at 
the wrist in premenopausal women, with no suggestion of an associated 
additional fracture risk [82].  The use of hypothyroid medication has been linked 
in association with AFF [31, 74, 78], which is attributable to 18.8% of the patient 
population scanned.  No mechanism for increased fracture risk has been 
specifically identified, with the exception for oversupply of thyroxine in patients 
who have not had levels checked regularly [81]. 
It is speculated that accelerated bone turnover is a consequence of untreated 
hyperthyroidism, with a figure of 10-20% loss in bone mineral density, mainly 
from cortical bone [78].  There appears to be residual risk of BMD not returning 
to expected normal with treatment, in a small number of patients [78].  There is 
little evidence to support thyroxine having an adverse effect on BMD where 
replacement therapy is tested and kept to minimum levels, but increased risk 
where thyroxine is over supplied through poor monitoring [78, 83].   
 
1.5.3 Anti-oestrogen therapy.   
Aromatase Inhibitors (AI) such as Letrozole, Exemestane and Anastrozole are 
commonly prescribed as a treatment for breast cancer, with the intention of 
reducing oestrogen levels by around 90% [84].  Medication is usually prescribed 
for a duration of five years, with many now extending to ten years of therapy to 
reduce the risk of breast cancer recurrence.  Such extended oestrogen-blocking 
treatment also potentially has a detrimental effect on bone mineral density, as 
bone is oestrogen dependent.  This oestrogen deficiency is responsible for 
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increased osteoclast activity and bone remodelling, in a state of higher bone 
turnover and accelerated bone loss, the rate of bone loss is approximately 
doubled in post menopausal women by the use of these drugs [85].  Evidence 
suggests that patients with a normal BMD at commencement of treatment with 
AI will subsequently have a normal bone mineral density at five years of therapy 
[86].  However, if the BMD is reduced at commencement of therapy, there is an 
increased risk of osteoporotic fracture after three to five years of treatment [86]. 
 
1.5.4 Androgen deprivation therapy. 
Androgen deprivation therapy (ADT) is used to reduce the circulating levels of 
testosterone, leading to bone loss and increased risk of fracture, especially hip 
and vertebral [22, 84, 86, 87].  These drugs are a recognised treatment for 
prostate cancer, and known to cause almost immediate hypogonadism, leading 
to rapid bone loss in the first 12 months of therapy [22].  It is suggested that 
around 20% of patients using this therapy will sustain a fracture within 5 years 
[87].  The same author suggests treatment thresholds be lowered for such 
patients, based on this increased risk.  There appears to be agreement that 
current evidence does not indicate additional risk of AFF in conjunction with 
ADT, but acceptance that there is no evidence on background incidence of AFF 
[87].   
 
1.5.5 Proton Pump Inhibitors. 
Proton Pump inhibitors (PPI) are used to reduce the secretions of acid within 
the stomach in order to reduce symptoms gastric ulcers and gastro-
oesophageal reflux.  It can also be utilised to give protection to the stomach 
whilst taking non steroidal anti inflammatory drugs (NSAID), glucocorticoids, 
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bisphosphonates and other medications which may cause stomach problems, 
making it complex to separate any detriment to bone specifically linked to PPIs 
[88-91].  PPIs suppress the production of gastric acid, which causes 
interference with the absorption of calcium, as lower levels of gastric acid 
reduce the amount of calcium which is dissolved and ionised within the 
stomach.  An increased pH within the stomach reduces the amount of calcium 
which is dissolved and rate of absorption is slowed, by as much as 65% [92, 
93].  This is postulated to result in calcium malabsorption, and therefore 
potentially resulting in a net reduction in bone mineral density [89]. The body’s 
ability to absorb calcium also decreases naturally with age, and the response to 
this is to increase the production of parathyroid hormone, giving rise to 
secondary hyperparathyroidism.  This increases osteoclastic bone resorption 
which diminishes and undermines the internal bone structure, increasing the 
potential for fracture [93].   
There is a suggestion that decreased calcium absorption coupled with stomach 
acid pH increase associated with PPI use could be responsible for a form of 
malnourishment [92].  The same study indicated an increased risk of any 
fracture in the first year of use, and increased hip fracture risk in subsequent 
years with prolonged PPI exposure [92].  In support of this assertion, others 
have cited increased risk of hip fracture in those taking regular PPIs, however 
they suggest this is owing to confounding factors unrelated to osteoporosis [89, 
90].  In contrast to these findings, other studies suggest that PPI has little or no 
association with BMD at either hip or spine [88, 94].  Statistics suggest that 
PPIs are in the top 5 most prescribed drugs in the western world [89], and are 
most likely to be prescribed in areas known to have poor social and socio-
economic status [90].   
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There is evidence within the literature which appears to identify an increased 
risk of hip fracture with PPI use [88, 90, 91, 93-95], and some studies identified 
a link between PPI and subtrochanteric and femoral shaft fractures [67, 96].  
However, with further detailed analysis of the figures, all agree that the 
association of hip fracture risk and PPI are due to unmeasured confounding 
factors.  Further to this, there appears to be no detrimental effect on DXA-
measured bone mineral density with the use of PPI, even if the use is prolonged 
[88, 91].  With no causal links between PPI and reduced BMD identified it can 
be assumed that, until further evidence is produced, PPIs do not have a 
detrimental effect on bone health and are not linked directly with increased risk 
of fracture [91, 93, 94].  
 
1.5.6 Glucocorticoids. 
It has been widely identified in literature that glucocorticoid use increases the 
risk of fracture, including risk of AFF [16, 31, 97, 98].  Glucocorticoid medication 
is prescribed for a wide range of inflammatory conditions, and the effect on the 
gastrointestinal system and on bone turnover means bisphosphonate drugs and 
PPI are often prescribed in conjunction, making it more difficult to separate 
individual causes of AFF [51, 99].  Glucocorticoids influence bone density in 
several ways; by inhibiting formation of new bone, stimulating osteocyte and 
osteoblast apoptosis, reducing growth factors which stimulate osteoblasts 
leading to net bone loss.  This is especially in the early stages of treatment 
when doses are higher and disease processes more active [100].  This is 
compounded by the reduction in calcium absorption coupled with the raised 
excretion levels of calcium in the urine [101, 102].  Vertebral fractures are more 
common than hip fractures in patients prescribed with long term glucocorticoids 
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[102], but there is increased fracture risk at all sites [100].  Several studies have 
reported higher risk of atypical femoral fracture with long term glucocorticoid 
use, but accept that most of the patients concerned were also having 
concomitant anti-resorptive bone therapy [31, 99, 100, 103].  In one study, six 
iAFFs were identified in patients with autoimmune disease, bisphosphonate use 
and glucocorticoids, using x-ray over a period of two years, similar to the data 
collected within this department [99].  The same authors also found 15 
incidences of beaking at the inception of the study, affecting 8% of the study 
population.  This presents a difficulty in defining whether bone strengthening 
treatment or glucocorticoids are the specific cause of AFF, and empirical 
therapy as recommended by both NICE and SIGN may compound this problem 
[28, 29].   
 
1.5.7 Selective Serotonin Reuptake Inhibitors. 
It is generally accepted that Selective Serotonin Reuptake Inhibitors (SSRIs) 
have a negative impact on bone mass, and although the pathophysiology of this 
is not fully known, there is a known association between depression, fractures 
and falls risk [104-106].  The risk appears to increase over time, and with the 
severity of the depression.  Serotonin blocking has the effect of lowering bone 
mass, therefore SSRIs should lead to increased bone mass, but the available 
evidence contradicts this hypothesis [104].  Depression and osteoporosis share 
many risk factors; smoking, alcohol consumption, poor nutrition leading to 
weight loss and lower BMI, reduced physical activity leading to sarcopenia, 
increasing falls risk and lack of exposure to sunlight leading to lowered levels of 
Vitamin D [107].  It is widely accepted in the literature that depression and 
SSRIs have a negative association on BMD and falls risk [105, 106, 108], with 
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increased risk of both hip [109, 110] and vertebral fracture [111], especially in 
conjunction with other chronic illnesses, which may induce falls [112].   
Some studies failed to identify BMD levels in the osteoporotic range, suggesting 
other factors may be at least partly responsible for fractures in patients taking 
long term SSRIs [113, 114], however this is not consistent with other findings, 
which found association between SSRIs, low BMD and increased fracture risk 
[115, 116].  There is consensus in the literature that further in-depth research is 
required in order to identify drug interactions, medical conditions, risk factors 
and effective osteoporosis therapies should they be required. 
 
1.5.8 Anticonvulsants and osteoporosis. 
Epilepsy affects around 1 in every 100 people in the developed world [117].  
The evidence suggests that patients with epilepsy are at increased risk of 
fractures and osteoporosis.  The use of anticonvulsants in the treatment of 
epilepsy has been demonstrated to affect the absorption of both calcium and 
Vitamin D [118].  Low levels of serum 25(OH)DV has been associated with 
increased risk of hip fracture, in patients with and without epilepsy [119].  The 
findings of one study indicated fracture risk in epilepsy is independent of BMD 
[120], and commonly patients will suffer vertebral fractures as a consequence of 
seizure activity [121].   
 
Co-morbidities in epilepsy are high, such as cerebral palsy, post brain surgery 
or injury, post stroke and physical disability causing balance issues, muscle 
weakness and falls, all contributing to increased fracture risk [118, 122].  The 
type and duration of epilepsy also influences BMD [122].  It has been identified 
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that BMD loss in men taking anticonvulsants can be ameliorated with the 
combination of Risedronate and Calcium/Vitamin D supplementation taken over 
a period of two years [123].   
 
1.5.9 Family history of osteoporosis and genetic links. 
There is increased personal risk of osteoporosis if a familial element has been 
identified.  This can lead to a two fold increase in risk of fracture in comparison 
with someone with no family history of osteoporosis [124].  This may be as a 
consequence of environmental similarities, or genetics, or a combination of 
these.  There is evidence that proximal hip BMD is greatly influenced by genetic 
factors [125].  A history of low BMD measurement in a sibling places any 
individual at around six times greater risk of low BMD themselves [126].  
Genetics and BMD is a very complex area, which is currently an area of interest 
with regard to both osteoporosis and also AFF.  There are around 60 genes 
with known association to BMD, with the most studied being the Vitamin D 
receptor (VDR) gene [126].  Work by a team in the Middle East has indicated a 
link between osteoporosis and the VDR gene [127].  The same research also 
identifies a need for more focused in-depth analysis of identifying genetic 
markers of osteoporosis, as no definitive association between VDR and fracture 
or indeed BMD has been proven [127, 128].  A meta-analysis of genetic 
susceptibility of fracture risk and BMD found 15 distinct genetic links to both 
fracture and BMD, but not to low Vitamin D levels [129].  It is speculated that 
genetics influence as much as 90% of inherited BMD, including 39 % increased 
risk of low BMD at femoral neck in affected siblings [130]. 
As AFF appears to be heavily associated, though not exclusively, with the use 
of bisphosphonate drugs, it would be assumed that all consumers be at similar 
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risk of developing a fracture related to the drug.  This is clearly not the case as 
AFF is a rare, but significant, event and as such this suggests there are other 
confounding factors which increase the risk, one of those being a genetic 
susceptibility [103].  Several studies were identified which attempted to identify 
genetic links to AFF, a highly complex field.  A study of three sisters found some 
gene mutations in common with AFF (GGPS1 and CYP1A1), although the 
same mutation was found in an unrelated person with AFF [131].  The authors 
speculate that an accumulation of several genetic variants/mutations may lead 
to susceptibility to AFF, given its rare presentation.  A further familial study 
failed to find a specific genetic mutation which could be responsible for AFF, 
suggesting a combination of factors, including genetics and environment, be 
responsible [132].  A further genetic study found a link between COL1A2 and 
AFF [133], however the significance of this finding was unclear.  Recent works 
on genome-wide association studies (GWAS) have identified 30 potential 
causal genes which have been demonstrated to influence BMD [134, 135].  As 
such, difficulties exist in provision of a comprehensive genetic screening 
programme which would better predict patients at risk of AFF linked to 
bisphosphonate exposure, but ongoing research has the potential to enable 
targeted testing to minimise risks of AFF from bisphosphonate exposure [134, 
136].  Also more commonly linked to these genetic profiles are Osteogenesis 
Imperfecta [137], hypophosphatasia [138] and osteopetrosis [139], complicating 
identification of bisphosphonate as the sole mechanism of damage to the 
femoral cortex.  There is acceptance across the literature available that further 
case-control research is required on an international scale to identify variants, 




1.5.10 Conditions known to influence bone density. 
1.5.10.1 Smoking 
Lifestyle choices of smoking and alcohol intake influence BMD, smokers have 
an increased risk of fracture, which diminishes on stopping, but not to non-
smoking levels.  The inhalation of toxic chemicals causes an imbalance in bone 
turnover, leading to net bone loss, and also having an indirect influence on BMD 
through BMI, parathyroid and sex hormones and oxidative stresses [140].  
Smoking has the potential to decrease the hormone levels of both sexes, 
especially oestrogen levels of women, giving a tendency toward reaching 
menopause up to two years earlier than non smokers [141], negatively 
impacting on bone mass, with evidence indicating the toxins released by 
smoking tobacco increases the production of oestrogen destroying enzymes, 
which has a direct impact on bone density [142].  This is especially true at the 
hip area, with one study quoting a 40% increased risk to male smokers of hip 
fracture, and 31% for female smokers [143].  The cessation of smoking has 
demonstrated improvement in BMD and a reduction in fracture risk [144], 
however as the effects of smoking are cumulative, fracture risk reduction does 
not happen immediately.  The commencement of tobacco smoking in 
adolescence has been shown in one study to reduce peak bone mass accrual, 
leading to lower BMD levels in later life [145], this claim was refuted by another 
[141], who suggested that no significant impact was found on bone health in 
smokers under the age of 40.   
 
1.5.10.2 Alcohol 
Alcohol intake greater than the UK Government recommended levels of 14 units 
per week can also impact BMD.  A study has shown that alcohol intake women 
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aged over 67 years detrimentally impacts on bone health, having a negative 
impact on bone formation rates.  Alcoholism is known as a major cause of 
secondary osteoporosis [146] and hypogonadism in men [147], and increased 
risk of falling [148].  In contrast, a small amount of alcohol is considered to have 
a neutral or even beneficial effect on BMD, depending on the type of alcoholic 
drink chosen, especially in post-menopausal women [148].  Of concern is the 
impact of binge drinking (6 or more units per day) on the BMD of younger 
people, where alcohol intake will potentially have a greater impact on hormone 
levels and consequently on BMD in the longer term [142, 146, 148].   
Alcohol excess can affect liver function, which in turn can affect the metabolism 
of Vitamin D from the diet.  Cirrhosis of the liver is a risk factor for osteoporosis, 
with one study suggesting that 90% of patients with alcohol-related cirrhosis are 
Vitamin D deficient [149].   
 
1.5.10.3 Vitamin D 
Adequate Vitamin D is required to aid the absorption of calcium, required for 
bone heath.  Vitamin D has also been identified as playing a critical role in the 
maintenance of muscle health, which in turn has an impact on falls risk [142].  
One study found that almost 75% of patients presenting with hip fracture were 
Vitamin D deficient, and over 80% were osteoporotic or severely osteoporotic 
[150].  Persistent Vitamin D deficiency is also linked to osteomalacia, a sub-
clinical lower bone mineral content, which can also lead to increased risk of 
fracture.  Around a third of the UK population aged between 19-64 years are 
considered to be Vitamin D deficient during the winter months, and 
supplementation of 10µg of Vitamin D should be considered by everyone aged 
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four years and over [151].  Vitamin D deficiency was identified within several 
studies as a finding of those with AFF [152-154]. 
 
1.5.10.4 Calcium 
Calcium supplementation has traditionally been prescribed in tandem with 
bisphosphonate medications, in a bid to reduce the risks of hypocalcaemia and 
allow the efficient mineralisation of new bone formed [155].  The intake of 
dietary calcium or supplementation of calcium leads to a directly proportionate 
fall in circulating parathyroid hormone, which has a short term impact on BMD 
[155].  At the formative stages of peak bone mass, links have been made 
between calcium intake at adolescence and adult BMD [156].  The evidence to 
support dietary supplementation is contradictory, where the benefits of calcium 
supplements appear to be greatest in the elderly who are at increased risk of 
hip fracture, and those who are institutionalised [156], however this group is 
also more likely to be deficient in Vitamin D and have a low dietary calcium 
intake [142, 157].  There are drawbacks to calcium supplementation, with 
gastrointestinal upset being commonly reported, along with an increased risk of 
renal calculi [158].  Anecdotal evidence gathered from clinical practice suggests 
patients do not adhere to the calcium and Vitamin D treatment regime 
prescribed, for some the tablets taste bad, leave a chalky residue in the mouth 
or cause digestive upsets and excessive flatulence, findings also supported in a 
previous study [159].  Others report that the “swallow whole” calcium and 
Vitamin D preparations are too bulky to swallow, leading to choking, and if 
broken in half are prone to sticking in the throat, similar findings were reported 
in a USA study of dietary supplementation, leading to guidelines on capsule 
size [160].   
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1.5.10.5 Malabsorption of nutrients  
Malabsorption of nutrients – specifically calcium and Vitamin D can also lead to 
primary hyperparathyroidism, a condition causing continuous excessive 
secretion of parathyroid hormone, predominantly affecting cortical bone [161].  
Untreated, this has the potential to reduce bone mass and increase fracture risk 
[162].  A study comparing BMD measurement with trabecular bone score (TBS) 
identified a degraded bone structure in over 50% of patients with 
hyperparathyroidism, yet only 37.5% of which were diagnosed with 
osteoporosis, identifying a discrepancy between measuring bone quality and 
quantity [163]. 
 
Coeliac disease (CD) is triggered by an immune response to gluten in the diet, 
thought to affect 0.5-1% of the world population [164], caused by gluten 
intolerance, and can contribute to osteopenia and osteoporosis.  In around 70% 
of cases BMD will be adversely affected in patients at time of CD diagnosis 
[165], as a consequence of malabsorption of nutrients caused by villous atrophy 
in the small intestine [166].  This leads to lower absorption rates of dietary 
calcium, however these effects are potentially reversed when a gluten-free diet 
is strictly followed.  Fracture risk associated with CD appears to be minimally 
increased, and BMD appears to improve after one year of a strict gluten-free 
diet with no additional supplementation [167], however a minority will not 
achieve normalisation of BMD [168]. 
 
1.5.10.6 Body Mass Index (BMI). 
There is a general consensus within the literature that low body weight and 
malnutrition adds to risk of osteoporosis.  These known risk factors for 
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osteoporosis can present as consequences of an eating disorder such as 
Anorexia Nervosa (AN), and have the potential to impact negatively on BMD, 
and increased fracture risk, especially at the hip [169-172].  One study indicates 
that over 90% of AN patients studied had significant bone loss in at least one 
skeletal site, and less that 15% of patients had a BMD in the normal range at all 
sites [173].  Risk of fracture increases and remains increased for many years 
post diagnosis of AN [169].  Oestrogen replacement therapy at higher levels 
similar to HRT has been indicated as being beneficial to BMD [170], and while 
most studies support the assertion that oestrogen deficiency related to AN may 
lead to bone loss, there have been studies which suggest oestrogen 
replacement through oral contraceptives does not appear to markedly improve 
BMD [171-173].  This may be as a consequence of the uncoupling of bone 
formation and absorption, caused in part by malnourishment [174].  Lower BMI 
and BMD than age matched contemporaries puts AN sufferers at increased risk 
of hip fracture and greater risk of osteoporosis [174], a BMI below 20kg/m² is 
associated with increased fracture risk [175].   
A BMI measurement of over 40kg/m² is considered as morbidly obese and adds 
a considerable heath burden to the cardiovascular system, increasing the risks 
of Type 2 diabetes mellitus, heart disease and stroke, and reduced life 
expectancy [176].  Elevated BMI has also been identified as a risk factor for 
AFF, however this is complicated by concomitant glucocorticoid use [73].  The 
increased BMI measured in some patients can provide challenges in 
undertaking a BMD examination, affecting the reproducibility of the 





1.5.11 Rheumatoid Arthritis. 
Rheumatoid arthritis (RA) is an auto-immune disease inducing an inflammatory 
process of the synovium causing joint destruction, accompanied by swelling, 
stiffness and pain which may severely limit patient mobility and activities of daily 
living [177], known to affect around 1% of the population and predominantly 
diagnosed in women [178].  Patient immobility as a consequence of the disease 
process and treatment with glucocorticoid drugs to reduce inflammation is 
known to cause osteoporosis in those diagnosed with RA, which in turn 
increases fracture risk [179].  However, it has been identified that RA increases 
fracture risk independently of glucocorticoid use or BMD [30].  While 
glucocorticoids may have implications in reducing BMD they can improve joint 
pain and inflammation, enabling a greater level of physical activity which in turn 
has a positive impact on BMD.  One study identified almost 80% of RA patients 
as reliant on low-dose glucocorticoids to remain mobile and active, and femoral 
neck BMD was not adversely affected by glucocorticoid use in the early stages 
of disease, however by 10 years post diagnosis the BMD at femoral neck had 
fallen below that of the control group [180]. 
 
1.5.12 Hormones and hormone replacement therapy. 
Oestrogen is widely recognised as a protector of BMD and as such there is an 
anticipated drop in BMD at menopause, with the greatest effect on BMD being 
recorded in the first decade post menopause.  The lack of oestrogen if 
menopause is reached before the age of 47 years has been demonstrated to 
increase risk of osteoporosis, fragility fracture and mortality [181].  The 
significance of oestrogen begins at menarche, with earlier age of menarche 
resulting in generally higher oestrogen levels, reduced fracture risk and 
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increased BMD.  Fewer years of menstruation and osteoporosis are directly 
linked [182].  This also affects patients with severe eating disorders where sex 
hormones are suppressed [183], and low BMI, which is also considered a risk 
factor for hip fracture [30]. [184].  It may be useful to offer HRT as bone support 
in women with premature ovarian insufficiency and premature menopause, 
although all benefits are controlled by dose and duration of therapy.  One 
recommendation suggests it should be used where tolerated to at least age 51, 
but with no arbitrary limit set on upper age of use [184].  The use of HRT may 
provide an early treatment solution for bone loss, sparing bisphosphonate 
therapy for later years [185]. 
Hypogonadism in men can be treated with testosterone hormone replacement 
therapy to supplement the low level of circulating testosterone in the body, 
which can alleviate symptoms while also improving BMD [186, 187].  Low 
testosterone levels have been linked with alcohol excess, chronic infection such 
as HIV, steroid treatment, and chronic liver disease; as many as 50% of diabetic 
men may suffer from hypogonadism [187], and are more likely to be obese 
[188, 189].  The increased risk of osteoporosis in untreated hypogonadism is 
overcome with testosterone replacement therapy along side bisphosphonate 
drugs where necessary.  The links between hypogonadism and osteoporosis 
are by association, not causation, owing to a paucity of studies of testosterone 
therapy in men with proven osteoporosis [187].   
 
Characteristically osteoporosis-related fragility fractures occur at the wrist, hip, 
humerus, pelvis and spine.  Sustaining a fragility fracture almost doubles the 
risk of sustaining a further fracture, and this risk is doubled again if the fracture 
is vertebral - independent of BMD measurement.  Almost half of all subsequent 
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fractures will occur within five years of the incipient fracture [161], indicating a 
window of opportunity for treatment to reduce fracture risk.  Around half of all 
hip fractures occur in patients who have already suffered a fragility fracture 
[190], and family history of hip fracture is known to confer additional fracture 
risk, again independent of BMD [30].  When patients are imaged in Accident 
and Emergency following fracture, osteopenia is rarely mentioned in the 
subsequent imaging report, and less than 20% of patients are given information 
regarding bone health, either with information regarding diet and lifestyle or with 
referral for DXA scanning [161].  One study indicated around 50% of patients 
scanned using DXA fell in the osteopenic category [191].   
 
1.5.13 Transplantation. 
Transplantation of donor organs generally induces a drop in BMD, especially in 
the first year post transplant, possibly as a consequence of immunosuppressant 
therapy, lack of mobility, treatment effects of chronic disease and end stage 
organ failure, which may predate the transplant.  Increased fracture risk 
continues for 10 years post solid organ transplant, with the exception of bone 
marrow recipients who have a reduced fracture risk after 5 years [192].  The 
exact mechanism for this is unknown, but may be as a result of anti-rejection 
medications, a consequence of poor mobility in end stage organ failure pre 
transplant or as a combination of several factors.   
 
1.5.14 Anti-retroviral therapy. 
Anti-retroviral therapy used in the treatment of HIV and AIDS has been 
demonstrated to reduce bone mass in long term therapy, with BMD being 
adversely impacted for up to two years post commencement of anti-retrovirals 
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[193].  This is pronounced in the use of Tenofovir, which is also used in the 
treatment of Hepatitis B [194].  The mechanism of bone loss has not been 
established definitively, although it appears women are more severely affected 
by the interactions of anti-retrovirals, hormones, BMD and the disease process 
of HIV [195].  There have also been indications that different combinations of 
medicines can lessen the impact on bone loss, with benefits seen in 
osteoporosis and also in renal function [196, 197].  Additional fracture risk has 
also been identified, primarily at the wrist and spine of both sexes and at the hip 
in men, and increasing with age [174].   
 
1.6 Summary 
This section has sought to provide a background to bone biology, osteoporosis, 
treatments and associated risk factors.  The following section provides an 
overview of atypical femoral fractures and contributing factors as supported by 
the current literature, and the use of DXA in the diagnosis and monitoring of 











2 Atypical femoral fracture - literature review. 
This chapter sets out the current knowledge of atypical femoral fractures 
presented in published literature, their aetiology and currently speculated risk 
factors.   
 
2.1 Search strategy. 
 
A literature search was conducted using Science Direct, PubMed, EBSCO, and 
Open Athens, using the NHS Knowledge network login. Search terms are listed 
















Table 2.1 Search inclusion and exclusion criteria. 
Inclusion criteria Exclusion criteria 
DXA Dysplasia 
Atypical femoral fracture Osteonecrosis 
Latent beaking Paget’s disease 
Thyroid  Malignancy 
Glucocorticoids   
SSRI   
PPI   
Anticonvulsant   
Lifestyle choices  
Rheumatoid arthritis   
HIV and AIDS  
 
2.2 Atypical femoral fracture. 
 
Atypical femoral fractures are differentiated from these standard fractures by the 
presence of fracture in the absence of trauma, increased cortical thickness in 
many cases, and originate in the lateral cortex of the femur.  Atypical femoral 
fracture, is classified in figure 2.1 as being extracapsular, not affecting the hip 




Figure 2.1 Atypical femoral fracture classification based on location. 
 
First case reports prepared in 2005 suggested an association with these 
subtrochanteric low impact fractures with antiresorptive therapies, in particular 
bisphosphonate therapy [1].  In 2010 the American Society for Bone and 
Mineral Research (ASBMR) produced a consensus statement [198] on what 
constituted an atypical femoral fracture, later revised in 2014 [199].   
Classification of atypical femoral fracture currently requires four of five of the 
following major criteria to be met [199]: 
 
 
Subtrochanteric fracture site, 
below both lesser and greater 
trochanter.  
Femoral shaft fracture site, 
considered to be anywhere from 
5mm distal to the lesser 
trochanter to just proximal to 




1. Fracture occurs with minimal or no trauma 
2. Predominantly transverse fracture line, originating from the lateral cortex, 
may become oblique as the fracture progresses across femur medially. 
3. Extends through both cortices and may be associated with medial spike 
as a complete fracture, or involving only the lateral cortex as an 
incomplete fracture.  
4. Non-comminuted or minimally comminuted fracture. 
5. Displays localised periosteal or endosteal thickening, known as beaking, 
of the lateral cortex at the fracture site.  
Minor criteria which may be present but not essential for classification of 
atypical femoral fracture: 
1. Cortical thickening of the femoral shaft. 
2. Prodromal pain preceding fracture – unilateral or bilateral. 
3. Bilateral incomplete or complete diaphyseal femoral fractures. 
4. Delayed fracture healing. 
There appear to be limited data published on the relationship between men and 
atypical femoral fracture, as the majority have focused on female patients [75, 
98, 200, 201], supporting findings that women were 75% more likely to suffer 
from AFF than men [33].  However in most studies which have documented 
male inclusion, the rates of male involvement are small at 5% [52], 4% [202] 
and 12% [1].  A study conducted by Schilcher, published in 2015 found that 
around 5% of women and 1% of men taking bisphosphonates would suffer 
atypical femoral fracture [33].  Incidentally, the study reporting the highest level 
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of male involvement of atypical fracture was a seminal work in the field [1], 
which should have encouraged others to consider it a condition affecting both 
sexes.   
This has prompted further research to determine incidence and potential 
underlying causes of atypical femoral fracture.  While this is not fully 
established, recent research indicates the importance of length of 
bisphosphonate exposure [31, 75, 76, 200], concomitant glucocorticoid therapy 
[31, 97], Asian ethnicity [32, 97] and hip geometry/bowing deformity [76, 201, 
203] are all relevant risk factors. 
Atypical femoral fractures are typically transverse in nature, frequently with 
medial spike, and are sub trochanteric or diaphyseal in location.  There is also a 
much higher possibility of fracture being bilateral than in typical fractures, with a 
reported increased risk of between 25% to 50% [2, 203] of contralateral 
fracture, especially when additional pressure is applied due to reduced weight 
bearing in the fractured limb [204].   
Evidence exists of contralateral fractures being identified after intramedullary 
nailing of an atypical femoral fracture.  It is speculated that this occurs as a 
consequence of additional stress from increased weight bearing placed on the 
non-fixed femur.  This may go some way to explaining the bilateral nature of 
atypical fractures in up to 50% of sufferers, as additional weight bearing is 
expected of the non-painful limb [32, 204].  It is also suggested that higher 
activity levels in younger patients places the femoral shaft under greater 
cumulative stress, offering a partial explanation for the increased likelihood of 
AFF in patients aged 40-60 years, and the regularly observed bilateral nature of 
said fractures [99]. 
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In contrast to typical fractures, atypical femoral fractures occur below the level 
of the subtrochanteric area, affecting the diaphysis of the femur.  These have 
been recorded as occurring in a slightly younger age group of patient – mean 
age reported as 73 years [52], 75 years [51], and around 10 years younger than 
those with typical fractures [202].  This type of fracture tends to atraumatic, 
indeed, it has been reported that patients feel the fracture occurs and causes a 
fall, rather than the fall instigating the fracture as is reported in typical fractures.  
Atypical femoral fractures may also be preceded by prodromal pain in the groin 
or upper thigh, reported by patients as occurring from one week to two years 
preceding fracture [31, 97].  This has been reported as occurring in anything 
from 30% to 90% of patients with atypical femoral fracture [31, 75, 76, 98].  In 
contrast however, some studies report few participants reporting prodromal pain 
prior to fracture, and having similar figures of pain reported in fracture and non-
fracture groups [76, 99, 205].   
 
Links have been identified with area of maximal tensile loading and atypical 
femoral fractures, identifying hip and femur geometry as contributing to fracture 
risk. It is speculated that bowing deformities are more commonly found in Asian 
women [32, 75, 203] with concurrence that femur geometry is a confounding 
factor in atypical femoral fractures. Reasons for this include smaller bone size, 
shorter hip axis length and a larger varus angle of the femur [203].  There is a 
suggestion that there is an 8:1 increased risk of fracture in Asian women 
compared with Caucasian women [203].  As previously identified, there is a 
paucity of study data which include males as subjects, with many investigating 
atypical femoral fractures retrospectively.  Currently there have been no links 
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made that indicate causation of atypical femoral fracture with the use of 
osteoporosis therapy [32, 203, 206].  
 
2.3 Atypical femoral fractures and osteoporosis treatments. 
 
A positive association has been identified between treatment adherence and 
risk of AFF [200].  This study indicated findings of reduced risk of 
intertrochanteric/femoral neck fractures after one year of high compliance with 
bisphosphonate therapy, and which remained reduced for the duration of 
therapy; however within this research, there is increased risk of 
subtrochanteric/femoral shaft fragility fracture from year two, culminating at 
greatest risk at year five [200]. In similar studies, there is more than double the 
risk of atypical femoral fractures linked with consistent bisphosphonate use of 
five years or longer [75, 203].  An association between atypical femoral fracture 
and bisphosphonate duration has been suggested by the ASBMR taskforce 
[198, 199].  There was a reported increase from 2 per 100,000 people on 
treatment per year following two years of therapy, up to 78 cases per 100,000 
people following eight years of bisphosphonate use.  There is a documented 
reduction in atypical femoral fracture risk of around 70% per year on cessation 
of therapy, supporting the theory that resorption and remodelling of bone at 
sites of microcracks allows damage repair in the absence of antiresorptive 
agents [207]. 
 
There are several theories on the causes of atypical femoral fracture, based on 
artificially lowered bone turnover allowing for greater levels of microdamage 
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accumulation over time [208].  It is speculated that bisphosphonate 
accumulation at the site of microdamage may inhibit the repair of micro cracks, 
allowing propagation of stress fracture.  It may also be the case that 
hypermineralisation of the bone coupled with reduced heterogeneity of the bone 
lead to changes in collagen structure resulting in brittleness of the bone [198].   
 
Bisphosphonates have a high affinity for calcium, and they concentrate in the 
body at sites of active bone turnover.  As fractures heal by bone remodelling, 
bisphosphonate therapy may delay the healing process, allowing the further 
development of fractures [207, 209].  Incomplete fractures are further 
complicated in the healing process by the fact that the microcrack is affected by 
the slightest of strains and therefore healing is disrupted regularly at the fracture 
site [204].  This presents a weakness in the bone structure, requiring minimal 
trauma to cause a complete fracture [3].  A further speculative explanation is 
that bisphosphonates in circulation will preferentially bind to a fresh fracture site, 
inhibiting the remodelling process and allowing microcracks to grow rather than 
diminish, with the ultimate consequence being a complete stress fracture [207]. 
The risk of atypical femoral fracture appears to be linked to nitrogen containing 
bisphosphonates as mentioned previously [210].  
Atypical femoral fractures present as pain in the affected limb, with little or no 
trauma, but may be preceded by pain in the groin or thigh of the affected limb 
[97, 98].  Fractures tend to occur prior to a fall, and there may be little visible 
outward change in the limb, in contrast to a conventional hip fracture.  Research 
indicates AFF is more likely to happen at a younger age than hip fractures: 70.6 
years in Caucasian women, 66.4 years in Asian women [32], in comparison to 
77 years for typical hip fracture [211].  One study found 5.9 AFFs per 100,000 
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person-years in patients exposed to bisphosphonate drugs [212], in contrast to 
finding 1 AFF per 100,000 person-years in bisphosphonate-naïve patients [213].  
These fractures will occur at or below the level of subtrochanteric fracture line 
indicated in figure 2.1.  
There is a general acceptance that intramedullary nailing is the preferred 
fixation option for complete AFFs, as they provide greater stability at the 
fracture site [214].  One study demonstrated surgical outcomes of AFF nailing 
can still be poor, with delayed healing and requirements for revision surgery 
[103], while another reported no failings of femoral nailing, with the only adverse 
effect being bone comminution during surgery [215].  Surgical fixation also 
reduces pressure being placed on the contralateral femur, reducing risk of 
contralateral fracture, which has been identified in anything from 38-69% of 
patients with AFF [201, 203].  It has also been identified that there is variation 
not only between hospital trusts, but between hospitals and surgeons on 
whether surgical fixation should be considered sooner rather than later, 
especially in the case of incomplete AFF in the context of contralateral complete 
AFF.  Some studies report a lower success rate in union of the bone in cases of 
conservative management, with patients taking longer to return to normal 
activity levels [4].  It is suggested that incomplete AFFs can be managed 
conservatively, at least in the initial eight to 12 weeks following diagnosis.  If no 
healing is demonstrated, then nailing should be considered in conjunction with 
the wishes of the patient, with a view to avoidance of complete AFF [5].  
 
Data suggests that the rise in subtrochanteric fractures is more or less parallel 
with the rise in the rate of prescribing of bisphosphonate drugs, and that the risk 
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of atypical femoral fracture is decreased on the cessation of bisphosphonate 
medication by 70% per year [209].  However, it was demonstrated that there 
was a 30% reduction in risk of hip fracture and no increased risk of femoral 
shaft fracture when Alendronate was taken as prescribed over a period of ten 
years [51].  It is universally agreed within the published literature that further 
research into the causal factors for atypical femoral fractures is required.  Many 
areas such as medication use, hormone imbalance, autoimmune disease and 
ethnicity have been researched as individual subjects of interest with regard to 
atypical femoral fractures and osteoporosis, but not as a whole.  Several papers 
speculate that atypical femoral fracture risk is greatest in females over the age 
of 70 years, with a low BMD, Asian ethnicity, previous vertebral fracture, high 
bone turnover markers, glucocorticoid therapy and low Vitamin D status [31, 32, 
75, 153, 200] . There is evidence of increased risk of AFF with Asian ethnicity at 
a younger age [32, 75, 76, 97, 201], BMI in range 18.5-24.9, and prior exposure 
to bisphosphonate therapy [75].  Findings of one study indicated that patients 
with AFF were less likely than the general population to have diabetes mellitus, 
while in contrast another found that diabetes was more common in patients with 
beaking [99].  This study was based on patients taking bisphosphonate drugs 
and glucocorticoids and this may have had an influence on these findings, as 
glucocorticoids are known to induce diabetes mellitus in some patients with long 
term use [216].  One study found that all AFF sufferers were female, with 75% 
of those taking bisphosphonate drugs, mean age of 72 years, accounting for 
just under 3% of all hip fractures studies [211]. 
  
Other issues related to long term bisphosphonate use can be ascribed to the 
length of treatment plan; osteonecrosis of the jaw, atypical femoral fracture and 
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damage to bone microarchitecture due to over suppression of bone turnover.  
Osteonecrosis of the jaw (ONJ) is diagnosed where the bone of the jaw is 
exposed following an extraction or other oral surgery and has not healed within 
8 weeks.  This is estimated to affect between 1-12% of patients using high dose 
bisphosphonate drugs as part of cancer treatment [217]. Identification of ONJ in 
patients taking antiresorptive medications is substantially lower, by factors of 
100-250 times reduced, and only when dental extractions have taken place 
[218].  Signs and symptoms include pain in the affected area, loose tooth, 
swelling and ulceration of the affected area [217], although it is unknown 
specifically in which order these occur [219].  
 
2.3.1 Treatment benefits and risks. 
The benefits of osteoporosis drug treatments include; reduced risk of fracture 
[51], repair of bone, increase in bone density with improvements identified in 
BMD within 6-12 months of initiation of therapy [220].  Modest increases in BMD 
of around 4% are associated with bisphosphonate use, alongside a 30-40% 
reduction in fracture risk [221], with one study estimating a fracture risk 
reduction of 26% after one year of complaint bisphosphonate therapy [222].  
Strict compliance with bone strengthening medications give optimum fracture 
risk reduction, but these medications also confer additional risk of significant 
associated side effects of taking these drugs, of concern to many patients is the 
risk of osteonecrosis of the jaw and also atypical femoral fracture.  Where there 
is patient concern regarding atypical femoral fracture, it may provide 
reassurance to know there was a relatively simple monitoring process in place 
which can be combined with the routine DXA scanning regime already in place 
to monitor bone density.   
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2.4 Current uses of DXA in management of osteoporosis.  
 
Bone mineral density measurements of the hip and lumbar spine are 
considered gold standard, providing sufficient data to evaluate the bone density.  
Scanning the proximal hip area takes around 45 seconds, with the addition of 
distal femur scan increasing the scan time by around 60 seconds, allowing an 
assessment of the femoral cortex to be made at the same as BMD acquisition.  
Minimal change in positioning technique is required to perform an extended 
femur scan, and the ability to compare newly acquired images with previous 
scans is unchanged.  The additional time taken and radiation dose is minimal, 
as demonstrated in table 2.2. 
 







Proximal femur 45 37.0 
Distal femur 57 18.5 
Total extended 






Figure 2.2 Extended femur DXA scan image. 
 
Scanning of the extended femur would not occur in patients under the age of 20 
years, as the femoral epiphyses may not have fused prior to this age rendering 
any result unreliable.  Patients with previous hip fracture, pinning or 
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replacement would not be eligible for scanning of the extended femur and hip 
as reliable measurements cannot be post fracture or following insertion of 
prosthesis.  Similarly, lumbar spine scanning and analysis is affected by the 
insertion of any structural metalwork, vertebral fractures and any other overlying 
artefacts/calcifications such as aortic calcification.  Both extended femur and 
spine scans are undertaken with the patient lying on the scanner, and using the 
positioning devices supplied with the scanner.  A typical extended femur scan is 
shown in figure 2.2.  
 
The primary management of osteoporosis uses bisphosphonate drugs to slowly 
rebuild the internal structure of the bone matrix, to add strength and reduce the 
incidence of fracture.  This has been demonstrated to slow age related bone 
loss and also stabilises the bone microarchitecture.  It has been demonstrated 
that up to 30% of the benefit of bisphosphonates are due to anti fracture effect 
and increase in BMD, the remaining benefit is due to improvement of the 
microarchitecture within the bone structure [223].  Such benefits can be 
quantified using serial DXA scans to measure increases in BMD, but do not give 
indication of the quality of the bone structure.  
 
As osteoclast activity is inhibited by bisphosphonate drugs, concerns have been 
raised regarding the over suppression of bone remodelling, resulting in the body 
having an impaired ability to repair micro fractures associated with stress 
fractures, specifically atypical femoral fractures.  In some circles it is believed 
that the reduced bone turnover makes the cortical bone brittle and easier to 
fracture, while others believe the cause to be the inability of stress fractures to 
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heal as there is constant movement at the site of the micro fracture [208].  
Though uncommon, these fractures are typically seen in patients with prolonged 
bisphosphonate exposure and higher treatment compliance levels, however 
there have been rare cases demonstrated in patients with no bisphosphonate 
exposure [211]. 
DXA scanning is considered as the gold standard test for the formal 
measurement of bone mineral density, and uses calculations based on two 
separate x-ray beams of differing energies to measure attenuation of soft tissue 
and bone. This system measures bone mineral content from the regions 
scanned, and a value for bone mineral density calculated by dividing the bone 
mineral content by the area measured.  From this, an evaluation of BMD can be 
made; measurement of BMD of one or both hips and lumbar spine is standard 
clinical practice.  Extended scanning of the femur may present an ideal 
opportunity to assess the cortex of the femur while concurrently evaluating 
BMD.  Full femoral measurement is taken at time of bone mineral density scan, 
with no detriment to BMD measurements [224], minimal additional radiation 
exposure and no extended appointment time required.  This scan can aid 
identification of any increased area of cortical width caused by localised 
periosteal reaction, which may be an early indication of a future fracture site.  In 
some cases this reaction, or peak, may represent an old injury, a prominent 
muscle insertion point or other irregularity unrelated to atypical femoral fracture 
or beaking.  Using the software alongside visual analysis of the femoral cortex 
and with identification of prodromal pain, it may be possible to identify 
prefractures earlier than relying on prodromal symptoms alone.  The software 
supplied by GE provides a quantitative measurement of beaking along the 
length of the visualised femoral shaft, measuring focal thickening of the lateral 
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cortex.  Over serial scan measurements a beaking profile is created, allowing 
graphical demonstration of any irregularities.  
This function is also useful on initial scan, as peaks may be identified at this 
point where present, with no requirement to wait for further scan images to 
identify irregularities.  The extended femur scan takes around 57 seconds 
longer to acquire, with an additional radiation dose of 0.18µSv per femur, the 
dose and time measurements are very similar to those quoted in the 2017 
works of Van De Laarschot and colleagues [225].  It is accepted that there is a 
paucity of data as to whether these cortical lesions accurately predict the future 
development of AFF, nor has the timescale involved in their development been 
confirmed [226].  It is also largely unknown if some of these lesions 
spontaneously resolve, or are associated with other factors.  There is very 
limited evidence on the use of extended femur scanning software on 
bisphosphonate-naive individuals, previous focus has been on establishing links 
between bisphosphonate use and atypical femoral fractures [15, 75, 200].  The 
main recommendation has been to use x-ray as a means of monitoring the 
cortex of the femur for thickening/beaking [97, 227].   
This body of work adds to the research already undertaken in analysis of the 
opportunistic identification of AFF at the time of routine DXA scanning using 
extended femur scanning and specialist software on a clinical population.  As 
the prevalence of AFF is low, there is a requirement for research to be 
conducted in exploration of cost effectiveness and clinical utility of this 





In the following section the methods used are considered in detail in order to 
extend the knowledge of atypical femoral fractures and DXA scanning, including 
a comprehensive review of the relevant literature, based on the objectives and 
questions below.  
 
2.5.1 Objectives: 
1) To prospectively evaluate the use of GE Lunar extended femur DXA 
scanning software in a routine clinical environment. 
2) To investigate the incidence rate and risk factors of iAFF/AFF within NHS 
Grampian and compare with those quoted in a review of the published 
literature. 
2.5.2 Research questions: 
1) What is the clinical utility of this measurement technique in conjunction 
with routine DXA scanning? 
2) Is the reproducibility of the hip BMD measurement affected by the 
software? 
3) Are the software measurements reliable and reproducible in a patient 
population? 







3 Method section. 
 
This section details the methodology and methods used to undertake the data 
collection (page 79), analysis of ten year data on hip fractures (page 81), 
various audits and service evaluation (page 83), and a small in-vivo precision 
study (page 89).  All of which were undertaken as part of this study to assess 
the extended femur scan software in clinical practice.   
 
3.1 Approvals process. 
 
This section outlines the processes required to gain approvals for each audit 
and in-vivo precision study, the relevant permissions and related documents are 
appendices at the end of the document. 
 
3.1.1 Phase 1 approvals. 
The following elements of the overarching study were categroised as a service 
evaluation by research and development (R&D) department of Grampian health 
board: femur scan positioning audit, scan technical analysis audit, visual 
assessment of femoral cortex for peaks, automated software analysis of peaks, 
patient demographics and data collection for comparative use, incidence of AFF 
in NHS Grampian 2008 – 2018. 
A service evaluation was carried out to evaluate current practices as part of 
routine clinical care, with extended femur scanning embedded in routine clinical 
practice within NHS Grampian in September 2018.  The outcomes of service 
evaluations are used to improve patient care pathways through objective 
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assessment and analysis of practice, and using the results to make evidence 
based changes to practice where appropriate [228]. 
The study proposal was registered with NHS Grampian clinical effectiveness 
department and study number 4194 was issued.  Caldicott guardian approval 
was obtained to access patient information and images for the purposes of the 
study.  Audit approval was also obtained from NHS Grampian for relevant parts 
of the study detailed in section 9.1 – 9.7.  
 
3.1.2 Phase 2 approval – In-vivo precision study.  
A study involving extended femur scanning of extended femur bench phantoms 
using the new version 17.0 scan software has been conducted by GE, therefore 
it was decided to conduct an in-vivo precision study in order establish whether 
any measurement differences were found in humans.  The precision study 
element required permissions from the Health Research Authority, with the 
University of Exeter acting as sponsors.  The study was registered with the 
Integrated Research Advisory Service (IRAS), study application number 
259999, North of Scotland Research reference 19/NS/0183, sponsorship 
number 1819/42 (University of Exeter).  A submission was made for ethical 
approval for precision study through the Integrated Research Application 
System (IRAS) and the Health Research Authority, and approval was granted 
by NHS research ethics committee in December 2019.  This was necessary as 
additional scans and radiation exposures were made to study participants in 
addition to routine clinical care, for a study population of 30 patients.  Each 
consenting participant had duplicate extended femur scans at the routine scan 
appointment.  All supporting documents and permissions can be found in 
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appendix 9.1 – 9.7, including patient information sheet, covering letter, consent 
from and study protocol. 
 
3.2 Outline of activity. 
 
From September 2018, the use of GE Lunar extended femur scan software, 
designed to provide early identification of AFF was embedded within routine 
clinical practice on all DXA scanners within NHS Grampian.  This software 
allows the visualisation and assessment of the full length of the femur, with 
automated software measurement of the lateral femoral cortex.  This was 
designed to allow identification of cortical defects including the thickening of the 
cortex, and incomplete atypical femoral fractures (iAFF), integrated with BMD 
measurement at the proximal femur.  As the software was new to the service, 
an evaluation was required to assess its clinical use in relation to AFF and iAFF, 
and as part of that evaluation an in-vivo precision precision study was 
conducted.  An in-vivo precision study was undertaken in order establish 
whether any measurement differences were found in humans, in contrast to the 
results of the phantom measurements found by GE using the same software.  
There is inherent inhomogeneity in human tissue, and the act of repositioning 
between scans can mean a small amount of change in how the tissue lies 
during scanning.  This can have the effect of altering the BMD results, which is 
the primary measurement obtained from DXA scanning.  In order for serial 
scans to be comparable, reproducible patient positioning is essential, to ensure 
best comparison of BMD.  This ensures any change in BMD is real, rather than 
something engineered by changes in equipment, positioning or staff.  Post 
scanning, there is a requirement to audit and assess the quality of scans, both 
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in technical terms and in patient positioning, to ensure no detriment to 
measurements acquired or to patient care from the implementation of the 
extended femur scan.  These images and figures are the basis of the clinical 
report, and are also used to evaluate the femoral cortex for signs of iAFF or 
other abnormalities.  It is critical to the identification and management of iAFF 
from extended femur scans that all staff are using a standardised criteria to 
assess scans, and that software automated analysis of peaks does not alter 
should any scan reprocessing be required post-scan.   
This led to the formulation of a series of audits, data collection and an in-vivo 
precision study, as listed below, in order to establish the usability and stability of 
the scan software in a clinical environment, and to establish the scale of AFF 
within NHS Grampian.  The timeline displayed in figure 3.1 gives an overview of 
the work undertaken within this study;   
 Prospective data collection and patient demographics of all patients 
scanned within the department over a six month period for comparative 
use 
 Retrospective health intelligence data on femur fractures and the 
incidence of AFF in NHS Grampian 2008 – 2018 
 Femur scan positioning audit 
 Scan technical analysis audit 
 Visual assessment of femoral cortex for peaks 
 Automated software analysis of peaks 




Routine quality assurance and control were performed throughout the process 
as normal, alongside cross calibration of all scanners using a spine phantom as 
per good clinical practice, details of which are in appendix 9.8.   
 
 
Figure 3.1 Visual representation of permissions, audit and study timeline. 
 
 
3.3 Data collection. 
 
Following the installation of extended femur scanning software, patient 
demographic data was collected on all patients attending for DXA scanning over 
a period of 6 months between Sept 2018-March 2019.  All staff were briefed in 
data collection requirements.  Caldicott approval was granted for patient 
identifiable information to be collected and used.  Data were gathered from all 
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scanners and sites – including age, sex, ethnicity, height and weight alongside 
self-reported exposure to the following: bisphosphonate/bone strengthening 
drugs, hormone replacement therapy (HRT), glucocorticoid tablets, smoking, 
alcohol, anti-oestrogens, anti-androgens, proton pump inhibitors (PPI), 
thyroxine, selective serotonin reuptake inhibitors (SSRIs), peaks >1mm as 
measured by software and groin/thigh pain.  These data will be used to give an 
overview of the patient demographics routinely scanned within the department 
and to offer comparative data for other sections of the study.  A Microsoft Excel 
(2013) spreadsheet was created and paper copies of this were positioned at 
each scanner area for completion by all operators following every patient 
appointment.  Instructions were reiterated via email on how to complete the 
data, a blank spreadsheet and instructions for completion are found in appendix 
9.9.  Data was collected on a yes/no basis for various medications, recorded as 
a tick or cross, and smoking was described as past, present or no.  All staff 
participated in the data collection, and each page of the spreadsheet was 
returned to the radiographers’ office for input to an electronic version of the 
same spreadsheet.  From this information, scan data was downloaded 
electronically from the scan database to the Excel spreadsheet, then matched 
with the patient data based on Community Health Index (CHI) number, and 
combined using an Excel macro based on patient CHI number.  A selection of 
randomly chosen patient data was then cross checked with date of birth to 






3.4 Retrospective ten year data on the incidence of atypical femoral 
fractures within NHS Grampian. 
 
Retrospective health intelligence data was obtained of all patients suffering a 
femur fracture within NHS Grampian.  This was collated using ICD coding for all 
patients over the age of 50 years over a ten year period from 2008 to 2018 
(n.7102).  Local Caldicott approval was obtained, and registered with NHS 
Grampian clinical effectiveness unit as a clinical audit.  
Collated to an Excel spreadsheet were fractures S722 subtrochanteric, S723 
shaft of femur, S724 lower end of femur, S728 other parts of femur, S729 femur  
part unspecified.  Fractures of the neck of femur S720, pertrochanteric S 721 
and multiple fractures of femur S727 were excluded from analysis as they do 
not meet the ASBMR criteria which specifies that to be considered as an AFF, 
the fracture must be located along the endosteal femoral cortex from anywhere 
distal to the lesser trochanter but to proximal to the supracondylar flare [198].  
Once these patients had been excluded from analysis, a total of 564 patients 
required adjudication, which was carried out by a specialist radiographer and a 
fifth year medical student using radiographic images held within the Picture 
Archiving and Communication System (PACS).  All patients with 
subtrochanteric fractures were investigated (n. 192) using medical records and 
radiological imaging, including previous DXA scans where available.   
Those patients with shaft of femur fracture (n. 131), fracture of lower end of 
femur (n. 173), fracture of other parts of femur (n. 28), fracture of femur – part 
unspecified (n.40) were investigated using radiological imaging primarily, and 
those fractures not meeting with the criteria laid down by the ASBMR task force 
in table 3.1 [199] were excluded.  Any patient with radiological imaging meeting 
80 
 
these criteria were investigated thoroughly using medical records and, where 
available, previous DXA scans.   
 
Fractures without radiological features in keeping with AFF were excluded from 
further investigation.  Electronic patient notes were checked for specific mention 
of AFF in orthopaedic notes or any other correspondence.  From this data, a 
small pool of patients were identified for further detailed investigation of records, 
medical history and background to build a profile of individuals affected by AFF.    
If no mention was found in patient records of AFF, the patient was excluded 
from further review, which may have inadvertently excluded some patients.  
There were a a number of images sent to an orthopaedic surgeon for 
adjudication, where there was a dispute between two viewers, with the results 




Table 3.1 Definition of atypical femoral fracture (major and minor criteria) 
adapted from ASBMR taskforce revised case definition (2013). [199] 
At least four of five major features 
must be present:*  
Minor features are not required for 
diagnosis  
1.  The fracture is associated with 
minimal or no trauma, as in a fall from 
a standing height or less.  
Generalised increase in cortical 
thickness of the femoral diaphysis. 
2.  The fracture line originates at the 
lateral cortex and is substantially 
transverse in its orientation, although 
it may become oblique as it 
progresses medially across the 
femur.  
Unilateral or bilateral prodromal 
symptoms such as dull or aching pain 
in the groin or thigh. 
3.  Complete fractures extend through 
both cortices and may be associated 
with a medial spike; incomplete 
fractures involve only the lateral 
cortex.  
Bilateral incomplete or complete 
femoral diaphysis fractures. 
4.  The fracture is noncomminuted or 
minimally comminuted.  
Delayed fracture healing. 
 
5.  Localized periosteal or endosteal 
thickening of the lateral cortex is 
present at the fracture site (“beaking” 





AFF – atypical femoral fracture, ASBMR – American Society for Bone and 
Mineral Research.  
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*Excludes fractures of the femoral neck, intertrochanteric fractures with spiral 
subtrochanteric extension, periprosthetic fractures, and pathological fractures 
associated with primary or metastatic bone tumours and miscellaneous bone 
diseases (e.g., Paget’s disease, fibrous dysplasia). 
 
 
3.5 Femur scan positioning and technical analysis audit.  
 
This service evaluation was undertaken to assess individual patient positioning 
and the technical quality and evaluation of the scans by all operators within the 
department.  Caldicott approval for given to access patient identifiable 
information in this context, appendix 9.7.  The audit was undertaken of 30 
random femur scans from all specialist radiographers employed within the 
service (n. 5) and scanners (n. 4) used within the department.  Scans were 
selected which took place between 01.12.2018 and 31.03.2019, no scans were 
excluded.  The analysis template and criteria are attached, appendix 9.10. 
All scanner operators are qualified diagnostic radiographers, registered with the 
Health Care and Professions Council (HCPC), and trained to scan in line with 
the GE Lunar DXA scanning user manual. All scan analysis techniques and 
technical criteria are taken from the same.  All operators have been trained and 
certified by the National Osteoporosis Society in bone densitometry, a template 





Extended femur scans were assessed using a standardised assessment 
template, adapted from GE Lunar scan manual and a DXA scan technique audit 
tool already in use within the department.  Scans were assessed on the 
accuracy of the bone mapping, indicated by the yellow lines around the bone, 
ensuring no ischium or greater trochanter mapped as bone in the measurement 









Assessment was also made of region of interest placement, where the femoral 
neck region of interest box should have four corners in soft tissue, the mid 
femur axis line bisects the femoral head correctly, running through the centre of 
the fovea capita, which allows positioning of the femur neck box perpendicular 
to the femoral neck.  Figure 3.2 is representative of a high quality scan with 
Figure 3.2 Extended femur DXA scan, 
representative of a technically high quality scan 




excellent technical accuracy.  No details were available of any difficulty with 
patient positioning, habitus or co-operation, which can all affect scan quality.  
 
3.6 Visual assessment of extended femur scans for beaking.  
 
This audit comprised the analysis and assessment by four experienced DXA 
scan viewers of 30 preselected individual femur scans for visual assessment of 
beaking.  Scan images were selected at random from scans acquired across all 
scanners and operators, between September 2018 and January 2019.  These 
were saved to a folder on a desktop computer for ease of access for all users, 
and to ensure users access scans in the same manner.  All assessments were 
carried out using the same workstation using the same generic login to 
minimise differences in screen resolution, windowing and ambient light.  The 
assessments were carried out independently, as convenient.  All scans were 
single femur, anonymised and saved with file numbers to ensure no identifiable 
patient data were presented, no patient history was provided, Caldicott approval 
was granted for the use of patient data. 
The viewers visually assessed the lateral cortex of the femur on each scan 
image individually from the file provided.  An opinion was then recorded on 
whether any signs of lateral cortical thickening/beaking were visible, and record 
as positive/negative on a spreadsheet.  This was based on the image alone, 
and without viewing the AFF tab of the scan software, or consulting with 




Beaking is classified as an area of diffuse periosteal reaction or thickening, 
occurring on the lateral cortex of the shaft of femur, which may be an initiation 
point for an atypical femoral fracture, a type of stress fracture.  The area of 
cortical thickening is known as a beak, and the process of thickening is known 
as beaking.  Any area of thickening is measured in millimeters (mm) to one 
decimal place by the scan software, and a coloured arrow automatically placed 
at the level of any peak measuring ≥1mm alerts the user to level of the 
irregularity.  The beaking index is measured as the distance from the inner 
cortical wall to the edge of the beak, minus the cortical wall measurement in 
areas above and below the beak – all measurements are made in millimetres 
(mm).  A pictorial representation of the measurement points are shown on figure 
3.5.  The suggested threshold from GE Lunar for flagging beaking is 1mm [229].  
 
The scan image in figure 3.3 gives an indication of a scan exhibiting beaking as 
measured by the scan software, which could be considered to be a false 
positive, as the cortex appears smooth and congruent.  Figure 3.4 
demonstrates a true positive beak on DXA scanning, showing a peak on the 




Figure 3.3 Software manufactured false positive beaking at distal femur on 
extended femur DXA scan. 
 
3.7 Scan analysis – software automatic beaking index measurement.  
 
Scan analysis and re-analysis was carried out in January 2019, examining 30 
random single extended femur scans in triplicate, acquired between September 
2018 and January 2019.  From this, the beaking index figure was recorded to 
one decimal place, as calculated by the scan software.  This was performed on 
3 separate dates, where the same scans were opened and automatically 
reanalysed using the scan software by the same specialist radiographer, and 
the measurements recorded.  No adjustments were made to any area of the 
scan, which were selected from all operators and scanners within the 




The beaking index is a quantitative measurement automatically acquired by the 
scan software, measuring the increase in cortical width of any localised 
periosteal reaction, in mm.  The threshold measurement for this is 1mm, 
anything greater than 1mm will be automatically flagged by the scanning 
software to the operator by means of a coloured arrow adjacent to the area 
concerned.  This is calculated by measuring the lateral cortex of the femur at 
the point of beaking in mm, then subtracting the thickness of the cortical wall 
where considered normal above and below the beaking area. 
 





3.8 Precision study. 
 
This section outlines the in-vivo precision study undertaken using DXA 
extended femur scanning software.  
 
3.8.1 Aim. 
The aim of the in-vivo precision study was to investigate the operator precision 
error of extended femur scans on a static scanner.  This was conducted by 
undertaking in-vivo precision study on patients >20 years routinely attending the 
Grampian Osteoporosis Service at Ashgrove House, Aberdeen Royal Infirmary, 
for DXA scan.  All scans were undertaken on the same scanner by the same 
specialist radiographer.   
When comparing BMD measurements over time in the same individual it is 
important to distinguish between a true change in the measurement and 
inherent precision error related to variability in the measurement procedure 
[230].  Scanner manufacturers General Electric (GE) Lunar suggest that 
accuracy and precision error of the measurements taken from the outer edge of 
the femur (thigh bone) during extended femur scanning software are within an 
error margin of 0.5mm, using simulated beaks contained within phantom.  No 
DXA measurements have been performed by GE on a clinical population, using 
real patients.  Correct and reproducible positioning of patients is necessary to 
ensure continuity and accurate comparison of measurements, incorrect 
positioning can result in measurement differences of greater than +/- 0.5mm 
[229].  This is new software and it is not yet known how reproducible these 
measurements are in a clinical population, or indeed any effect this may have 
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on BMD measurements, and no published evidence has been found to suggest 




Figure 3.5 Extended femur scan image with measurement points identified. 
 
 
By investigating the precision error, or reproducibility, in a patient population 
typical of those referred to the service, it can be ascertained that the 
measurements obtained are true.  This was done by measuring the thickness of 
the outer edge of the cortex of the femur, used in routine clinical practice within 
the department.  This will assist in ensuring the best care for all patients and 
inform medical imaging pathways in future.  
Top line, measurement 
point of normal cortex 
above beak. 
Central line with arrow, 
measurement point at 
widest point of cortical 
peak.  
Lower line, measurement 
point of normal cortex 




3.8.2 Inclusion/exclusion criteria for precision study. 
The request for DXA scanning was made by the referring physician and vetted 
in the usual way as per local referral guidelines for DXA scanning and IR(ME)R 
Regulations.  All patients >20 years routinely attending the Grampian 
Osteoporosis Service at Ashgrove House, Aberdeen Royal Infirmary, for DXA 
scan were considered  eligible for inclusion. 
Exclusion criteria were as follows: Patients <20 years of age, patients unable to 
give consent, patients who have had bilateral hip surgery, patients who are 
pregnant.  Any patients under the age of 20 years were  automatically  allocated 
to have proximal hip scan only, as epiphyseal fusion of the proximal femur is not 
guaranteed to have occurred prior to this.  Also excluded were  patients with 
bilateral hip replacement/pinning as no BMD measurements were obtainable, 
and pregnant patients who would not be scanned in routine clinical practice. 
 
 
3.8.3 Precision study recruitment. 
Recruitment was planned of 30 participants, with study information sent to 
around 75 participants, in the assumption that approximately 50% of those 
would consent to participate [231].  It is suggested that 30 participants be 
scanned to obtain statistically valid results [232, 233].  It is a recommendation of 
the International Society for Clinical Densitometry (ISCD) that 30 degrees of 
freedom be used to assess short term precision in DXA measurement, scanning 
30 patients, representative of the typical scan population within the department, 
in duplicate [230].  This posed least inconvenience for participants as they 




Routine clinical care involved one DXA scan (bilateral extended femur and 
lumbar spine), performed on a GE Lunar Prodigy DXA scanner with version 
17.0 software (GE Healthcare, Bedford, UK).  Each study patient received 
additional scans of both extended femur, plus standard clinical care.  
Appointment times were 30 minutes long with one visit per participant and no 
further follow up except standard clinical care.  All eligible patients weresent an 
invitation letter to participate in the study and a participant information sheet in 
addition to their standard clinic appointment letter.  These were  routinely sent 
out in advance. 
 
On the day of the appointment, potential participants were approached by the 
specialist radiographer undertaking the scan and asked if they have read and 
understood the information sent out.  They were then asked if they would be 
willing to participate.  Any questions or queries were  discussed.  If the patient 
was happy to participate, written consent was obtained, a copy of the completed 
consent form was  given to the patient to take away with them. 
 
 
3.8.4 Patient pathway. 
All participants had their personal details checked with departmental records, 
discussed the standard osteoporosis department questionnaire, and 
measurements of height in centimetres (cm) to the nearest 0.001cm using a 
Holtain stadiometer (Crymych, Dyfed, UK) and weight in kilograms (kg) to 
nearest 0.1kg using Marsden professional digital scales (Rotherham, UK) are 
taken as part of routine care.  Body mass index was calculated as 
weight(kg)/height(m²), automatically calculated by the scan software.  Patient 
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preparation followed standard clinical care, with removal of underwired bras, 
jeans and any clothing with metal studs/zips/decoration which may have 
interfered with scan measurements.   
The participant was then asked to lie centrally on the scanner bed, and scans 
were taken of each extended femur individually, then the lower spine scanned 
(three individual scans) as per standard practice.  For the extended femur 
scans, a rigid plastic positioner was used to position the legs for scanning.  This 
was supplied with the scanner, fitted with Velcro to support the feet, allowing the 
patient to relax the leg muscles.  The purpose of this was to rotate and abduct 
the femur, and used as standard to ensure reproducible images and results.  
The scanner arm passed up and down the length of the scan table, over the 
body acquiring images as it did so.  The images acquired were used initially to 
ascertain straightness and centralisation of the femur, and alterations in 
positioning were made until the femur was straight and central in the scanner 
field of view.  
  
After this process, the participant wasasked to rise from the scanner bed, and 
then lie back down, mimicking  a patient returning for a second scan and  
considered best practice for short term precision scans.  A further scan of each 
extended femur was taken (two additional scans) in the same manner as the 
first, using the foot positioner.  Following this appointment, the participant was 
able to access a clinical diagnosis via the referring clinician as per standard 





3.8.5 Scan analysis. 
All scans were analysed by the operator, following the departmental protocol.  
As part of the extended femur scan analysis, the regions of interest should be 
considered as follows: acetabulum  fully visualised, adequate visualisation 
above the greater trochanter, recommended as two to three sweeps.  All four 
corners of the femoral neck box should be located in soft tissue, no ischium 
mapped as bone in femoral neck box and the mid femoral line should bisect the 
femoral head, running from the greater trochanter through the fovea capita to 
the pelvic brim.  The neck box should be perpendicular to the femoral shaft.  If 
there are any changes made to the size, position or angulation of the neck of 
femur box, the search button should be used to return the box to the point of 
lowest BMD.  The femur should be central, straight and vertical in the field of 
view, at the proximal end the lesser trochanter should be minimised as far as 
patient habitus allows; at the distal end there should be no patella or 
supracondylar flare in the scan field.   
 
3.9 Departmental scan protocol. 
 
Standard departmental clinical scanning protocol consists of bilateral extended 
femur scans and lumbar spine, with the addition of lateral vertebral assessment 
scan at the discretion of the operator if clinically indicated.  Exceptions  are hip 
surgery, and the inability to transfer to the scan table independently.  In the 
case of limited mobility and inability to transfer, a forearm scan can be 
performed.  
Diagnostic radiographers must be registered with the Health and Care 
professions council (HCPC), all staff acting as operators are diagnostic 
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radiographers who have completed in-house bone densitometry training as well 
as completing the Royal Osteoporosis Society (formerly the National 
Osteoporosis Society) training course and subsequent examination in bone 
densitometry.  Standard operating procedures (SOP) are written for each scan 
acquisition process, and new staff read, follow and are supervised by an 
experienced staff member until both parties feel that scan acquisition and 
analysis is consistently of a high standard.  This ensures all staff are trained 
consistently to the same high standards.  The scan acquisition protocol is 
summarised below, the full SOP is attached in appendix 9.12, and training 
record template in appendix 9.11.  Following the implementation of the version 
17.0 software upgrade, a briefing of all staff individually was undertaken by the 
installation engineer on the use of the new software.  The extended femur 
scanning was the only modification to routine practice, and all staff appeared 
confident in positioning for and performing the scan.   
 
It is standard clinical protocol to perform PA spine scan and bilateral extended 
femur scans which cover hip area measurement.  Exceptions to extended femur 
scanning : bilateral hip replacements in situ, previous hip fracture or metal work 
inserted, even if metal work has subsequently been removed – scan unaffected 
hip only.  It is not considered clinically appropriate to acquire hip scans if the 
patient is under 20 years of age, as the femoral epiphyses may not be fused until 







Scan acquisition standard protocol – extended femur scanning 
 
 Patient details are input and edited correctly to the appropriate DXA scan 
database. 
 Click measure. 
 Click dual femur or single femur as appropriate (hip pinned or replaced). 
 Click position – scanner will home to foot. 
 Patient lies supine on the table centred to the mid line. 
 The arms are placed on the patient’s chest away from the area to be 
scanned. 
 Ensure that the pelvis is centred in the middle of the scanning field. 
 The patient should not be rotated – ASIS of the pelvis must be equidistant 
from the table-top or as can be reasonably achieved. 
 The supplied angled foot support is placed between the patient’s feet, 
abducting the leg to be scanned approximately 15 degrees away from the 
midline, and internally rotated by around 25°, to rotate the greater trochanter 
anteriorly and the lesser trochanter posteriorly. 
 Knees should be internally rotated and toes should be up – shoes should be 
kept on. 
 Ensure the shaft of femur is straight to allow ease of positioning for follow 
up scans. 
 Using the positioning lights the scanner is centred over the left patella, and 
the scan ends approximately 30 mm (two sweeps) above the greater 
trochanter. 
 Click Start 
 Scan hip – when completed - option to re-measure or save data 
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 Re-measure if appropriate  
 Save 
 Scanner automatically moves to scan R femur 
 Position laser light appropriately as above 
 Scan femur 
 Save, Analyse, Save 
 Close  
 
 
If a patient has been scanned before, the previous scans may be accessed by 
using the ‘Settings’ facility.  This allows previous scan to be viewed 
simultaneously whilst scanning.  The previous scan is essential to enable 
accurate positioning, the original positioning should be reproduced where 
possible, this allows superimposing of the original scan over the new scan using  
the copy feature, which is departmental policy.  The regions of interest should not 
be altered if possible when a patient has been previously scanned, as slight 
positioning differences may lead to inappropriately positioned to ROI boxes. 
 
3.10 Data analysis. 
 
Data analysis was conducted using Microsoft Excel 2013 and IBM SPSS 
Statistics software (Version 26, IBM, NY, USA).  Data were tested for normality 
and data found to have a Gaussian distribution reported as means and standard 
deviation, and analysed using parametric methods, data with non–Gaussian 
distribution reported as median and range, and analysed using non–parametric 
methods.   
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Means were calculated using Excel for normally distributed data, in beaking 
index and cross calibration of DXA scanners.  The mean figure was also used 
to calculate a 95% confidence interval, where upper and lower intervals found 
by the addition or subtraction of 1.96 respectively from the mean value to give 
two standard deviations from mean [234].  These data were utilised in the 
construction of a Bland-Altman plot.  
 
Median calculations were used to analyse data which did not confirm to a 
Gaussian distribution, such as in the investigation of BMI, using Excel.  The 
standard deviation was calculated using Excel to express variability in the 
population, and also to measure confidence in statistical results.  It is 
considered that only data outwith two standard deviations is seen as statistically 
significant [235].  Calculation of BMI was made by the DXA scan software GE 
Lunar version 17.0 (2017), using raw height and weight data, calculated as 
weight (kg)/height² (m). 
Extended femur scan precision measurements were used to calculate inter-
operator precision error at total hip and femoral neck using the ISCD online 
advanced precision calculator.  The precision measurements of beaking index 
were calculated using the same program.  The precision error is represented as 
the square root of the mean of the sum of the squares of differences between 
first and second measurements.  The precision parameters, root mean square 
standard deviation (RMS SD) and root mean square coefficient of variation 
(RMS CV%) and the resulting least significant change values (LSC) were 
calculated.   
The LSC was calculated by multiplying the precision error RMS CV% by 2.77, 
and the resultant figure indicates the change in BMD that should be considered 
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as statistically significant as a true biological change rather than one 
manufactured by the equipment, operator and changes in patient positioning.  If 
the change in BMD exceeds that of the LSC for the scanner/operator then it can 
be regarded as a real change in BMD.  Accepted figures quoted by the ISCD for 
95% least significant change (LSC) for femoral neck is 6.9%, and total hip 5.0% 
[236].   
 
A Bland-Altman plot was used to display the differences between sets of 
beaking index measurements, with agreement between measurements and 
95% confidence interval calculated. 
Cohens Kappa scores were calculated using IBM SPSS Version 26 software 
(NY USA), to calculate correlation of subjective viewing of extended femur 
scans.  Percentage agreement was also calculated, using Microsoft Excel 2013. 
Scan positioning and analysis results were calculated as a percentage 
frequency, number/total scans*100.   
Beaking index analysis and reanalysis was automatically calculated by DXA 
scan software (Version 17.0, GE Lunar, Bedford, UK). 
Sensitivity, a tests ability to identify true positive results, or in this case those 
patients with iAFF on extended femur scanning, and specificity, a tests ability to 
correctly identify patients who do not have iAFF on extended femur scanning 
were calculated using a series of figures based on the following format: a = true 
positive, b = false positive, c = false negative, d = true negative.  The following 
formulae were used to calculate:  Sensitivity = [a/(a+c)]x100, Specificity = 
[d/(b+d)]x100, Positive predictive value (PPV) = [a/(a+b)]x100, Negative 
predictive value (NPV) = [d/(c+d)]x100.  This allowed the assessment of 
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probability that a positive (or negative) screening test correctly identified the 
presence of iAFF on extended femur scanning.  
 
3.11 Summary 
This section has provided in depth details on the audits and in-vivo precision 
study methods and data analysis techniques.  The following section will cover 

















4 Service evaluation. 
 
This section will present the demographics of the routine clinical DXA 
population collected over a period of six months, plus five patients who were 
found to exhibit true beaking on DXA scans who attended outside this six month 
window, but within the wider study period.  Data on patients with confirmed AFF 
within NHS Grampian from 2008 to 2018 has also been collated and reviewed 
to provide an estimation of the incidence of AFF and iAFF in NHS Grampian.  
 
4.1 Service evaluation and data collection. 
 
Patient data were collected over 6 months for all patients attending for routine 
DXA scans within NHS Grampian centres in Aberdeen and Elgin, and satellite 
sites in Aboyne, Orkney and Shetland, as documented in methods section 2.3.  
This included six paediatric patients who did not have extended femur scanning 
performed as the scan software does not allow this prior to age 20 years and 
clinically this would be inappropriate.  In addition, there were 67 patients who 
did not have extended femur scans performed for a variety of reasons.  The 
participant demographics for all patients attending for scan over the six month 







Table 4.1 Routine DXA scan patient population descriptive statistics. 
Variable Population (n. 2588) 
Sex female/male no. (%) 2055/533 (79.4/20.6) 
Age, years, mean (SD)  
Age range (years) 
66 (12.5)  
3 – 95 
Ethnicity (%)  
   Caucasian (%) 2384 (92.1) 
   Asian (%) 12 (0.5) 
   Black (%) 1 (0.0) 
   Hispanic (%) 2 (0.1) 
   Not recorded (%) 
Smoking  - past (%) 
Smoking – present (%) 
Alcohol >14 units per week (%) 






SD – Standard Deviation        
 
Modifiable risks for osteoporosis are considered as lifestyle choices, as 
identified in table 4.1, including smoking and alcohol intake.  Current smokers 
accounted for over just over 11% of all patients scanned.  Over a third of all 
individuals scanned had smoked in the past, with a greater number of men 
being past smokers compared with women.  More than 7% of patients scanned 
indicated they regularly consumed more than 14 units of alcohol per week.   
Information on medications known to affect bone metabolism were collected 
and are outlined in table 4.2. 
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 Table 4.2 Patient medications divided by gender. 
MEDICATIONS Male n. 533 (%) Female n. 2055 (%) 
Anti androgen/oestrogen 7 (1.3) 139 (6.8) 
Oral glucocorticoid  178 (33.4) 508 (24.7) 
SSRI 30 (5.6) 246 (12) 
Levothyroxine  21 (3.9) 306 (14.9) 
Proton pump inhibitor 188 (35.3) 689 (33.5) 
Bisphosphonate  84 (15.8) 607 (29.5) 
HRT  7 (1.3) 547 (26.6) 
SSRI – selective serotonin reuptake inhibitor; HRT – hormone replacement 
therapy.  Bisphosphonates include alendronic acid, Risedronate, zolendronate, 
ibandronate, Denosumab and parathyroid hormone.  
 
The use of hormone blocking drugs such as Arimidex and Zoladex was higher 
in women than men, with just under 7% of women taking of have taken in the 
past, compared with just over 1% of men.  Glucocorticoid use was higher in 
men than in women, with 33% of men and just under 25% of women taking oral 
steroids in the past or at the time of scanning.  Patients with prescribed 
medications are displayed in table 4.2, separated by gender.   
Hypothyroid treated with Levothyroxine was reported by almost 15% in women, 
in contrast to less than 4% of men.  However, men were found to be more likely 
to be taking proton pump inhibitor drugs, with 35% of men scanned found to be 
taking these.  The difference between the sexes was not marked however, as 
over 33% of women were also taking these. 
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The use of Selective Serotonin Reuptake Inhibitor drugs was also more than 
double in women at 12% compared to men, at just under 6% of men.  However 
there was almost double the number of women prescribed bisphosphonate 
drugs compared with men, with almost 30% of women taking or having taken 
bone strengthening drugs. 
 
From the data gathered, there is no statistically significant difference in the 
mean age of those displaying peaks on DXA scanning and those who do not.  
The demographics of patients who exhibited peaks > 1mm on scanning is found 
in table 4.3, compared with those who did not, separated by gender, alongside 
medication use.  There was no difference between the BMI of men who 
displayed peaks and those who did not, however female subjects who displayed 
peaks on scans had around 5% higher BMI than those who did not.  Over 27% 
of patients scanned had a BMI ≥30kg/m².  None of the patients scanned over 
the six month period demonstrated a peak which was considered significant as 
a true thickening of the lateral cortex of the femur.  However, in the 6 months 
following the data collection period, five patients presented with peaks related to 
AFF which was confirmed in further imaging.  To explore the annual incidence 
of AFF in the DXA population, the 6 month data were doubled to extrapolate 
numbers so that the positive predictive value could be calculated.  Any data 
manipulated in this manner will be clearly outlined within this chapter.   
 
 
Over a quarter of all women scanned had been on HRT either at the time of the 
scan or in the past.  The average BMI for this cohort of patients is just over 27.3 
kg/m², the range is between 13.6 and 57.8 kg/m². 
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The data were divided into bisphosphonate users and non-users for males and 
females and for those with and those without peaks of greater than 1mm 
demonstrated on the long femur scans.  The numbers are outlined in figure 4.1 
and full information on these groups is presented in table 4.3  
 
 
Figure 4.1 Patient characteristics: separated according to peaks on DXA scan 
and bisphosphonate use. 
 
Of the patients displaying peaks >1mm on DXA scan (n. 464), three quarters of 
patients were bisphosphonate naïve.  Within the male population, 21% of those 
scanned had peaks measuring >1mm, in comparison to 17% of female patients.  
Bisphosphonate use (past or present) affected almost 27% of the scan 
population, no timescale was recorded for the consumption or cessation of 
these drugs, or self-reported compliance.  Figure 4.1 demonstrates the 
demographic of patients who displayed peaks >1mm on scan software, 
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separated by gender.  The mean age of those displaying peaks on scanning is 
66.5 years, identical to those with scans deemed normal. 
The results of Chi squared test of association (2x2) indicated a significant 
association between bisphosphonate use and peaks greater than one 
millimetre, (Chi square value = 4.568, df = 1, number analysed = 2293, p = 
0.033) on extended femur scans.  No other p value was found to indicate 
significace between exended femur scans displaying peaks greater than one 
millimetre and smoking, glucocorticoid use, alcohol intake ≥14 units per week, 




Table 4.3 Patient demographics of individuals scanned between September 2018 and March 2019, split by peaks <1mm and >1mm as 





Peaks – No Peaks - Yes      
       
Male Female Male Female 
Mean Count  Mean Count  Mean Count  Mean Count  
BMI (mean) 28.0    26.9    28.2    28.3    
BP 
 
  68    469    11    102  
HRT     6    421    1    108  
Alc    70    67    28    13  
Smoking  
 
Past   163    520    50    128  
Present   52    154    16    52  
PPI    140    522    37    127  
Thyroxine    15    233    4    64  
SSRI    18    181    10    52  
GC    133    376    40    109  
AA/AI    5    114    1    21  
Age (mean) 65.1     66.8     65.8     66.7     
 
 
            
BMI  - body mass index kg/m², BP – Bisphosphonate use, HRT – Hormone replacement therapy past or present, Alc – alcohol ≥14 units per week, 
PPI – proton pump inhibitor, SSRI, selective serotonin uptake inhibitor, GC – glucocorticoids, AA/AI – anti androgen/aromatase inhibitor.  
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4.2 Positive and negative predictive values of AFF 
 
There have been five cases where it was felt there was sufficient clinical doubt 
on extended femur DXA imaging of peaks seen (true positives) while scanning 
in the space 12 months, and 928 false positives identified by the scan software 
on extended femur scanning, which were subsequently downgraded to normal 
on visual assessment by the scan operator and Rheumatologist, from a total 
population of 5176 patients.  The 5176 patients are calculated by extrapolating 
the numbers from the 6 month initial data collection and multiplying by two to 
provide data for a 12 month period.  All scans are visually assessed for peaks 
and irregularities at the time of reporting, allowing identification and referral for 
further tests where necessary  The false positives are based on visual 
inspection of automated scan software measurements > 1 mm.  No patient had 
follow-up femoral imaging as a result of software cortical measurement alone, 
because the visual assessment of the peaks by the operators and reading 
clinicians did not provide sufficient clinical suspicion based on the image to 
warrant further imaging.  This leaves 4243 patients as true negatives, although 
it has yet to be ascertained if any false negatives exist, and would only come to 
light if a patient had a DXA scan prior to suffering from an AFF, however there 
is acceptance that a test with high specificity is less likely to produce false 








  Peak  No peak 
Number  
5176 





 n. 5 
 



















Table 4.4. Breakdown of DXA scans with peaks ≥ 1mm and peaks <1mm – 
representing false positive and true negative findings, extrapolated to one year 
from six months scan data. 
Based on one year’s data, using the figures presented in table 4.4, a calculation 
was made of the positive and negative predictive value of extended femur DXA 
scan results.  All scans acquired over the six month period were visually 
assessed by the operator and the reporting clinician.  Alongside this, sensitivity 
and specificity calculations were also made, as shown in table 4.5, 
demonstrating the high sensitivity and negative predictive value of extended 
femur scanning, giving confidence that the patient does not have any indication 
of iAFF on the imaging acquired.  Specificity values indicate the scan software 
produced a high number of false positivies with  a large  number of patients 
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exhibiting peaks greater than 1mm, which were found to relate to anomalous 
identification of the femoral cortex by the scan software. 
 
Table 4.5 Sensitivity, specificity and predictive value of extended femur 
scanning and prevaence of software detected peaks , calculations extrapolated 
to one year from six months scan data. 
 Value 95% CI range 
Sensitivity 100% 47.82% – 100% 
Specificity 82.1% 80.98% - 83.09% 
Positive predictive value (PPV) 0.01% 0.051% - 0.057% 
Negative predictive value (NPV) 100%  
Accuracy 82.1% 81.0% - 83.11% 
Prevalence of iAFF 0.1% 0.03% - 0.23% 
CI – Confidence Interval, iAFF – incomplete atypical femoral fracture  
 
Over a period of six months, no peaks considered as suspicious were identified 
in any extended femur scan.  Over the subsequent six month period five 
patients had extended femur scans performed where a suspicious peak was 
identified and investigated.  These figures represent the very low prevalence of 
incomplete atypical femoral fracture found using extended femur DXA scans 
over the course of six months, which led to the data being extrapolated to one 





4.3 Individual cases. 
 
There follows a summary of all five cases of peaks found in DXA scans during 
2019 which were thought to be suspicious both using scan software peak 
images, peak measurements greater than 1mm and also on visual analysis by 
operator/reporting Rheumatologist.  These five patients were investigated 
initially using radiographs to further assess the femoral cortex.  A summary of 
patient characteristics is found in table 4.6. 
 
Table 4.6 Patient demographics overview of five patients identified with 
suspicious peaks ≥ 1mm on extended femur DXA scan. 











1 80 35 154.7 84 220 3.6 
2 72 30.2 164.7 82 200 3.1 
3 79 30.7 162.5 81 110 2.0 
4 72 28.2 161.1 73.1 180 3.3 
5 77 29.4 162.8 78 205 1.5 
Cm – centimetres, mm – millimetres, kg – kilograms, BMI – body mass index, 
(kg/m²). 
 
4.3.1 Case one. 
Patient number one was scanned in March 2019, a Caucasian female, aged 80 
years, with a BMI of 35.  Alendronate was commenced in 2011, following a DXA 
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scan diagnosing osteoporosis, with good self-reported compliance.  Past 
medical history included lumbar spine fractures, short courses of oral 
glucocorticoids, and hypothyroid treated with levothyroxine since the 1990’s.  
The follow up scan was requested as the patient had suffered further fractures 









During the extended femur scan, a peak was observed on the cortex of the right 
femoral shaft at 220 mm, as shown in figure 4.2.  A suggestion was made in the 
scan report that the patient be referred for bilateral femoral x-rays to rule out the 
possibility of iAFF.  This was done in the same month, with the reporting 
radiologist mentioning an “organised periosteal reaction on the lateral side of 
the middle third of the femoral shaft, aetiology unclear”.  A referral was made to 
orthopaedic department on this basis.  The patient is awaiting follow up with an 
Figure 4.2. Case one, displaying a suspicious 
peak on extended femur DXA scan at 220 mm, 
highlighted by arrow. 
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orthopaedic surgeon, but this has been delayed by the temporary suspension of 
non-urgent appointments due to COVID-19.   
 
4.3.2 Case two.  
Case number two was female, Caucasian, aged 72 years with a BMI of 30.2.  
No prodromal symptoms were reported, and the patient considered herself very 
active, participating in regular weight bearing sports and high impact exercise 
activities.  Alendronate had been prescribed for 10 years to 2012, with excellent 
compliance, and recommencement of Alendronate in 2014.  Calcium and 
Vitamin D had been prescribed from 2002.  The past medical history given: 
HRT for five years, previous smoker having given up around the age of 30, hip 
fracture in 2005.  Only the right femur was scanned on account of this.  When 
the extended femur scan was taken, there was a clear peak of 3.1 mm in the 
midshaft of femur at around 200 mm from tip of greater trochanter, as shown in 
figure 4.3.   
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Figure 4.3 Case two displaying a suspicious peak at 









As this patient was attending the one-stop metabolic bone clinic, she was seen 
by a consultant rheumatologist and sent for x-ray of bilateral femora at an 
outpatient clinic the same day.  This identified bilateral peaks at similar levels.  
An urgent referral was sent to orthopaedics.  The patient has been followed up 
at three monthly intervals, with MRI imaging to assess any changes to the 
beaking sites, and conservative management agreed between surgeons and 
the patient.  Follow up is now on hold due to suspension of clinical activity due 




4.3.3 Case three.  
Case number three, a Caucasian female, aged 79 years with a BMI of 30.7 and 
a never smoker.  Osteoporosis was diagnosed in 2007, with calcium and 
Vitamin D had been prescribed from 2009, Alendronate had been prescribed on 









Denosumab six-monthly injections were prescribed in 2014, tolerance and 
compliance were excellent.  Previous medical history: menopause age was self 
reported at 42-43 years, with no HRT, oral glucocorticoids for around seven 
years, as treatment for asthma and also polymyalgia rheumatica, previous 
vertebral fractures at T11 and T12 on radiographic imaging. 
On extended femur scanning, a peak of 2 mm was identified at around 100 mm 
from tip of greater trochanter, as shown in figure 4.4, an area which was 
covered in two previous scans also.  The peak was observed at 0.5mm in 2007, 
increasing to 1.3 mm in 2012.  As a consequence of the increasing peak size,  
the patient was referred for bilateral femoral x-rays.  The subsequent imaging 
Figure 4.4 Case three displaying a peak at around 100 





report did not identify any features consistent with iAFF, with no follow up 
recommended.  The area of the distal lateral femoral shaft which appears to be 
stepped is due to a software facility used to maximise image quality, and has no 
effect on the cortical measurement above this.   
 
4.3.4 Case four.   
Case number four was female, Caucasian, aged 72 years with a BMI of 28.2.  
Previous medical history included a six month period of HRT, oral 
glucocorticoids from 1995 to treat sarcoidosis, warfarin from 2005 following a 
deep vein thrombosis, and home oxygen for several years to 2019.  Age at 
menopause was 50.  A number of different bisphosphonate drugs were 
prescribed from 1995, along with calcium and Vitamin D, however the patient 
did not find bisphosphonates to be agreeable, and took irregularly.  In 2014, a 
subtrochanteric fracture of the left femur was surgically fixed, therefore only the 















On DXA scanning, a peak of 3.3 mm was identified on the lateral femoral cortex 
at 180 mm from the tip of the greater trochanter, as shown in figure 4.5.  This 
was especially concerning, given that the lady had been prescribed long term 
glucocorticoid therapy, warfarin, limited mobility due to oxygen requirement and 
having suffered a previous subtrochanteric fracture five years previously.   
A referral was made on this basis for bilateral femoral x-rays following the 
reporting of the DXA scan; however the patient became acutely unwell and died 




Figure 4.5 Case four extended femur DXA scan 
showing peak at 180 mm, highlighted by arrow. 
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4.3.5 Case five.   
Case number five was female, Caucasian, aged 77 years with a BMI of 29.4, 
menopause age was self reported as 47 years.  Calcium and Vitamin D 
supplementation was commenced in 1998, and continued at a rate of 1 tablet 
per day, Alendronate was prescribed from 1998 to 2004, then restarted in 2012.  
No report was made of prodromal groin or thigh pain; however a right hip 
replacement was undertaken for osteoarthritis several years earlier.  Past 
medical history: past smoker, family history of hip fracture in sister, who was 
also diagnosed with osteoporosis, breast cancer diagnosed 2002, cervical 
cancer 2016, followed by bowel cancer in 2019, with known metastatic spread 
to liver.  On DXA scanning, a peak was seen on the lateral cortex of the left 
femur at around 200 mm from tip of greater trochanter, measuring 1.5 mm, as 
shown in figure 4.6.  This was viewed as suspicious, in the context of 
bisphosphonate treatment, and the patient was referred for bilateral femoral x-
rays.   
Figure 4.6 Case five with suspicious peak at 205 mm 









The x-rays and subsequent imaging report highlighted a peak at a similar point 
of the femoral shaft, but with a differential diagnosis of metastatic deposit, 
suggesting nuclear medicine imaging to confirm this.   
A radionuclide scan was performed which confirmed the presence of 
widespread metastatic disease, including the area of femoral midshaft identified 
as concerning on conventional imaging.  The patient declined further medical 
intervention.   
 
4.4 Ten year incidence data of AFF from hip fracture data 2008 – 2018. 
 
Statistics from NHS Grampian health intelligence data were reviewed covering 
the period between 2008 and 2018, for patients aged 50 years and over with an 
ICD 10 coding for femoral fracture.  This yielded a total of 7102 patients over 
the 10 year period.  From this, in accordance with the revised ASBMR definition 
of AFF [199], those with fractures of neck of femur (n. 483), pertrochanteric (n. 
1052) and multiple femoral fractures (n. 3) were excluded.  Itemised in figure 
4.8 are the numbers of patients whose imaging required further investigation, 
totalling 564.  This yielded a potential AFF rate of 2% when these fracture sites 
are discounted.   
Typically, AFFs are found in the subtrochanteric or femoral shaft region and 
should be coded as such using ICD 10 codes S722 and S723 for ease of 
identification.  It is possible some AFFs may be incorrectly coded as neck of 
femur, and therefore not identified by this study.  There were also several 
imaging sequences which were coded as shaft of femur, but when the 
radiographs and radiology reports were examined these were actually humeral 
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fractures.  One barrier identified to the extraction of AFF numbers from femur 
fracture data was the lack of an ICD code specifically for AFF.  Incorrectly 
coded fractures could lead to AFFs not being identified from health intelligence 
data. 
On assessment of clinical information and viewing radiographs, 13 patients 
were identified as suffering from AFF.  Eight patients were coded as having 
subtrochanteric fractures, four were coded as femoral shaft fracture and one 
coded as “fracture of femur, part unspecified”.  This was found to be within the 
subtrochanteric region on examination of radiographs.  The rate of AFF in NHS 
Grampian over the ten year period 2008 to 2018 was calculated as 0.18% (n. 
13) of the total number of patients aged 50 years and over and identified as 
having a femoral fracture (n. 7102).  A breakdown of fracture numbers per area 
over the ten year period is shown in figure 4.8.  The approximate annual 
incidence of femoral fracture within NHS Grampian is 0.15% of the population, 
or 710 fractures, with over 90% of these found at the femoral neck or 
pertrochanteric region.  All patients reviewed were over the age of 50 years, 
and with assessment of images flagged as femoral shaft fracture, in keeping 
with ASBMR criteria [199], which may have discounted patients with a fracture 
labelled as insufficiency, which appears to be how atypical femoral fractures 
have been reported historically in this health board if there is no record of 
bisphosphonate exposure.  These may exhibit elements of AFF but not 
considered for visual assessment as part of the data collection process, which 
potentially skewed the data presented.   
All patients affected were Caucasian, with a mean age of 74.9 years, 92% 
female, with only 15% of patients complaining of prodromal pain ranging from a 
few days to several months in duration.  Over half the patients affected had 
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been prescribed glucocorticoids, for various medical conditions.  All patients 
had been exposed to bisphosphonate therapy, although it was difficult to 
ascertain exact durations, from the information available the timescales vary 
from 2 – 13 years, with a median of nine years.  All fractures were repaired 
using intramedullary nailing, with 38.5% of patients suffering complications of 
non-union, fracturing of the nail or both.  Patient demographics are listed in 
table 4.6 .  One patient suffered a complete contralateral AFF at a similar level 
to the index fracture, a full thickness fracture which required intramedullary 
nailing around six months following the initial fracture.  On review, this was 
identifiable on the MRI imaging performed prior to surgical repair of the index 
fracture.  The area of abnormality is highlighted in figure 4.7 in red. During the 
period between the index and contralateral fractures, the patient continued on 
bisphosphonate medication.   
 
  
Figure 4.7 Magnetic resonance Imaging identifying contralateral iAFF of the 
right femur following index fracture of the left femoral shaft. 
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Patients in NHS Grampian over the 
age of 50 years who have sustained 
a femoral fracture in the last 10 years
n. 7102 




































Figure 4.8 Femoral fracture incidence in NHS Grampian between 2008 and 2018, separated to fracture regions. 
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Table 4.7 Available patient history of those identified with AFF within NHS Grampian 2008 to 2018. 
 
MOI – mechanism of injury, bisphos – bisphosphonate, IM – Intramedullary nail fixation of fracture, N/A – not applicable, Approx – approximately.   
Age  Gender Region  MOI Prodromal 
Symptoms 
Right/Left Steroid Use & Duration Bisphos Use & Duration Management Complications 
71 Female Subtrochanteric  Leg gave 
way 
No Right  N/A Yes – approx. 8 years  IM Non-union, IM 
nail fracture  
70 Female  Subtrochanteric  Fall  No Right  N/A Yes – approx. 8 years  IM Non-union, IM 
nail fracture  
72 Female Subtrochanteric  Fall Yes – left 
thigh pain for 
several 
months 
Left  Yes – insufficient 
information 
Yes – approx. 11 years  IM   
64 Female Subtrochanteric Leg gave 
way 
No Left Yes – approx. 20 years Yes – approx. 11 years  IM Non-union, IM 
nail fracture  
55 Male Subtrochanteric  Fall No Left Yes –  approx. 25 years  Yes – approx. 13 years IM  
80 Female  Subtrochanteric  Slipped, 
fell 
downstairs 
No Right N/A Yes – approx. 9 years IM Non-union, IM 
nail fracture  
88 Female  Subtrochanteric  Lost 
balance 
No Right  Yes – approx. 11 years  Yes – approx. 11 years IM Non-union 
75 Female  Subtrochanteric  Fall No Left Yes – 3 short courses in 
1 year 
Yes – insufficient 
information 
IM  
79 Female Shaft of Femur Fall No Right  Yes –  insufficient 
information 
Yes – insufficient 
information   
IM  
84 Female  Shaft of Femur  Fall No Left Yes – insufficient 
information   
Yes – approx. 3 years  IM  
80 Female  Shaft of Femur  Lost 
balance 
No Right  N/A Yes – approx. 2 years IM  
81 Female  Shaft of Femur  Lost 
balance 
No Left N/A Yes – approx. 9 years IM  
75 Female Fracture of 





Yes – right 
thigh pain 2 
days 






The section has focussed on the service evaluation and patient demographic of 
the service within NHS Grampian, presenting results of the population studies 
which have been undertaken in relation to the extended femur scanning 
software and its routine clinical use in the department.  The recent history of 
AFF within NHS Grampian gives a perspective on the scale of the rare but 
serious complication of AFF alongside the implications and complications of 
fracture repair in the patient cohort affected, and the likely association of 
bisphosphonate use and prolonged glucocorticoid use in this patient group.  
The next section will present the results of the use of the extended femur 

















5 Results – Departmental audits and in-vivo precision study. 
 
This section will provide an overview of the results gathered from the precision 
study, and related audits as detailed previously in methods section 2.  This 
forms part of the evaluation and assessment process of the GE Lunar extended 
femur DXA scan software. 
 
5.1 Femur scan positioning and technical analysis audit. 
 
30 scans selected at random from 5 operators across 4 scanners used within 
the department, as outlined in methods section 2.3.  Scans were analysed on 
criteria supplied by GE, which sets out expected standards for assessing 
proximal femur scanning, and for assessment of extended femur scans. 
The summarised results of the positioning and technical analysis audit are 











Table 5.1 Results of audit on femur scan positioning and technical analysis of 
30 extended femur DXA scans. 
Assessment criteria  Number correctly 
identified/scanned (%)  
Elimination of patella and supracondylar 
flare   
23               (77) 
Mid femoral line bisecting the femoral head 30               (100) 
Sufficient shaft of femur evident 30               (100) 
Acetabulum included fully in scan field 25               (83) 
Lesser trochanter minimised 30               (100) 
Elimination of ischium and greater 
trochanter from measurement area 
28               (93) 
Bone mapping accurate 29               (97) 
Neck of femur box correctly placed, at 90° 
to femoral neck, all corners in soft tissue 
28               (93) 
Is the femur vertical in the field of view 23               (77) 











The scan audit revealed that in most cases, scans were acquired and analysed 
















In several areas the audit identified good practice in 100% of scans: placing of 
the mid femoral line to bisect the femoral head, sufficient shaft of femur evident 
and lesser trochanter is minimised.  Over 90% of scans also demonstrated  
excellent bone mapping, with iscium and greater trochanter eliminated from the  
neck of femur measurement area, and the neck of femur box placed at 90° to 
the neck of femur line.  Several areas fell below the levels of 90% expected: 
placing the femur vertical in the field of view, elimination of patella and distal 
metaphysis of femur from the scan field, and the lack of full acteabulum from 
the scan area.  The positioning of the femur can be dependent on the patient 
Figure 5.1 Inclusion of patella in extended 
femur scan field, incorrectly identified as a 





habitus and ability to abduct and rotate hips, and therefore can be difficult to 
achieve in every situation.   
 
However, the positioning of the proximal femur and assessment of the lateral  
cortical border is reliant on best possible positioning to allow reproducibilty of  
measurements and subsequent results.  One operator appeared to misinterpret  
the training and scan start point, and purposely started scanning at a point more  
distal to the patella in order to include it in the scan image, as demonstrated in  
figure 5.1.  This has the consequence of the scan software attempting to  
measure the cortex of the patella, giving false positive peaks. 
In areas of less than 90% compliance, it was felt that patient habitus may have 
played a minor role in positioning of the femur, however the scan checklist used 
for audit of scan positioning and technical analysis found in appendix 9.10 has 
been shared among operators to ensure they can assess the quality of their 
scans as they are acquired, thus enabling repeat where necessary.  This 
checklist also includes the inclusion of acetabulum to the pelvic brim, and 
explanation that this facilitates the measurement of hip-axis length which is 
useful in some research settings.   
  
In-house individual training has already been undertaken to reinforce that 
operators should not include patella in the scan field, and use it only as a 
centring point for scan commencement.  The informal one to one training 
included the discussion of the difficulties that inclusion of patella creates for the 
extended femur scan software and the creation of artificial peak measurements.  
Further audit of this will be required to assess the efficacy of these measures, 




5.2 Visual assessment of extended femur scans for beaking. 
 
Four individuals experienced in viewing DXA scans independently visually 
assessed the lateral cortex of the femur from just below the level of the lesser 
trochanter to distal end of the shaft of femur on previously reported individual 
scans from the file provided.  An opinion was then recorded on whether any 
signs of suspicious lateral cortical thickening/beaking were visible, and record 
as yes/no on a spreadsheet.  This was based on the image alone, without 
viewing the beaking measurement tab of the scan software, no patient history, 
or consulting with colleagues, avoiding external influence.  The participant 
characteristics are similar to those of the precision study and also the 
population study in section 3.1. 
The results of visual assessments of 30 individual femur scans were collated as 
described in methods section 2.4, and compared with the results of the 
automated scan software measurement.  A summary of patient characteristics 
is displayed in table 5.2.  It was established from the data collected that there 
was no ground truth, as there was no agreement between viewers.  
Abnormalities of the lateral cortex of the femur are indicated as focal thickening 
at either the endosteal or periosteal edge of the lateral femoral cortex and 
peaks which are located between the lesser trochanter and the supracondylar 
flare at the distal femur [16].  These are the key areas measurable using 
densitometry, and do not rely on a fracture line being visible.  Should a focal 
thickening be identified on the lateral femoral cortex, additional imaging is 
recommended.  Based on scan software cortical measurements, 33% of scans 













n. 0  
(0) 
False positive 







n. 0  
(0) 
True negative 
n. 20  
(20) 
 
Table 5.2. Breakdown of DXA scan assessment of femoral cortex by four 
viewers, compared with automated scan software measurements. 
 
These results yielded a specificity result of 66.7%, with a confidence interval 
between 47.2% and 82.7%, and a negative predictive value of 100%.  No 
further imaging was undertaken in any of these cases, as visual assessment 
had been carried out at the time of reporting and all peaks > 1 mm identified as 
having been erroneously created by the scan software.   
Had further investigation been required, plain bilateral femoral radiographs are 
first line investigation, being cost effective and with good general availability.  
The largest peak size measured 3.7 mm, which was considered abnormal by 
one viewer.  This was identified as a software anomaly, not representative of a 




Table 5.3 Participant characteristics of peaks as assessed by four viewers. 
Height in cm, weight in kg, BMI kg/m², beaking index millimetres.   
 
The criterion for reviewing images assesses the scan image in conjunction with 
the AFF software revolves around the lateral cortex of the femur and specifically 
the periosteal border of the same.  Viewers were making assessment of the 
lateral cortex of the femur; ensuring continuity of the periosteum, with no 
abnormal lumps or bumps.  The periosteal border of the lateral cortex is 
highlighted in figure 5.3.  If any abnormalities are identified, are they in the area 
of the femoral shaft or subtrochanteric area?  Is there any indication of 
involvement of muscle insertion if the suspicious area is in the subtrochanteric 
region?  Is there anything in the patient history which would arouse suspicion of 
AFF – such as bisphosphonate use, glucocorticoid use?  Is there any history of 
previous femoral damage, even in childhood? 
 Male (10) Female (20) 
Median age yrs. (range) 68 (38 - 79) 71 (30 - 95) 
Median height cm 
(range) 
171.15 (162.5 – 183.5) 159.5 (151.3 – 168.2) 
Median weight kg 
(range) 
86 (68 - 108) 60.25 (40.5 – 113.5) 
Median BMI kg/m2 
(range) 
28.9 (24.1 – 35.3) 24.25 (17.5 – 42.2) 
Median Beaking Index 
mm (range) 

















Viewer one recorded 0 scans from 30 as having suspicious features of beaking 
on the scan, with the second querying only 2 of the images as having features 
worthy of further review.  There was less agreement between viewers three and 
four, where one identified eight images as having suspicious features, and the 
other finding three.  On visual assessment, none of the images used were 
thought to have suspicious features at time of scanning and reporting, however 
several of the images were considered as exhibiting false positive peaks as 
measured by the scan software.  Five of eight scans identified as abnormal by 
viewer four exhibited false positive peaks of greater than 1mm.  Findings of the 
assessment are presented in table 5.3.  Consequentially, an assessment was 
made of the position of the femur on each scan which was subjectively selected 
Figure 5.2 DXA scan image with the 






as displaying beaking, as it was felt that incorrect positioning of the femur may 
contribute these findings.  
Table 5.4 Beaking assessment of DXA scans by four viewers 







felt to be 
abnormal 
% scans marked 
abnormal which may be 
positioning related 
Viewer 1 30 0 0% - 
Viewer 2 28 2 7% 50% 
Viewer 3 22 8 27% 12.5% 
Viewer 4 27 3 10% 33% 
 
Percentage agreement was calculated at 89%, across all viewers.  Viewers one 
and two had 93% agreement across cases, where viewers three and four had a 
lower agreement at 63%.  Cohen’s Kappa scores for both groups were below 
zero, viewers one and two were -0.034, three and four -0.224.  The 95% 
confidence interval range was found to be -0.023 – -0.046 for viewers one and 
two, and -0.213 - -0.236 for three and four.  The calculation of Cohen’s kappa 
scores show a disparity in results, due to the method of calculation, where 
observed agreement and chance agreement are used to calculate a result, 
taking into account the potential for guessing by raters, leading to excessive 
lowering of agreement.  However in a clinical research environment a kappa 
score cannot be relied upon as a basis for changes to clinical practice, 
potentially having a negative impact on patient care and clinical outcomes,  
owing to its leniency and the implication that lower scores are acceptable [238].   




than chance between raters [234].  However as the sample size is at the lower 
end of assessment recommendations, the results produced are no better than 
coincidental, therefore unreliable; a much larger sample size is likely to give 
more accurate results [234].  As the scan assessments were all carried out by 
experienced staff, who were asked to give a yes or no answer to one question, 
the use of percentage agreement provides a more accurate overview of the 
visual analysis of beaking on extended femur scans.  This may suggest that 
there is a requirement for a more prescriptive checklist to be provided for scan 
assessment to ensure all viewers are assessing scans in the same manner.   
 
5.3 Scan analysis – software automatic beaking index measurement. 
 
A group of 30 randomly allocated single extended femur DXA scans were re-
analysed in triplicate, from across all scanners and operators within the 
department, as detailed in methods section 2.5.  Beaking index measurements 
were taken from automatic software scan analysis and recorded to one decimal 
place.  Scans were automatically re-analysed using the scan software on two 
further separate occasions to determine the reliability of the scan software.  All 
scans recorded identical measurements to one decimal place, exhibiting no 
precision error.  Measurement can only be taken to one decimal place on the 
scan viewing screen as this is the limit of the scan software.  This reassures 







5.4 Precision study. 
 
An in-vivo precision study of 30 patients referred for routine DXA scanning 
measured the short term operator precision of extended femur scans as 
outlined in methods section 2.2.  The study was undertaken using BMD 
measurements obtained at neck of femur and total hip, along with beaking index 
measurements on extended femur scans. 
 
5.4.1 Participant characteristics. 
The participant group for this study had an age range of 49-89 years, participant 
characteristics are displayed in table 5.4.  Male participants made up 37% of the 
total scanned, slightly higher than the 21% of total patients scanned from the 
general departmental data found in section 4.1.  Participants had a median age 
of 70 years, slightly older than the 66.4 years median age of those scanned in 
section 4.1 and had a median BMI of 26.8, similar to those in data collection 
with a BMI of 26.5.  Three female participants and one male participant were 









Table 5.5 Participant characteristics – in-vivo precision study. 
 Male (11) Female (19) 
Median age yrs. (range) 70 (49-78) 67 (49-89) 
Median height cm (range) 175.4 (163.6-177.6) 157.9 (148.5-175) 
Median weight kg (range) 86 (71-130.9) 68.75 (47.5-100) 
Median BMI kg/m² (range) 29.8 (24-42) 26.5 (20.4-36.8) 
Osteoporotic on scan (%) 1 (9.1) 3 (15.8) 
Osteopenic on scan (%) 3 (27.3) 13 (68.4) 
Normal BMD on scan (%) 7 (63.6) 3 (15.8) 
Patients with mean Beaking 
index >1mm (%) 
4 (36.4) 2 (10.5) 
 
 
5.4.2 Precision calculations. 
The results at both sites indicate precision to be well within the parameters set 
by the ISCD.  Accepted figures quoted by the ISCD for 95% least significant 
change (LSC) for femoral neck is 6.9%, and total hip 5.0% [236], as displayed in 
table 5.5, the actual figures for femoral neck precision of 5.68% and 3.96% for 
total hip measurement, again displayed in table 5.5 .  Least significant change is 
calculated by multiplying the RMS CV by 2.77, giving a 95% confidence interval, 
and represents the required change in measurements to indicate a true 
biological change in a patient, which cannot be attributed to measurement error.  




using the Bland-Altman method of 95% limit of agreement [239] and plotted as 
shown in figure 5.3. 
  
Table 5.6 In-Vivo precision study results at total hip and neck of femur BMD and 
beaking index values. 
 Total hip 
BMD 













    
RMS  - Root mean squared, SD – Standard deviation, CV – coefficient of 






Figure 5.3 Bland-Altman plot displaying the precision study beaking index, 
measurements in millimetres. 
 
As demonstrated by the Bland-Altman plot in figure 5.3, 28 of 30 duplicate 
beaking index measurements fell within two standard deviations (SD) of the 
mean, or 93.3%.  This is only marginally lower than the expected 95% of points 
falling within two SD of the mean [240].  Six participants exhibited a mean 
beaking index measurement greater than 1mm, and six 30 participants had a 
beaking index measurement difference greater than 0.5mm, quoted by GE as 
the error margin of measurements.  The error margin of the beaking index 
measurement using bench phantoms was set at 0.5mm by GE, with a caveat 
that measurement error may be higher in a clinical population [229].  This in-
lower limit of 
agreement






































Mean of beaking index measurements (mm)




vivo precision study found the mean of the measurements on human 
participants to be 0.5mm. 
 
5.4.3 Outliers in beaking index measurement. 
One set of beaking index scan results for a female participant demonstrated a 
software inaccuracy in identifying the cortex of the femur, displaying a result of 
4.2 mm in one scan, and 1mm in the subsequent scan.  This measurement of 
beaking index difference was found to be out with two standard deviations, 
attributed to erroneous placing of cortical borders by scan software, perhaps 
confounded by a slight change in patient positioning as shown in figure 5.4.  
 
Figure 5.4 DXA scan image 
showing duplicate scan with 








The second outlier was similarly placed, with the scan software identifying a 
thickening at the endosteal border of the lateral femoral cortex on one scan, as 




index measurements greater than 1mm; however no features suggestive of 










One of these images is shown in figure 5.5, demonstrating an irregularity in the 
positioning of the femoral cortical margin, where the endosteal border of the 
lateral femoral cortex is incorrectly identified by the scan software.  This created 
a step which the software analyses as a cortical thickening or peak. 
In some cases, there was substantial measurement variation between pairs of 
beaking index scans, no reason was found for this aside from erroneous 
placement by the automated scan software, as both scans appeared similar.  
An example of an automated software measurement creating false positive is 
demonstrated in figure 5.6. 
 
Figure 5.5 DXA scan image 
showing second outlier image 
with thickening on endosteal 




















This section has presented the results of the precision study and associated  
audits undertaken in the assessment of the extended femur scan software when 
used routinely in a clinical environment.  A discussion of the findings of both 
section three and four in the context of the available research and literature will  




Figure 5.6 Inaccurate software 







This body of work sought to investigate the incidence of AFF, underlying 
associations and the GE Lunar DXA extended femur scan software in clinical 
practice in NHS Grampian.  The discussion will compare the findings of these 
areas in the context of available literature and published research. 
 
6.1 Review of study aims. 
 
The motivation for this study was the evaluation and assessment, in routine 
clinical practice, of the extended femur scanning software developed by GE.  
This software is designed to be used as part of routine DXA scanning to identify 






The data collected within NHS Grampian found that the demographics of 
patients affected by AFF was broadly comparable to similar studies undertaken 
in terms of age, gender, lifestyle choices and risk factors.   
The age range of the group of patients identified in this body of work is in 
keeping with the findings of a 2013 retrospective study of radiographic imaging 




years [241], and slightly higher than that of a Korean-based study of post 
menopausal Asian women which found a mean age of 68.1 years [73].   
The available research indicates that AFF affect both sexes and although the 
incidence of both bisphosphonate use and AFF is lower in men, they should be 
included in any prospective or retrospective research.  The lower rates of males 
affected by AFF may be as a result of historically lower rates of DXA scanning 
in males, and association of osteoporosis as a women’s disease.  In a seminal 
study of bisphosphonate – related fractures [1], one of the nine patients 
included in the data set was male, who suffered from bilateral femoral shaft 
fractures having taken Alendronate for eight years previously, where BMD 
measurement had been osteopenic on commencement of therapy and 
remained so following cessation of treatment.  A retrospective review of two 
years of patient data from across UK hospitals found four males affected by 
AFF in the study period, with half of these patients not having bisphosphonate 
exposure.  It was noted however that of the five bisphosphonate naïve patients 
identified within the AFF cohort, one had glucocorticoid exposure and another 
had been taking methotrexate for psoriatic arthritis [242], no breakdown was 
available on patient gender.   
 Patients identified as suffering from AFF from collected data over 10 years 
within NHS Grampian were all found to have bisphosphonate exposure of 
varying lengths, which is not in keeping with data presented in the literature.  
Several other studies have identified patients with AFF who are bisphosphonate 
naïve, indicating that bisphosphonate use is not the sole mechanism for such 
fractures occurring [33, 212, 242].  In contrast, one study found the rate of AFF 
in patients not exposed to bisphosphonate was a rate of one per 150,000 




patients studied in this case was too low (7500) to identify non-bisphosphonate 
related AFFs [243].  This may be as a consequence of the inexperience of the 
viewers, the search criteria used, the images sent for adjudication to 
orthopaedics remaining unclassified, or a mix of all these reasons.   
 
The population identified as having iAFF on extended femur DXA scan in this 
study had a BMI significantly higher than the general scan population.  Obesity 
has been indicated as one of multiple risk factors for AFF in other studies, 
regardless of ethnicity, alongside bisphosphonate and glucocorticoid exposure 
[73, 244, 245].  This finding was supported by a retrospective study undertaken 
with an Asian population found that while patients with AFF had a mean BMI of 
25.1 kg/m² and not considered obese, they had a higher BMI than the study 
control group, who had a mean BMI of 23.5 kg/m² [246], suggesting that a BMI 
which is higher than the routine scan population is a significant risk factor.  
Evidence has been presented that a BMI >30 kg/m² can also have a 
confounding effect on DXA scan results, artificially altering BMD results at the 
hip area by +/- 2%, without certainty of whether this will elevate or reduce BMD 
[247].  There is a risk that this may lead to over (or under) treatment, where 
patients have a borderline hip BMD. 
Presented within the published literature is evidence which suggests patients of 
Asian ethnicity are more likely to suffer iAFF and AFF at an earlier age than 
their Caucasian contemporaries.  This theory is supported by a 2016 study 
undertaken in California of female patients taking bisphosphonate, also 
suffering an AFF, which found that Caucasian women were four years older 




interpreted with caution however, as it was indicated in the same study that 
Asian women were prescribed bisphosphonates around four years earlier than 
Caucasian women.  Ethnicity was not investigated as part of this body of work, 
as the geographical area is a settled Caucasian population and very few Asian 
patients were scanned, all of the patients found with AFF or iAFF were 
Caucasian. 
Each study documented in the available literature investigating the incidence 
and identification of iAFF/AFF used slightly different methodology and 
technology which makes direct comparison difficult, and this presented 
challenges in drawing any solid conclusions [73, 245, 248].  It appears in 
several studies that although the patient demographic was broadly similar in 
each, there were fundamental differences in the way each study was 
conducted.  The use of proximal femur DXA scanning extended to its full 
window will measure less than half of the shaft of femur, which would mean that 
a significant number of femoral shaft abnormalities could be missed [15, 249].  
An earlier study using the maximum scan length of conventional proximal femur 
DXA scanned 257 patients aged over 50 years, with bisphosphonate use of 
greater than 5 years [250].  The results found that 2.7% (n.7) of this specific 
population exhibited signs of iAFF on DXA imaging, which is high in comparison 
to the data acquired in this study.  This patient group was considered as high 
risk, having been prescribed bisphosphonate drugs for five years, which is also 
known to increase risk by around 0.22%, when treatment is extended out to 
seven years [251].  Scanning of no more than half the shaft of femur, without 
the benefit of scan software or program designed to aid the detection of such 
abnormalities will prevent visualisation of all defects within the femoral shaft 




Only two patients from the seven identified as exhibiting abnormality on DXA 
were subject to onward referral for orthopaedic intervention in the form of IM 
nailing, the other five appear to have had no follow up or intervention.  The 
authors accept that there are limitations to the study, small sample size, the 
specific group of patients chosen and the age restriction.  The software used is 
not specifically designed to identify all AFFs through the full length of the femur, 
as this is a small extension of proximal femur scanning, therefore there is 
potential for further cases to be missed due to the lack of full length imaging.  
Femoral shaft fractures account for anywhere from 47% to 63.2% of AFFs, 
commencing the scan just proximal to the supracondylar flare allows for 
greatest visualisation and therefore optimal benefit [4, 75, 98].   
 
A study undertaken in Sweden, which has a similar mainly Caucasian 
population, identified that 78% of patients with AFF had fractures in the femoral 
shaft, as opposed to the subtrochanteric area, highlighting the importance of 
visualising the full length of the femoral shaft [252].  This is comparable with the 
findings of a subsequent study which found 82.4% of iAFFs were located within 
the mid shaft area of femur [245], and similar to the iAFFs found within NHS 
Grampian using extended femur DXA scanning, 80% of which were mid shaft.  
It should be noted that there are numerous definitions of where measurements 
should be taken to classify a fracture as subtrochanteric, therefore it may be 
difficult to compare studies where a measurement definition has not been 
provided [241].  One European study found a dichotomy of fracture location, 
with subtrochanteric fractures more likely to occur in those with a median age of 




[241], very much in keeping with the ages of those patients identified in NHS 
Grampian between 2008 to 2018 suffering AFF.  
 
Other studies have used very specific high-risk populations which limits 
generalisability in a clinical population.  The findings of a 2013 study identified 
2.7% of a DXA scan population as having iAFF on radiological imaging [249], 
however in this 16 month prospective study, the patient group selected were 
identified as high risk of AFF, who had been diagnosed as osteoporotic and 
been taking bisphosphonate treatment for at least five years.  These patients 
were scanned using the maximum length proximal femur scan window using 
Hologic single energy scanners, and although the BMD results may not be 
directly comparable to those acquired from a GE Lunar dual energy scanner, 
the same principles apply to the cortical measurement and identification of 
iAFFs.  This study also found the rate of false positive to be over 4.5%, which 
although higher than the true positive rate, was much lower than the 20% false 
positive rate found using the GE Lunar scan software alone.  A subsequent 
study using Hologic scanners and long term bisphosphate users failed to 
identify any patients with iAFF on DXA scanning over a further period of 16 
months, using identical study methods to 2013 study [249], scanning 173 high 
risk patients with a view to requiring somewhere between 27 and 59 patients to 
find one iAFF [15]. 
There have been various methods documented in the measurement and 
analysis of the femoral cortices, with some using radiographs and measurement 
software, while others performed measurement on images acquired using DXA.  




to replicate using the extended femur scanning software, and also making direct 
comparisons virtually impossible.  A consistent and standardised approach to 
future studies involving extended femur DXA scanning would allow much closer 
comparisons to be made, with no detriment identified to the reproducibility of 
proximal hip BMD measurements by extending the scan length and therefore 
could be utilised as a screening tool for all patients [224].   
The difference between male and female beaking index results may be as a 
consequence of differing physical characteristics such as greater femur size 
and prominence of muscle insertion points in men [253], but there is no reason 
why this should affect the rate of peaks between male groups.  It has been 
suggested that cortical contouring at the level of the femoral gluteal insertion 
could present additional difficulty in identifying iAFF at this level, as callous 
identification may be masked [241].  This is compounded by the assumption 
that peaks seen in the subtrochanteric region of a DXA scan are muscle 
insertion points and therefore deemed insignificant and not investigated.  This 
may be the case in patient number three within the case studies in section 4.1, 
where a peak increasing in size was measured over serial scans. 
In a similar study, 173 patients who were all prescribed long term 
bisphosphonate therapy, almost 7% of participants had abnormal findings on 
extended femur scanning, a quarter of which were deemed to be prominent 
gluteus maximus insertion points, identified using CT imaging [15].  This study 
performed DXA imaging, then subsequently performed a single energy femur 
scan of each femur remaining in position as for proximal hip scan.  This adds to 
the time taken for the examination, and the radiation burden for the patient.  
Were the two examinations to be combined it would prove more efficient for the 




possible to answer the diagnostic question and to assess the femoral cortex 
[254].  The lack of any indication of AFF should not be considered as a reason 
to abandon the extended femur scanning software or practice, as somewhere 
between 3.2 and 5 per 100,000 person-years are predicted to be at risk of AFF 
[103].   
As identified earlier in the section, direct comparison between studies is 
challenging, as no study has been found that examines a general population 
using extended femur DXA scanning, irrespective of age, sex or 
bisphosphonate exposure.  There is also consensus that as femoral shaft 
imaging is novel for most patients, no definite link can be made between 
bisphosphonate and peaks, as no evidence is available to confirm or deny 
cortical thickening or abnormality prior to therapy commencement [227].   
Indeed, studies have identified atypical fractures in bisphosphonate-naïve 
patients [2, 4, 33, 75, 76], this is in contrast to the findings of ten year data 
analysis in NHS Grampian, where all patients had bisphosphonate exposure of 
varying duration, despite bisphosphonate use not being part of inclusion criteria 
at the time of the audit.  One study found previously unidentified beaking in 
around 8% of patients at bisphosphonate initiation, of unknown duration, 
although all patients had recently been prescribed bisphosphonates in 
conjunction with glucocorticoids.  This would suggest benefit in examining the 
entire shaft of femur prior to commencement of bisphosphonate or 







6.3 Performance of software in clinical practice. 
 
The extended femur scanning software provides an opportunity to combine 
cortical assessment of femur through an extended DXA scan covering the 
femur, in addition to routine bone mineral density measurements at the hip.  It 
has been established that this has no detrimental effect on the BMD 
measurements, and with the addition of less than two minutes to the 
examination time of a dual extended femur scan, and 37 µGy to the cumulative 
radiation dose, it is not a major burden of time or radiation for the patient or for 
service delivery.  It appears to be tolerated well by patients, with only minor 
adjustment to positioning and patient preparation required.   
The negative predictive value of scans can be used to reassure patients that 
there is no indication of damage to the femoral cortex caused by anti-resorptive 
treatments, indicated as a major reason for non-adherence, non-compliance or 
refusal of treatment [222].  There is real concern in the patient population of the 
dangers of bisphosphonate therapy, with regard to atypical femoral fractures 
and osteonecrosis of the jaw, with one study reporting an alarming 50% drop in 
bisphosphonate use over a four year period [255].  The findings of a study of 
bisphosphonate therapy benefits indicated a risk reduction of up to 32% after 
two years of therapy in patients with good compliance, in contrast to an 
increased risk of up to 50% in those non-compliant with prescribed 
bisphosphonates [222].  The same study also indicated that BMD measurement 
had a positive influence in compliance and persistence with bisphosphonate 
therapy, despite the side effects.  The risk of life-changing hip fracture is much 
greater than the risk of either of these rare but concerning side effects, with one 




the risk of intertrochanteric and femoral neck fractures after one year [200].  A 
similar study reported that although general fracture risk continues to decrease 
after 2 years of therapy, the risk of atypical femoral fractures, although still very 
small, is reported to increase by fifty times after compliant therapy with 
bisphosphonates [213].  A positive predictive value of 0.01% may seem low, but 
as the prevalence of atypical femoral fracture is very low in the measured 
population, these results may be skewed by the prevalence of AFF in the 
patient population scanned [256] .  A much larger sample size would be 
required to ascertain more accurately the prevalence of AFF, perhaps in a more 
targeted population such as those patients who have been on bisphosphonates 
for more than three years, with concurrent chronic glucocorticoid use, which has 
been identified as increasing the risk of AFF [257]. 
 
The scan software has been demonstrated to regularly misidentify peaks in the 
femoral cortex through incorrect automated positioning of cortical edges by the 
software, and supported by visual assessment of scans to confirm that this is 
false positive.  Visual assessment is carried out by the operator at scan 
acquisition and also by the individual writing the scan report, whether this is a 
specialist radiographer or a medical professional.  The lateral femoral cortex is 
examined from the level of the intertrochanteric line to the distal femoral shaft 
for anomalies or inconsistencies, with the recommendation that a comment is 
made on the scan report of whether the femur appears normal to the viewer.   
Caution should be applied to the misidentification of peaks by the scan 
software, as patients have not been sent for formal imaging to confirm or deny 




peaks greater than one millimetre, this would have led to approximately 600 
patients per annum being worried unnecessarily, additional pressures being 
placed on imaging services and a drain on NHS resources.  Based on the 
departmental feedback collected, GE agreed to investigate the issue alongside 
scan images and technical data, and have indicated a version upgrade will be 
provided of the current software in an attempt to reduce the likelihood of this 
occurring.  This was due to be released in 2020, however, in light of Covid-19 
pandemic, the upgrade has been delayed indefinitely.  In summary, there is a 
requirement for all scans to be visually assessed in conjunction with the scan 
assessment criteria in appendix 9.12 and the automated scan analysis, as 
already indicated reliance on the scan software would lead to over investigation 
in a huge amount of cases.   
 
6.4 Beaking index measurements in clinical practice. 
 
The software allows visualisation of the length of the femur, the purpose of this 
being primarily to measure the thickness of the lateral femoral cortex.  Benefits 
of this are the ability to identify irregularities of the femoral cortex measuring 
more than 1mm, allowing investigation using x-ray where appropriate.  The 
observation of scans is very subjective, and relies on sufficient training and 
experience to differentiate between software generated peaks and those which 
are genuine abnormalities of the femoral cortex.   
Beaking index measurements were collected in duplicate, however there is no 
data available in the published literature of similar works to provide a 




the only comparator available, and as this does not measure differences on a 
human population, caution should be exercised on direct comparisons.  Human 
tissue is mobile, and moving patients between scans causes a tissue 
distribution change, leading to inevitable differences between pairs of scans 
acquired as part of the in-vivo study, identified as especially relevant in patients 
who are overweight [258].   
This may go some way to explaining the anomalies found between beaking 
index measurements in three patients in which a beaking index difference was 
found to be greater than 1mm, as two of three of these patients had the highest 
measured BMI in the study group.  Evidence from other studies suggests that 
BMI is known to influence precision of DXA scanning [258, 259].  The third 
duplicate scan with measurement difference >1mm had a BMI within normal 
range, but on examination of the femoral cortex it was found the software had 
incorrectly identified the cortical border on one scan, and correctly on the other; 
this emphasises the requirement to visually assess the femoral cortex of all 
scans, as the automated measurements are not consistently reliable.  
It was found that the vast majority of the peaks identified by the software were 
false positives created by incorrect positioning of the cortical border, equating to 
around 20% of all scans performed.  On initial use of the software, these peaks 
were all flagged to the reporting consultant, who then had to study each 
individual and report accordingly.  Almost all of these scans demonstrated 
peaks which were clearly created by incorrect cortical identification by the 
software, as seen in figure 5.1.  It was agreed on software installation that 
initially all scans demonstrating peaks >1mm should be referred to the reporting 
consultant, regardless of the BMD measurement.  Most of the scans with peaks 




have been reported by the radiographer performing the scan, as per 
departmental protocol.  This had the consequence of adding to the reporting 
burden of the consultant, creating a backlog.  All radiographers are now trained 
and confident to perform the initial visual assessment of the extended femur 
scans and identify those where the software has incorrectly positioned cortical 
borders, minimising the number of scans which are sent for consultant 













When this was raised by the reporting consultant, additional training was 
undertaken to demonstrate the differences between true beaking and software-
manufactured false positives.  This involved viewing scans obtained within the 
Figure 6.1 A DXA scan with software 
inaccuracy in identifying the endosteal 





department, having asked all operators to note details of scans where they felt 
there were peaks which may be suspicious, those which they felt were false 
positives, comparing and discussing with the reporting consultant who gave her 
assessment on the peaks.  This allowed explanation of which peaks were 
considered suspicious and why, also giving detailed explanation regarding 
peaks on scans with no suspicious features, and how the groups could be 
separated.  It was also emphasised that if anyone found anything they felt was 
a true positive, that it should be raised with one of the rheumatology consultants 
at the first opportunity to allow prompt investigation.  These suspicious areas 
should be identified on the lateral femoral cortex below the level of the lesser 
trochanter, and the full length of the femur should be assessed for raised areas, 
peaks, pimples, a dark transverse line emanating from the lateral periosteal 
border or any other anomaly.  This can be observed at scan acquisition and 
discrepancies examined later at leisure before making a decision on whether 
any suspicion remains.  Discussion of suspicious or unusual cases with 
colleagues is also beneficial, sharing opinions and knowledge allows further 
development of general knowledge surrounding both the software and AFFs.   
 
Although not formally audited or assessed, this additional group discussion has 
resolved the reporting issue in the main, although there are still occasional 
scans being sent for consultant reporting that could have been reported by 
radiographers.   
The reanalysis of scans as part of the software assessment identified no 




operator to be confident that beaking index figures will not alter with scan 
reanalysis.   
When the data transfer from paper to electronic database was undertaken, 
some gaps in the data were found, along with some inconsistencies in recording 
patient CHI numbers.  When this was identified, all staff were reminded to 
double check their data, however one radiographer remained inconsistent in 
CHI number recording throughout the data collection period.  This was identified 
at the time of data input and corrected where possible, to allow the subsequent 
matching of scan result data and patient demographic data sets.  
 
6.5 Staff engagement. 
 
Some staff development issues were highlighted during the process.  These 
included initial staff buy-in of the extended femur scanning software, where 
there was a lack of awareness of the purpose of the software.  A short informal 
training session at each workstation was held with the GE engineer at the time 
of software installation.  This updated operators on the differences in the 
centring and scan starting point for the extended femur scan, minor changes to 
the screen prompts, and to emphasise that no change was required to the 
routine positioning for femur scanning.  A brief background was given on the 
purpose of the software, how the software worked to identify suspicious peaks 
on the lateral cortex of the femur using automated measurements, the 
information provided in the new AFF tab and what the internal process of raising 
concerns with the departmental manager/consultant reporting on any suspicious 




surrounding the use of scan software, patient preparation, positioning and scan 
start points.   
The first issue raised was resistance to the new software, as the scan time was 
extended.  In real time, the extended femur scans, if performed bilaterally, 
resulted in a maximum additional scan time of 114 seconds.  This caused some 
feelings of anxiety, especially in the initial period as operators familiarised 
themselves with slight alterations to scanning a much longer scan field.  Some 
operators reported difficulty in positioning the shaft of femur centrally in the field 
of view, while also having to include the acetabulum at the proximal end of the 
scan.  This resulted in the termination and restarting of the scan in an altered 
position, which lengthened the scan time, however operators conceded that 
with further use and experience, it became much easier to estimate the position 
of the acetabulum in relation to the femoral shaft, thereby minimising the 
requirement to reposition and repeat the scan.   
A specific issue was identified in one scan centre, where the operators 
repeatedly included the patella in the scan field, despite the clear instruction 
given that the patella was a centring point for the scan field, not an inclusive 
part of the scan.  One operator understood this to mean the patella was being 
missed off the scan as a software flaw, and started all scans at a lower point 
deliberately to include the patella.  The same operator insisted that a colleague 
should be doing the same, and it was only when this difference of opinion was 
raised among all operators that the issue came to light.  Agreement was shared 
among all operators that the patella was a centring point only, not for inclusion 
in the scan field.  This was assessed by a later audit, which found that 28/30 
scans were compliant in the elimination of patella and supracondylar flare from 




sessions, some operators were still uncertain how to position patients for the 
extended femur scans, and began to adapt technique inappropriately to include 
patella in the scan field.  The scan software gives on screen instructions on 
positioning for each scan, ensuring a common initiation point at the patella, from 
where the software will calculate a start point for scanning.  It was also 
established that where a patient may be able to slip trousers below the hip area 
for a scan previously, this was no longer feasible.  The trousers would have to 
be moved to below the knee to give full clearance for the scan, which in turn 
reduced the degree of femoral abduction that was achievable.  For this reason, 
one operator felt that it would be more appropriate to omit the use of the foot 
positioner rather than to ask the patient to change their clothing.  The reason 
cited for this was lack of time to change the patient and perform the extended 
femur scan.  This resulted in protocol deviation and potentially leading to 
confusion and complication should the patient require follow up scanning, where 
it would be virtually impossible to recreate the original scan position.  These 
scan deviations could be considered as teething troubles, however they may 
also indicate a requirement for a more formal training structure as initial training 
was ad-hoc and brief – no other scan centres in Scotland are utilising the 
software, and there is little practical experience in the knowledge and use of the 
software to refer to.  The applications specialist had no personal practical 
knowledge of the extended femur scan software, therefore all her training was 
theoretical, and relied on the supply of images of false positives and true 
positives from our department to discuss and also to feed back to GE.   
When these issues came to light, a further training session was organised on a 
one-to-one basis with the operator who was deemed to have the greatest 




scanning a routine patient clinic list, and suggestions made to improve practice, 
aid the analysis of scans acquired and explain the value of the extended femur 
scan, as well as answering any questions raised.  The additional time taken to 
complete the extended femur scan was identified as causing anxiety with some 
radiographers, especially those who were trying to include patellae in the scan 
field.  Once satisfied that this was not necessary, and further practical 
supported scanning experience using the extended femur scanning software 
was gleaned, protocol was adhered to and scan quality improved to previous 
levels.  It may also have been beneficial to have the GE applications specialist 
present when the software was initially used to ensure a structured approach to 
training in the new elements of the scan process, although the benefit may have 
been insignificant as she had little practical knowledge of the software and the 
provision of scan images may aid the software development in future.  
Following these issues, it was agreed that a face-to-face professional 
development meeting of all operators would allow all concerns to be raised and 
shared, reiterating the importance of the new protocol and what the software 
was looking to identify.   
Highlighted issues: 
1. Removal of inappropriate trousers is a necessity, rather than pulling 
down past hip area. 
2. Relevance of beaking/peaks identified on scan. 
3. Differentiation of true peaks and those manufactured by software – with 
some examples of software created peaks. 




5. The importance of identifying anything thought to be a true positive as 
soon as possible with the reporting consultant to allow review.  
 
These issues were resolved with in-house training sessions on a one-to-one 
basis, which allowed each person to ask questions and seek support based on 
their own needs.  This took place during a clinical scan list, allowing 
demonstrations of good technique and best practice with scan positioning and 
analysis.   
Explanation was made of the relevance of prodromal pain, which has been 
linked in numerous studies as an indicator of AFF, indeed it is one of the minor 
criteria for AFF specified by the ASBMR[199].  Prodromal pain was reported to 
affect almost 90% of study participants in a small retrospective study of nine 
AFF sufferers in India [98], however other studies have reported a much lower 
level of prodromal pain among participants, reported as 27% in a larger, longer 
running study of 86 patients [76].  Both studies agree that the sample size is 
small, but there is recognised difficulty in large scale recruitment for a rare 
condition.  Until the software was installed, no consideration was given to 
asking patients whether they had any prodromal pain.  This was addressed 
during the 6 month data collection, where every patient was asked if they had 
any groin pain.  Further to this, it is intended that the question be asked of each 
patient at every scan appointment, and the response recorded on the patient 
questionnaire.  In practice, this is not always recorded, in some cases it will only 
be recorded if the patient gives a positive response.  
Supplementing this, an applications specialist from GE spent a day with all staff 
running through the advanced software applications, emphasising the need for 




of serial scanning, which all felt aided in their understanding of the software 
processes and measurements.  A further audit of scan positioning and analysis 
is planned for 2020, which will give an indication of levels of compliance with 
training and development as previously delivered, however this has been 
postponed as scanning activity has been halted due to Covid 19 pandemic.   
 
6.6 Service recommendations. 
 
Several points for service development have been identified: lack of formal 
training in the use and evaluation of extended femur DXA scanning software, 
audit of scans, development of a formal training structure for extended femur 
scans, ongoing staff development in the identification of both true and false 
positive scans and the creation of an image set of scans as a reference base for 
future staff training and development. 
The auditing of positioning and technical analysis of extended femur scans 
should become routinely embedded in clinical practice, to be performed every 
three months, aiding the identification of any deviation from best practice and to 
identify ongoing training or support needs.   
At present there is no formal training structure available for the practical use 
and application of extended femur DXA scanning.  The ad-hoc nature of the 
training provided by GE at software installation allowed for slight differences in 
practice between operators, with no in-depth practical training or demonstration 
available.  The lack of practical use of the software by the engineer or the 
applications specialist meant they were unable to resolve some of the queries 




more formal training structure with recorded supervision may aid the elimination 
of differences in practice between operators, therefore improving consistency in 
scanning practice and analysis.     
Especially relevant to this would be the ability to identify false positives, based 
on scan presentation and the positioning of cortical borders placed by the scan 
software.  Some images in which the software appeared to misjudge the 
femoral cortex were anonymised and sent on to GE software developers in 
Europe for analysis as a basis for modifications to the software program.   
A compilation of images with irregularities and anomalies could be gathered and 
used as a basis for training and development, presenting images with both true 
and false positive peaks would allow operators to become more familiar with the 
visual appearance of peaks on images, and differentiating between real peaks 
and software generated peaks on DXA scan images.  The reference images 
found online for AFF and iAFF were all from radiographs or other imaging 
modalities, not extended femur DXA scans using the GE Lunar software 












6.7 Limitations of this work. 
 
Several limitations of this study have been identified.  The predominant ethnicity 
of the study area is Caucasian, as are the vast majority of all patients scanned.  
This affects the transferability of results across populations which are ethnically 
diverse.  It has been identified in several research papers that those at 
increased risk of AFF are of Asian ethnicity.   
There has been no identification of false negative extended femur scans in the 
short term, however this may change in future with prolonged use of the scan 
software.  There may be the possibility of missing an iAFF at the proximal femur 
around the area of the gluteus insertion point, where cortical thickening may be 
missed, or conversely a prominent muscle insertion may lead to over 
investigation.   
All the audits and precision study undertaken directly for this study have been 
reliant on small sample sizes, which limits the statistical power, and should be 
repeated on larger sample size to improve this. 
When assessing ten year data for potential AFFs, not all radiographs were 
reviewed, therefore some cases may have been missed.  As a consequence of 
this, the percentage quoted may under-represent the actual numbers of 
individuals affected by AFF in the time period, due to the absence of 
orthopaedic arbitration data.  Lack of patient notes and the relative inexperience 
of the retrospective reviewers in assessing images for AFF may also be 
potential weaknesses of this work.   
The lack of ICD coding specifically for AFF has also been identified throughout 




fractures.  The number of patients found with AFF identified from NHS 
Grampian health intelligence data may under-represent the actual numbers of 
AFF as several issues were found with missing or inaccurate ICD coding in 
common with several other studies examining AFF [5, 32, 153, 200].  Other 
confounding factors were non-specific wording of imaging reports and failure to 



















7 Conclusion and future research. 
 
This section summarises the conclusions of the studies undertaken, along with 




The precision study undertaken provides reassurance that total hip and femoral 
neck BMD measurements are not adversely affected by the use of the new 
software with scanning using the extended femur option.  The precision errors 
for the beaking index were much greater than those for BMD measurements 
from the same study.  The beaking index precision errors are above acceptable 
limits and underpin the recommendations made in this thesis for visual 
assessment of identified beaks without over-reliance on the software.    
The study explored the ability of the analysis software to accurately identify 
beaking.  The software made errors in 20 percent of the population and created 
what have been termed as false peaks, characterised as those peaks artificially 
created by the scan software.  It is recommended that the impact of false peaks 
can be minimised through visual assessment of the scan images in conjunction 
with the software measurements.  False positive peaks on scan images cannot 
be conclusively defined as such without further formal radiographic imaging, 
therefore reliance on the scan software alone would lead to over investigation in 
around a fifth of DXA scans performed in an adult population.  Visual inspection 
of the lateral femoral cortex has been demonstrated to be more effective than 




investigation, in addition to the use of the software assessment of the femoral 
cortex within the scan software.  As a consequence of the findings of this study, 
it may be prudent for GE to consider adding a warning to the extended femur 
scanning software both on the packaging and on installation/use alerting users 
to the requirement for visual assessment of scans in conjunction with the 
software assessment, especially if an automated report is produced highlighting 
the beaking index measured on the extended femur scans.  Specifically, 
abnormalities should be below the level of the trochanters, as documented by 
the ASBMR criteria [199], and consideration given to the lateral cortex of femur 
only.  Any raised area, peak, pimple or dark line should be assessed and 
considered in conjunction with the AFF software tab.  This should take place 
during scan acquisition and also at the time of scan reporting, and a statement 
should be made on each report on findings of the extended femur scan, even if 
entirely normal. 
Based on the evidence available on the finding of AFF and iAFF in patients who 
are bisphosphonate naïve, it may be prudent to consider scanning all patients 
over the age of 40 years using the extended femur scanning software.  There is 
little evidence of AFF occurring in patients below the age of 50 years.  To date 
no iAFF or AFF have been seen on extended femur scan patients in NHS 
Grampian who are bisphosphonate naïve or aged under 50 years, however the 
baseline scans being undertaken now provide a serial record of the femur, 
identifying any abnormality within the lateral femoral cortex, allowing monitoring 
and planned intervention prior to a fracture occurring.  Prophylactic nailing has 
been indicated as reducing patient recovery and healing time, pressure on 
traumatic orthopaedic services is minimised from this area and has a cost 




The average incidence of AFF in NHS Grampian over a ten year period was 
0.18% of all femoral fractures in patients aged 50 years and older, with all 
patients being of Caucasian ethnicity and having bisphosphonate exposure in 
keeping with a similar UK study [242].  The majority of these patients were 
female, with a mean age of around 75 years, and the bulk of the fractures were 
classified using ICD 10 coding as subtrochanteric.   
Training in the use and application of the extended femur scanning software 
should be considered as two phases; initial and ongoing, with audit suggested 
within three months of installation to ensure any digressions from gold standard 
positioning and scan technique are identified and addressed.  The lack of a 
formal training package from GE on the background and clinical use of the 
extended femur scan software was identified as a drawback in the initial use of 
the software program in a routine clinical DXA scan environment.  The ongoing 
training should include education around muscle insertions, which may cause 
peaks on scanning, but are not considered suspicious, and the presentation of 
false positive peaks.  The lateral cortex of the femur should be visually 
assessed from below the level of the trochanters to the supracondylar flare on 
each scan acquired, and any suspicious areas of cortical thickening or beaking 
highlighted.  Auditing of positioning and technical quality of extended femur 
scans should be repeated on a quarterly basis to ensure continuity and quality 
are maintained.  This is especially relevant when new operators are introduced, 
or where scan equipment or software is upgraded. 
Additional time taken for scans is minimal, but in the advent of service redesign 
and waiting times management post Covid-19 pandemic, this may be an area of 
cutback due to time pressures.  If this is the case, recent moves toward 




site and concomitant medications as recommended by the SIGN guidelines [29] 
may lead to over-treatment, risking a future increase in iAFF and AFF.   
 
 
7.2 Future research. 
 
There has been no investigation of false negative extended femur DXA scans in 
clinical practice, classified as patients who have no indication of 
peaks/irregularity on extended femur DXA scan who subsequently suffer an 
AFF.  As AFFs are rare events, and the extended femur scan software has only 
been in clinical use for a short time, no false negative scans have been 
identified.  This may change in the longer term, and a study of false negatives 
may only be possible in a large scale, multi centre study including many 
thousands of patients and DXA scans, which is outwith the remit of this small 
scale research.   
A large scale in-vivo precision study encompassing all operators and scanners 
associated with the department would add statistical power to the work already 
completed, provide ongoing quality assurance and ensure consistency 
throughout the department.  This work would be valuable in assessing the LSC 
of newer members of staff, who have not yet had this assessed; particularly 
relevant as two operators have retired and been replaced in the process of this 
research study. 
There is no formal education or training structure available for the use and 




a short core training module which introduces the software, its uses in a clinical 
setting and evaluation of the scans acquired.  With the addition of DXA scan 
images of software and bone irregularities, true and false positives and 
descriptions, this could provide a resource for operators to refer to for reference 
purposes and continuing development.   
It may be prudent to devise and refine a set of criteria specifically for the 
assessment of false negative scan peaks, which operators can use to check 
scans as they are acquired.  There is also the possibility of then re-auditing 
some areas of technical assessment, positioning and scan analysis to measure 
any change in operators and viewers perception of images.  
As the duration of software use increases, the use of DXA may aid the 
identification of pre-existing defects within femoral shaft, and measurement can 
be made of cortical thickening, allowing monitoring of serial scan data to predict 
iAFF.  The collection of iAFF data from DXA and AFF on radiographic imaging 
over a specified time period would allow comparison of iAFF and AFF rates in 
parallel.  
There are various studies of genetics and osteoporosis, an area still in its 
infancy, and it may be valuable to perform gene sequencing using samples 
obtained from patients with iAFF as a further study route in identifying genes 
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9 Appendix section. 
9.1 Patient information sheet  
 
    
  
 
Participant Information Sheet 
 
 
Title of Project: Short-term precision study of dual energy x-ray 
absorptiometry (DXA) bone density scanning of the extended femur scan 
for atypical femoral fracture in routine clinical population. 
 
Chief Investigator: Karen Knapp 
 
 
Invitation and brief summary: 
  
We would like to invite you to take part in a research study. Before you decide 
you need to understand why the research is being done and what it would involve 
for you. Please take time to consider the information carefully and to discuss it 
with GP, family or friends if you wish.  Please ask the researchers any questions 





Measurement of bone mineral density (BMD) by DXA scanning is routinely used 
to diagnose osteoporosis (thinning bones).  It also measures how well treatments 
are working. When we compare scans it is important to be able to tell the 
difference between real changes in you and those made by measurement 
process itself.  This is known as the reproducibility (precision) of measurements.  
This is an extension of our current scanning software and because it hasn’t been 
used by us before, we don’t know how reproducible these measurements are.  
We would like to test this by scanning your thigh bones twice, with you getting up 
of the scanning couch between scans. We want to see if there is any change is 
between two scans of your whole femur bone.  We can do this by comparing 
scans of 30 patients aged 20 years and over.   
 
Anyone referred for a DXA scan at Ashgrove House, Foresterhill, Aberdeen could 
be asked if they would like to take part in the study.  Routine care means having 
one DXA scan of the lower spine and extended femur (thigh bone).  We want to 
see if there is any change in the measurement precision between two scans of 
your thigh bone.  Each person who participates in the study will receive an 
additional scan of both thigh bones. 
Appointment times are 30 minutes long and one visit only.  There is no further 
follow-up except for your routine clinical care. 
It is sometimes necessary to compare our scan measurements over time. This 
helps doctors to decide whether to start or stop treatment. When we compare 




changes related to the scan process.  This includes the reproducibility (precision) 
of measurements taken.  
The skill of the radiographers performing the scans affects the precision of the 
measurements.  Their ability to position a patient for the scan is the biggest 
source of change.  A test of this is best made by scanning a sample of people, in 
this case 30.  This allows us to tell more accurately if the changes we see in the 
femur bone are significant.  This is important to make sure we are provide all our 
patients with the best possible care. 
Purpose of the research:   
 
The aim of this study is to determine the precision error, or reproducibility, for 
measuring the outer edge of the femur bone.   This will help ensure best care for 
patients attending Grampian Osteoporosis Service, and will form part of an 
educational award for a Masters degree in Medical Imaging.  
 
 
Why have I been approached? 
 
We are inviting all patients over the age of 20, who have not had both hips 
replaced to take part.  If you have had both hips replaced you will not be able to 
participate. 
 
Do I have to take part? 
 
No, it is up to you to decide whether to take part.  If you decide to take part, you 




withdraw at any time, or a decision no to take part, will not affect the standard of 
care you receive. 
 
What would taking part involve?  
 
Taking part would involve a second extended femur scan being done at the same 
time as your routine appointment.  You would need to get up from the scanner 
and then lie down again between scans.  No additional time or further visits are 
required.  If you decide to take part, you are still free to withdraw at any time and 
without giving a reason. If you do not want to take part, or change your mind, you 
will still receive the bone density scan requested by your doctor, but the second 
scan will not be carried out. This will not affect the standard of care you receive 
now or in the future.   Everything else done during the appointment is part of 
standard clinical care.  This is described in the scan information leaflet sent out 
with your letter. 
 
What will I be asked to do if I decide to take part? 
 
You will attend for the bone density scan requested by your doctor at the time 
and date stated in your appointment letter. You may be asked by the radiographer 
if you wish to take part in the study. If you agree, you will be asked if you have 
read and understood this information sheet.  You have the opportunity to ask any 
further questions.  You will then be asked to read and sign a consent form, you 




When you attend for your appointment, the radiographer will check your name, 
date of birth, and address with our records.  Your height and weight will be 
measured.  We will chat about the details of the ‘osteoporosis questionnaire’ that 
you received in the post with your appointment letter and the answers entered 
into the DXA computer.  
You will be asked to lie flat on a firm couch whilst the arm of the scanner passes 
over you to take the images.  It does not involve going into a ‘tunnel’ or having an 
injection.  The areas routinely scanned are the lower back and extended femur. 
 The lower back and extended femur scan are performed as routine care.  After 
this first scan, you will be required to come off the scanning table and back on 
again to be repositioned for the second study scan of the extended femur.  
The scan appointment will take approximately 30 minutes and the extra extended 
femur scan will be done during your routine clinical appointment. You will not be 
required to attend for any further appointments as part of the study. 
 
What are the possible benefits and disadvantages of taking part? 
The study has no immediate benefits for you.  Your participation will help us 
understand how extended femur measurements taken on our scanners may 
differ.  It will also help us to know what the reproducibility (precision) of these 
measurements is. This enables us to more accurately report changes over time. 
This can inform important decisions such as stopping or starting treatment.   
If you take part in this study you will have an additional scan of your extended 
femur performed.  This will be extra to those that you would have if you did not 




and provide clinical information.  Ionising radiation can cause cell damage that 
may, after many years or decades, turn cancerous.  We are all at risk of 
developing cancer in our lifetime.  The normal risk is that this will happen to about 
50% of people at some point in their life.  Taking part in this study will add only a 
very small chance of this happening to you.  To put this risk into perspective it is 




What will happen to the results of my bone density scan? 
The bone density scan performed as part of your routine clinical care will be 
reported in the usual way and a copy of the report sent to your GP and filed 
electronically in your medical notes. The extra extended femur scan taken as part 
of the study will be stored in the usual way alongside the first scan. The extended 
femur measurements from these scans will be used as part of the study. 
 
 
What will happen to the results of the study? 
They will be presented at conferences and written up in journals and publicly 
available for you to see on the University of Exeter website 
https://ore.exeter.ac.uk/repository.  Results are normally presented in terms of 
groups of individuals. If any individual data are presented, the data will be totally 
anonymous, without any means of identifying you as an individual and to protect 





How will my information be kept confidential? 
The University of Exeter is the sponsor for this study based in the United 
Kingdom. We will be using information from you in order to undertake this study 
and will act as the data controller for this study. This means that we are 
responsible for looking after your information and using it properly. The University 
of Exeter will keep identifiable information about you for 5 years after the study 
has finished.  There will not be any transfer of identifiable patient data between 
NHS and Uni.   
Due to recent regulatory changes in the way that data is processed (General Data 
Protection Regulation 2018 and the Data Protection Act 2018) the University of 
Exeter’s lawful basis to process personal data for the purposes of carrying out 
research is termed as a ‘task in the public interest’. The University will endeavour 
to be transparent about its processing of your personal data and this information 
sheet should provide a clear explanation of this. If you do have any queries about 
the University’s processing of your personal data that cannot be resolved by the 
research team, further information may be obtained from the University’s Data 
Protection Officer by emailing dataprotection@exeter.ac.uk or at 
www.exeter.ac.uk/dataprotection. If you have any concerns about how the data 
is controlled and managed for this study then you can also contact the Sponsor 
Representative, Pam Baxter, Senior Research Governance Officer, whose 
details are at the end of the information sheet. 
We will collect your name, address and contact details and information about any 
relevant clinical conditions, medication and additional personal data such as date 




securely in the study files and on an encrypted University of Exeter laptop, and 
scan data on our encrypted NHS scanning computers. The files will be protected 
in a locked room within the DXA department with only research team having 
access. The building which houses all the research data is security protected by 
the NHS.  When the data is stored the name and addresses will be removed from 
the data so that it can be identified only by an ID code (pseudonymised) and the 
data will be stored for no more than 10 years. This pseudonymised data will be 
shared with staff at the University of Exeter.  When the results of the study are 
analysed individual participants will not be identifiable in order to protect their 
confidentiality. The data will be accessed and analysed only by the researchers, 
the supervisors of the research and research auditors. You are welcome to 
request a copy of the results of the project. With your consent, we will inform your 
GP that you have taken part in this research. 
 
Your rights to access, change or move your information are limited, as we need 
to manage your information in specific ways in order for the research to be reliable 
and accurate. If you withdraw from the study, we will keep the information about 
you that we have already obtained. To safeguard your rights, we will use the 
minimum personally-identifiable information possible. 
 
Who is organising and funding this study?  
This study is sponsored by the University of Exeter, no funding is required. 
Who can I approach if I have a complaint about this study? 
If you have a concern about any aspect of this study, you should ask to speak to 




details are shown below. If you remain unhappy and wish to complain formally, 
you can do this via the NHS Grampian feedback service based at Summerfield 
House. They can be contacted on 0845 3376338. 
 
What will happen if I don't want to carry on with the study? 
 
You can stop taking part in the study at any time without giving a reason and 
without any disadvantage to yourself of any kind. If you decide that you wish to 
stop taking part in the study then all of your research data and any personal data 
that has been collected in order for you to participate will be securely destroyed 
and will not be used in any write up or publication about the study.  Once the data 




Will I receive any payment for taking part? 
 
No payment will be made to participants.  
Who is organising and funding this study? 
 
This research is being Sponsored by University of Exeter and supervised by Prof 
Karen Knapp. 
 





This project has been reviewed by the North of Scotland research Ethics 
Committee (1) and NHS Grampian R&D.  
 
Contacts for further information 
If you have any questions or would like some more information about the study, 
please do not hesitate to contact us: 
Mrs Diane Smith 
Specialist Radiographer 
Grampian Osteoporosis Service 
Ground Floor 
Ashgrove House 
Aberdeen Royal Infirmary 
Aberdeen, AB25 2ZN 
Tel: +44 (0) 1224 550820 
Email: diane.smith26@nhs.net 
Dr Rosemary Hollick 
Consultant Rheumatologist  
Grampian Osteoporosis Service 
Ground Floor 
Ashgrove House 
Aberdeen Royal Infirmary 
Aberdeen, AB25 2ZN 




If you wish to talk to someone who is independent of the study team, please 
contact Ruth Garside 01872 258148. 
If you feel your treatment either prior to, during or after the study is of concern to 
you in any way, or if wish to complain, please contact the supervisor for the 
research, Dr Karen Knapp on 01392 264133. 
If you have any questions related with Ethical concerns or data management, 
please contact the Research Ethics and Governance Office of the University of 




Research Governance Officer who can be contacted by e-mail 
p.r.baxter2@exeter.ac.uk or Tel: 01392 723588. 
 




















9.2 Patient letter  
    
  
Grampian Osteoporosis Service 
 Ground Floor 
 Ashgrove House 
Aberdeen Royal Infirmary 
Aberdeen, AB25 2ZN 
 






Dear [Recipient Name] 
 





Short-term precision study of extended femur scans using DXA scanners 
in routine clinical practice. 
 
We are looking to recruit 30 volunteer patients to help us complete this study.  
You are invited to have a second extended femur (thigh bone) scan, in addition 
to the scan you are scheduled to attend for.  This will be undertaken during the 
same appointment, lasting around 30 minutes in total. Dual Energy X-Ray 
Absorptiometry (DXA) is currently the most accurate and reliable method used to 
measure bone density and is a simple and painless procedure. 
 
This study will help us to understand if the changes we see in a patient’s 
measurements are real, or simply represent the fluctuations in the measurement 
itself due to differences in the scanning technique of our radiographers. It will help 
us more accurately report changes in bones when comparing scans over time. 
This can inform important decisions such as stopping or starting treatment.   
 
 
Further information about this, and about the study, are included in the participant 
information sheet accompanying this letter. If you do not wish to participate it will 
have no effect on the care you receive, you should still attend for the appointment 
you have been sent. If you are interested in taking part in this study, please let 





























9.3 Patient consent form In-vivo precision study 
 






Short-term precision study of dual energy x-ray absorptiometry (DXA) 
bone density scanning of the extended femur scan for atypical femoral 
fracture in routine clinical population. 
 
Chief Investigator: Karen Knapp       
         Please initial box 
 
1.  I confirm that I have read and understood the information sheet (version 1.1 
dated 2nd December 2019) for the above study.  I have had the opportunity to 







2.  I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving reason, without my medical care or legal rights being 
affected, either now or in the future.  
 
3.  I understand that data collected during the study may be looked at by 
individuals from the University of Exeter, regulatory authorities or from the NHS 
Board/Trust, where it is relevant to my taking part in this research.  I give 
permission for these individuals to have access to my records. 
  
4. I understand that taking part involves anonymised clinical data from my DXA 
scan being used for the purposes of this research study.   
 
5.  I understand that the anonymised data will be securely stored for 10 years 
after the study has ended. 
 
6.  I understand that the anonymised data from the study may be used for 
presentations and publications. 
 
7.  I agree to take part in the above study. 
 
8.  I agree to being contacted by post or email with a summary of the findings of 















Name of Researcher   Date     Signature 
taking consent       
 
 









       
   
 
 
FULL/LONG TITLE OF THE STUDY 
 
Short-term precision study of dual energy x-ray absorptiometry (DXA) bone 
density scanning of the extended femur scan for atypical femoral fracture in 
routine clinical population. 
 
SHORT STUDY TITLE / ACRONYM 
Short term precision of extended femur scans using DXA. 
 
PROTOCOL VERSION NUMBER AND DATE 
 Version 1.0 8th November 2019 
RESEARCH REFERENCE NUMBERS 
 













The undersigned confirm that the following protocol has been agreed and 
accepted and that the Chief Investigator agrees to conduct the study in 
compliance with the approved protocol and will adhere to the principles outlined 
in the Declaration of Helsinki, the Sponsor’s SOPs, and other regulatory 
requirement. 
I agree to ensure that the confidential information contained in this document 
will not be used for any other purpose other than the evaluation or conduct of 
the investigation without the prior written consent of the Sponsor 
I also confirm that I will make the findings of the study publically available 
through publication or other dissemination tools without any unnecessary delay 
and that an honest accurate and transparent account of the study will be given; 
and that any discrepancies from the study as planned in this protocol will be 
explained. 
 





Name (please print): Ms Pam Baxter   










Name: (please print): 
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Study Title Short-term precision study of dual energy x-ray 
absorptiometry (DXA) bone density scanning of the 
extended femur scan for atypical femoral fracture in 
routine clinical population. 
Internal ref. no. (or short title) Short term precision of extended femur scans using 
DXA 
Study Design In vivo precision study. 
 
Study Participants Patients >20 years routinely attending for DXA scanning 
at Grampian Osteoporosis Service at Ashgrove House, 
Aberdeen Royal 
Infirmary 
Planned Size of Sample (if 
applicable) 
30 participants  
Follow up duration (if applicable) None 
Planned Study Period 9 months 
Research Question/Aim(s) 
 
The aim of this study is to determine the precision error, 
or reproducibility, for measuring the outer edge of the 
femur, found using extended femur scan software as 
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ROLE OF STUDY SPONSOR AND FUNDER 
 
This research is being sponsored by the University of Exeter and supervised by 
Dr Karen Knapp.  
Role of Sponsor 
The study sponsor will ensure that the research team has access to resources 
and support to deliver the research as proposed and that responsibilities for 
management, monitoring and reporting of the research are in place prior to the 
study commencing. The sponsor will ensure that there is agreement on 




proceeds and approve any modifications to design, obtaining requisite 
regulatory authority. 
The sponsor will assume responsibility for operating the management and 
monitoring systems of the research. 
Prior to the study commencing the sponsor will be satisfied that: 
 The research will respect the dignity, rights, safety and well-being of 
participants and the relationship with healthcare professionals. 
 Where appropriate the research has been reviewed and approved by an 
NHS Research Ethics Committee and/or the Health Research Authority 
Approval Programme. 
 The Chief Investigator, and other key researchers have the requisite 
expertise and have access needed to conduct the research successfully. 
 The arrangements and resources proposed for the research will allow 
the collection of high quality, accurate data and the systems and 
resources will allow appropriate data analysis and data protection. 
 Organisations and individuals involved in the research agree the division 
of responsibilities between them. 
 Arrangements are in place for the sponsor and other stakeholder 
organisations to be alerted to significant developments during the study, 
whether in relation to the safety of individuals or scientific direction. 
 There are arrangements for the conclusion of the study including 
appropriate plans for the dissemination of findings. 
The sponsor plays no role in the design of this study, and will have no role in 






 Contributors to the protocol are Dr Karen Knapp, Dr Chris Wright, Dr 
Rosemary Hollick and Diane Smith.  
 
 
KEY WORDS: Osteoporosis  
Atypical femoral fracture 
Bisphosphonates 
Extended femur scanning 




STUDY FLOW CHART 
 
What? When? Period of time? 
Patient invitations sent October/November 2019 
approx 
5 weeks approx 
Study scans December 2019 – January 
2020 
3 weeks approx 








Short-term precision study of dual energy x-ray absorptiometry (DXA) bone 
density scanning of the extended femur scan for atypical femoral fracture in 
routine clinical population. 
 
BACKGROUND 
Measurement of bone mineral density (BMD) by Dual Energy X-Ray 
Absorptiometry (DXA) is the gold standard imaging modality routinely used to 
diagnose osteoporosis (thinning bones) and monitor response to treatment. 
When comparing scans it is important to distinguish between real changes in 
patients opposed to changes related to the measurement process itself e.g. the 
reproducibility (precision) of measurements.  
Interest has arisen in the use of software developed by DXA scanner 
manufacturers General Electric (GE) Lunar in 2015, which is routinely used 
during a DXA scan, to identify irregularities on the lateral cortex of the femur.  
This potentially allows the identification of cortical lesions at an early stage, as 
part of routine clinical scanning, with no detriment to bone mineral density 
measurement at the hips[224]).  GE have conducted test scans using phantoms 
with simulated beaking to establish an in vitro precision error margin of 0.5mm, 
however these phantoms are not available to us to utilise.  Phantoms under-
estimate the actual precision errors in-vivo because they lack the biological 
range found in humans.  There have been no published studies found that have 
undertaken precision measurements using this software in a human population. 
The software incorporates the ability to measure the thickness of the lateral 
 
 
cortex of the femur, using serial measurements over time to assess change in 





The aim of this study is to determine the precision error, or reproducibility, for 
measuring bone cortex of the outer edge of the femur bone using human subjects 
as described above.   This will help ensure best care for patients and develop 
further resources within the medical imaging community.  It will also form part of 





The aim of this study is to determine the precision error, or reproducibility, of the 
scanner for measuring the outer edge of the femur and any identifying any 
areas of thickening. Thickening, or "beaking" is classified as an area of 
thickening, occurring on the outer edge of the shaft of femur. This will help 
ensure best care for patients and will form part of an educational award for a 






To determine the in-vivo precision error of femur cortex measurements using 
DXA scan.  
STUDY DESIGN and METHODS of DATA COLLECTION AND DATA ANALYIS 
 
 
We look to recruit 30 participants for inclusion in the study.  It is estimated that 
we will send information to around 75 patients, assuming that approximately 
50% of patients will participate. It is suggested that 30 participants be scanned 
to obtain statistically valid results (Gluer et al., 1995). 
 
All eligible participants will be sent a participant information sheet and a 
covering letter in addition to their standard clinic appointment letter and 
osteoporosis questionnaire within the same envelope. These are routinely sent 
out around 6 weeks in advance. 
 
Each patient will attend for one routine scan appointment, which will be 
approximately 30 minutes in length. 
On the day of the appointment, potential participants will be approached by a 
suitably qualified member of staff and asked if they have read and understood 
the information sent out. They will then be asked if they would be willing to 
participate. Any questions or queries will be discussed.  If the patient is happy to 
participate, consent will be gained in writing, a copy of the completed consent 
form will also be given to the patient to take away with them. 
 
All participants will have their name, address and date of birth checked with 
departmental records, measurement of height and weight, and discussion of the 
 
 
standard osteoporosis department questionnaire with the radiographer in 
private as part of routine care. These will be recorded in the secure DXA 
scanner computer, also part of routine clinical care. 
 
The participant will then be asked to lie on the scanner bed, and have scans 
taken of each extended femur individually, then a scan of the lower spine (three 
individual scans) as per standard practice. The scanner arm passes over the 
body and takes images as it does so. This does not involve any injections or 
going into a tunnel. 
  
After this process, the participant will be asked to rise form the scanner bed, 
then lie back down. This mimics a patient returning for a second scan and is 
considered best practice for short term precision scans.  A further scan of each 
extended femur will be taken (two additional scans). 
Following this, the participant is free to leave, with no further study follow up 
required.  They will be provided with a clinical diagnosis via the referring 
clinician as per our standard protocol, but they will not be given precision error 
results.   
 
Personal data from participants will be identified by the direct clinical care team. 
The personal data, including scans, of all patients attending the service for a 
DXA scan are stored on a secure NHS server that complies with NHS data 
protection, security and confidentiality policies. The additional DXA scan 
performed as part of the study will be captured and stored in the same manner 
as routine clinical scans. Only those with appropriate access controls i.e. 
members of the direct clinical care team will have access to this. 
 
 
All data collected from the study DXA scans will be pseudonymised. Data of 
from the extended femur will be collated along with the age range and gender 
mix of those scans. This will be stored on a secure NHS server. This file will not 
contain any personal data of participants and will be pseudonymised by means 
of a unique code, stored on a separate file on the secure NHS server, linking 
the non-identifiable data to the original DXA. 
No identifiable patient data will be transferred from NHS server or outwith the 
direct clinical care team. 
Pseudonymised data will be stored and analysed on a University of Exeter 
computer by members of the research team, which is password protected and 
accessible only be the research team. 
Consent forms will be kept in the study file, stored in a locked filing cabinet 
within the Grampian Osteoporosis Service. 
The filing cabinet can only be accessed by members of the direct healthcare 
team. The department has restricted access to authorised personnel via a 
keycard.  
 
Patients will be assigned a unique identification number. The information that 
links the ID number to participants’ personal data will be kept separately and 
securely. Hard copies of consent forms will be kept in locked filing cabinet and 
electronic data kept on a password-protected spreadsheet in the secure NHS 
Grampian server. The personal data will be kept separately so that only 
approved staff members of the research team who have need to use personal 
data will have access to the information linking ID numbers to participants, or 




All information and data will be handled and processed in accordance with the 
Data Protection Act 2008 and the General Data Protection Regulation.  
Pseudonymised data will be analysed by researchers at NHS Grampian and the 
University of Exeter in Aberdeen under the direction of the chief investigator.  
Descriptive statistics (mean and standard deviation) to describe the patient 
population (age, gender, height, weight, body mass index (BMI) kg/m2, beaking 
measurements, bone mineral density (BMD) in g/cm2, T-scores) and 
comparison with mean age and gender of standard patient population, 
calculated from 2018/2019 departmental referral data. 
 
The pseudonymised research data will be archived according to University of 





Anyone referred for a DXA scan at Ashgrove House, Foresterhill, Aberdeen could 
be asked if they would like to take part in the study.  Routine care means having 
one DXA scan of the lower spine and extended femur (thigh bone).   
 
 





Inclusion criteria:  
All patients >20 years routinely attending the Grampian Osteoporosis Service at 
Ashgrove House, Aberdeen Royal Infirmary, for DXA scan are eligible for 
inclusion. The request for DXA scan will be made by the referring physician and 





Patients <20 years of age. 
Patients unable to give consent. 
Patients who have had bilateral hip surgery. 





To obtain statistically valid results, multiple determinations of femur scanning 
are performed for a specific anatomical site e.g. femur. The mean 
measurements are then determined.  
 
 
6.2.1  Size of sample 
 
 
It is recommended that precision testing be performed to allow for 30 degrees of 
freedom to ensure that the upper limit for the 95% CI of the precision error is no 
more than 34% greater than the calculated value. Since one of the 
measurements on a specific patient does not contribute independently to 
calculation of the mean result for that individual, it is recommended to perform 2 
extended femur measurements on 30 individuals.  It is recommended that 
precision testing be performed to allow for 30 degrees of freedom to ensure that 
the upper limit for the 95% CI of the precision error is no more than 34% greater 
than the calculated value.  
 
 
6.2.2  Sampling technique 
To achieve a target of 30 patients > 20 years for each precision study, we will 
send study information to approximately 75 patients. This assumes 




6.3  Recruitment 
All potential participants will be sent a letter and participant information sheet in 
the post, along with their standard DXA appointment in advance of the 
appointment. During that time period, patients will have the opportunity to 
contact a member of the research team if they have any questions or concerns. 
When they arrive at the clinic they will be asked to confirm whether or not they 
have read and understood the participant information and whether they wish to 
 
 
participate when they arrive at clinic for their appointment. Further time will be 
made available then to clarify any points, provide further information if required 
and to sign the consent form.  Some patients may inadvertently be sent 
information regarding the study, but not eligible to take part as may lack 
capacity to consent, or have bilateral hip replacements.   
  
 
6.3.1 Sample identification 
 
 
The direct clinical care team (Grampian Osteoporosis Service) will approach 
potential study participants via a covering letter and participant information 
sheet (attached) which will be sent along with their standard DXA appointment 




Patients will be asked to confirm whether they have read and understood the 
participant information sheet and understand what participation would involve, 
and whether they wish to participate when they arrive at clinic for their 
appointment. Further time will be made available then to clarify any points, 
provide further information if required. 
The person seeking consent will then go over the information with the 
participant again, answer any questions, and if satisfied that they are capable of 
 
 
consent ask them to sign the consent form.  A copy of the signed consent form 
will be provided to the patient prior to departure from the department.  
Patients will participate in the study for a total of 30 minutes maximum, the 
majority of this time will be spent receiving standard clinical care. We therefore 
assume for the purpose of the study that capacity is unlikely to be lost within 
such a short timeframe and continued capacity for the 30 minute duration of the 
study will be assumed. 
Should a patient not wish to participate, or continue with participation in the 
study, no reason needs to be given.  It will be made clear there is no detriment 
to their standard clinical care, and no pressure will exerted to participate in any 
way.   
 
ETHICAL AND REGULATORY CONSIDERATIONS 
Assessment and management of risk 
Minor intrusion and inconvenience as a result of reading through the patient 
information sheet, understanding the study information and completing consent 
form. There is the potential for minimal discomfort in terms of having to 
physically move off the scanning table and back on again for the additional 
scan. All participants attending for a DXA scan are required to get onto the table 
once then off again. All other activities are per standard clinical care (completion 
of bone health questionnaire, measurement of height and weight). DXA 
scanning is a very safe test with a radiation burden considered equivalent to a 
few hours of average natural background radiation in the UK 
 




Before the start of the study, a favourable opinion will be sought from the Health 
Research Authority (HRA) REC for the study protocol, consent forms and other 
relevant study documents e.g. advertisements, participant information sheets; to 
obtain the required Health Research Authority Approval. Local site approval will 
be sought once HRA Approval is in place. 
Substantial amendments that require review by the REC will not be 
implemented until that review is in place and other mechanisms are in place to 
implement at site. All correspondence with the REC will be retained. It will be 
the Chief Investigator’s responsibility to produce the annual reports as required. 
The Chief Investigator will notify the REC of the end of the study. An annual 
progress report (APR) will be submitted to the REC within 30 days of the 
anniversary date on which the favourable opinion was given, and annually until 
the study is declared ended. If the study is ended prematurely, the Chief 
Investigator will notify the REC, including the reasons for the premature 
termination. Within one year after the end of the study, the Chief Investigator 
will submit a final report with the results, including any publications/abstracts, to 
the REC.  Copies of all correspondence and reports will be forwarded to the 
sponsor.  
 
Regulatory Review & Compliance  
The Sponsor localises the Organisation Information Document(s) and emails it 
to NRS Permissions Coordinating Centre (NRS Permissions CC) who will then 
make the Local Information Pack available to participating NHS organisations in 
Scotland (R&D, research teams and networks, as applicable). There is no need 
 
 
to supply documents already electronically submitted as part of the IRAS Form 
application as they will be made available to participating NHS sites in Scotland 
via NRS Permissions CC.  
 
The Sponsor or their delegate will email the localised Organisation Information 
Document(s) after the IRAS Form submission is validated. If there is more than 
one localised Organisation Information Document, then they should be sent via 
a single email to NRS Permissions CC or as available.  
 
Amendments  
For any substantial amendment to the study, the Chief Investigator or designee, 
in agreement with the Sponsor will submit information to the original REC and 
the HRA via IRAS in order for them to assess and approval above the 
amendment. The Chief Investigator or designee will work with sites (R&D 
departments at NHS and University sites as well as the study delivery team) so 
they can put the necessary arrangements in place to implement the amendment 
to confirm their support for the study as amended. 
 
Following agreement with the Sponsor, all amendments considered to be non-
substantial amendments should be emailed to hra.amendments@nhs.net using 
the HRA template.    






A summary of the key findings will be sent to participants. Participants will be 
asked for consent to receive this via post or email and the report will be written 
in language understandable to non researchers 
 
The data arising from this study will be owned of the University of Exeter.  The 
data will be handled according to the Open Research Exeter (ORE) policies, 
University of Exeter. The data may be potentially disseminated by internal 
reports, conference presentations, publication on websites, and a Masters 
thesis. Although participants will be not be notified of their own individual 
results, they will be advised that the overall outcome and results of the study 




8.2  Authorship eligibility guidelines and any intended use of 
professional writers 
The authorship of scientific journal papers, reports, website publication, thesis 
generated from this work will be named according to the contribution of the 








Dr Karen Knapp Dr Chris Wright, and Dr Rosemary Hollick as academic 
supervisors on this project have both peer reviewed the proposed study.  
As this is new technology, it is important to undertake a precision study to 
understand both the precision errors for the hip bone mineral density 
(BMD) measurements since this is using a full femur scan rather then 
previous technology which used a focused scan of the hip.  In addition the 
errors in measurement of the cortical thickness for the indication of 
“beaking” need to be explored as poor reproducibility could mean the 
difference between the scan indicating an incomplete fracture or not.  The 
precision study has a robust design and meets the minimum requirements 
for a precision study using DXA as outlined by the International Society for 
Clinical Densitometry.  The statistical analysis is appropriate and in line 
with the standard analysis for this type of study within this field.  The 
analysis methods are widely translatable. 
 Prof Karen Knapp, Associate Professor in MSK research.   
  
 
Protocol compliance  
 
Accidental protocol deviations can happen at any time. They must be 
adequately documented on the relevant forms and reported to the Chief 
Investigator and Sponsor immediately.  
 
 
Deviations from the protocol which are found to frequently recur are not 
acceptable, will require immediate action and could potentially be classified as a 
serious breach. 
 
Data protection and patient confidentiality  
Personal data from participants will be identified by the direct clinical care team. 
The personal data, including scans, of all patients attending the service for a 
DXA scan are stored on a secure database (SQL server) that complies with 
NHS data protection, security and confidentiality policies. The additional DXA 
scan performed as part of the study will be captured and stored in the same 
manner as routine clinical scans. Only those with appropriate access controls 
i.e. members of the direct clinical care team will have access to this. 
All data collected from the study DXA scans will be pseudonymised.  Data of 
from the extended femur will be collated along with the age range and gender 
mix of those scans. This will be stored on a secure NHS server. This file will not 
contain any personal data of participants and will be pseudonymised by means 
of a unique code, stored on a separate file on the secure NHS server, linking 
the non-identifiable data to the original DXA. 
Pseudonymised data will be electronically transferred to the University of Exeter 
for statistical analysis, and will also be held on a password protected University 
of Exeter laptop computer.  No identifiable data will be shared outwith the direct 
clinical care team.  
The personal data, including scans, of all patients attending for routine DXA 
scans are currently stored on secure databases (NHS Patient Management 
System and the DXA scanner database).  These fully comply with NHS GDPR 
 
 
regulations, data protection, information governance, security and confidentiality 
policies.   
Data will be pseudonymised by allocating a unique number to each participants’ 
data and with the linking key to the personal information kept separately and 
only accessible to the researcher. Hard copies are kept in locked filing cabinet, 
electronic data will be held on a secure password protected NHS server.  
Security measures in place meet with NHS IT standards.  No patient identifiable 
data will be reported in research outputs. 
For the purposes of analysing results, data from the extended femur scan will 
be collated along with relevant patient demographic data (age, gender and 
ethnicity). This will be collated from the DXA reports generated and stored on a 
secure NHS server.  
 
The data custodian for this study is Chief Investigator Dr Karen Knapp, 
Associate Professor in Musculoskeletal Imaging, University of Exeter.  Personal 
data from study participants will be kept for 6-12 months following the study, 
where after it will be destroyed in line with NHS Grampian confidential waste 
policy.  The pseudonymised research data will be uploaded to the Open 
Research Repository of the University of Exeter. Access to this is controlled by 








Arrangements have been made through the University of Exeter for insurance 
and/or indemnity to meet the potential legal liability of the sponsor for harm to 
participants arising from the management of the research. 
 
Arrangements have been made through the University of Exeter for insurance 
and/or indemnity to meet the potential legal liability of the sponsor for harm to 
participants arising from the design of the research. 
NHS indemnity scheme will apply for insurance and/or indemnity to meet the 
potential legal liability of the investigator arising from harm to participants in the 
conduct of the research. 
 
There are no arrangements in place for payment of compensation in the event 
of harm to the research participants where no legal liability arises. 
 
Access to the final study dataset 
The access to final dataset will be provided by the Chief Investigator acting as 







Appendix 1- Required documentation  
CV of research team 
Participant Information sheet 
Participant invitation letter 
GP letter 
Consent form  
 







On day of 
visit 
   
Invitation letter and 
participant information 
sheet sent.  
X     
Obtaining written 
consent 












of height and weight 
 X    
Routine DXA scan of 
lower spine and 
extended femur (3 
scans) 
 X    
Additional study scan of 
extended femur (2 
additional scans) 
 x    
 
 









Details of changes made 







9.5 Departmental standard operating procedure for use of extended 
femur DXA scanning. 
Document Number: SOP/DXA/12/19 
 
Title: Short term precision study of dual-energy absorptiometry (DXA) 
bone density scanning of the extended femur scan for atypical femoral 
fracture in routine clinical population. 
 
REC reference      19/NS/0183 
Protocol number   v1, 08/11/19 





Effective from: 06/01/2020 
Valid to: 29/02/2020 
Superseded Version Number & Date (if applicable) 










Reviewed by:  
Date:  








1.0 Purpose/Background  
This SOP describes the procedure for obtaining Bone Mineral Density 
Measurements (BMD) of PA Spine and Dual Femur, on the GE Lunar Prodigy 
scanners, to evaluate the precision of measurement at hip and extended femur 
scanning within the clinical bone density service. 
 
Equipment 








It is the responsibility of the clinic coordinator to ensure co-ordination of 
appointments within the DXA suite. 
Referrals for BMD measurements will be scrutinised and prioritised, as per 
departmental procedures.    
Patient to be consented by Diane Smith, Specialist Radiographer, on day of 
appointment, prior to scanning for BMD measurement. A copy of the completed 
consent form is given to the patient, and the original kept in the study file. 
It is the responsibility of the person obtaining consent to allocate a unique 
patient identifier (numbers running concurrently). The patient identifier should 
be entered into the consent form, by the investigator taking consent and entered 
into the patient biography by the radiographer. Record of unique ID’s to be kept 
in study folder.    
It is the responsibility of the radiography staff to ensure correct data entry. 
It is the responsibility of the radiography staff to ensure daily calibration, 
phantom measurement as per Grampian Osteoporosis Service (GOS) Protocols  
It is the responsibility of the staff, within the DXA Suite, Ashgrove House, to 
ensure that, all data is kept secure in a locked environment according to GOS 
Protocols.  
All electronic data to be archived and backed up on the secure hospital SQL 





Biography entry in SQL Prodigy patient database on the GE Lunar Prodigy 
Database Name  SQL Prod3 Patients 
Database Path    Ari-sql- prodigy\SQL_prod3_patients 
Working Folder    \\Ari-sql-prodigy\Lunar Databases\db_prod3\prod3 data 
Normal Biography entry as per GOS Protocols with addition In Department ID 
e.g. –  DS/PS2020/xx 
In Comments Box – patient ID e.g. as above 
Patient attends as per routine clinical Bone Mineral Density ( BMD ) 
measurement. 
Ionising Radiation Medical Exposure Regulation check (IR(ME)R) 
Ask patient if they have read and understood information sheet and have any 
questions. 
Ask the patient if they are happy to take part in the study 
If agreeable, ask the patient to read over and sign the consent form. 
Person taking the consent to check the consent form is correctly signed and 
dated, sign the consent form and allocate a unique study ID. 
A copy of the consent is then retained by the patient, original in study file. 
Give full explanation of study procedure. 
Dual X-ray Absopitometry (DXA) reported as per departmental protocol. 
HT and WT as per GOS Protocols 
BMD measurements as per GOS Protocols 
Routine BMD evaluation, PA spine, extended femur +/- LVA. Patient is then 
asked to come off scanning table and then return to be repositioned for 
extended femur measurement only. 
 
 
Transcribe results to excel spread sheet using headings as marked. 
                             
 Neither hard copy or copy facility should be referred to by the 
radiographer obtaining the measurement for the 2nd sequence of 
scans  
 
 Related Documents   
Grampian Osteoporosis Service Protocols, held electronically on the 
Rheumatology website. 
IR(ME)R held electronically on Radiology website NHS Grampian Intranet 
Local Rules held electronically on Radiology website NHS Grampian Intranet 
 
Approval and sign off  
Author: 
Name:    
Position:    




Signature:     Date: 




Member of staff Version 
number of 
SOP 





    
    
    
    
    
    
    
    
    













9.6 Research and development/clinical effectiveness approvals 
 
 












Mrs Diane Smith 
NHS Grampian 




United Kingdom   
  
 
Date  11/12/2019 
Project No 2019RA001 
 
Enquiries to Louise 
Extension 53846 




Dear Mrs Smith 
 
Management Permission for Non-Commercial Research 
 
 
STUDY TITLE: Short term precision study of dual energy x-ray 
absorptiometry (DXA) bone density scanning of the 
extended femur scan for atypical femoral fracture in routine 
clinical population   
PROTOCOL NO: v1, 08/11/19 
REC REF: 19/NS/0183   
NRS REF:  259999 
 
 
Thank you very much for sending all relevant documentation.  I am pleased to 
confirm that the project is now registered with the NHS Grampian Research & 
Development Office.  The project now has R & D Management Permission to 
proceed locally.  This is based on the documents received from yourself and the 
relevant Approvals being in place. 
 
All research with an NHS element is subject to the UK Policy Framework for 
Health and Social Care Research (2017 v3), and as Chief or Principal Investigator 
you should be fully committed to your responsibilities associated with this. 
 
 




1) The R&D Office will be notified and any relevant documents forwarded 
to us if any of the following occur: 
 Any Serious Breaches in Grampian (Please forward to 
pharmaco@abdn.ac.uk).  
 A change of Principal Investigator in Grampian or Chief Investigator.  
 Any change to funding or any additional funding  
 
2) When the study ends, the R&D Office will be notified of the study end-
date.  
 
3) The Sponsor will notify all amendments to the relevant National Co-
ordinating centre. For single centre studies, amendments should be 






We hope the project goes well, and if you need any help or advice relating to your 












cc:  CI/Sponsor 
 Research Monitor 
 Radiology  
 
Sponsor: University of Aberdeen 
 
 
    
cc: (CI) Dr Karen M Knapp 
 
 
North of Scotland Research Ethics Committee (1)  
Summerfield House  
2 Eday Road  
Aberdeen  
AB15 6RE  
  
Telephone: 01224 558458        
 Facsimile: 01224 558609  
Email: nosres@nhs.net  
  
  
09 December 2019  
  
  
Dr Karen Knapp  
Associate Professor in Musculoskeletal Imaging  
University of Exeter  
College of Medicine and Health, South Cloisters  
Heavitree Road  
EXETER   
EX1 2LU  
  
  




Study title:  Short-term precision study of dual energy x-
ray absorptiometry (DXA) bone density 
scanning of the extended femur scan for 
atypical femoral fracture in routine clinical 
population.  
REC reference:  19/NS/0183  
Protocol number:  1819/42  
IRAS project ID:  259999  
  
Thank you for the e-submission on 09 December 2019.  I can confirm the REC 
has received the documents listed below and that these comply with the 
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9.8 QA, QC, Cross calibration of DXA scanners. 
 
Document Number: SOP/DXA/03/2020 
 
Title: Grampian Osteoporosis Service quality assurance measurement 
(QA) 




Effective from: 01/04/2020 
Valid to: 01/04/2025 
Superseded Version Number & Date (if applicable) 


















This SOP describes the process of performing a QA measurement obtained 
from GE Lunar Prodigy DXA scanners within NHS Grampian. A QA 
measurement indicates the current operating status of the system. QA must be 
performed each morning before a patient is scanned. It is good practice to 
perform a QA measurement at least three times per week even though no 
patients are being scanned. If no QA is performed and time lapsed has been 
greater than 48 hours the scanner will not allow patient measurements.    
 
 
Equipment         
GE Lunar Prodigy (Prod3) 303532 
GE Lunar Prodigy (Prod4) 304002 
GE Lunar Prodigy (Mobile) 302308 
GE Lunar Prodigy (Elgin)    130139 
Calibration block                       




It is the responsibility of the radiography staff to ensure QA is performed each 
day, before a patient is scanned, or at least 3 times per week if no daily list,  as 
per Grampian Osteoporosis Service (GOS) Protocols  
All electronic data to be archived and backed up on the secure hospital 
SQLserver.     
 
Procedure 
Scan acquisition  
Select Quality Assurance form the main screen or from the common tool bar. 
The Quality Assurance screen is shown. 
Select Start from common toolbar and wait until the calibration block appears on 
screen. 
Put the calibration block on the table top so that the laser light shines in the 
centre of the cross-hair label. Align light with cross and click OK. 
Select OK.   Follow the screen prompts to complete the QA procedure. 
QA trending and system status is automatically shown after the QA procedure is 
completed (approx10 minutes). 
Make sure the Detector Status and System status have passed as shown on 
the Quality Assurance screen (green light)  
It the QA test did not pass i.e. yellow or red light on System Status repeat 
measurement 
If the procedure fails a second time, call Lunar Support for assistance.  Do not 
scan any patients until the fault is corrected. 





Document Number: SOP/DXA/03/2020 
 
Title: Grampian Osteoporosis Service aluminium phantom (Encapsulated) 




Effective from: 01/04/2020 
Valid to: 01/04/2025 
Superseded Version Number & Date (if applicable) 




















This SOP describes the process of performing an Aluminium Phantom 
measurement, obtained from GE Lunar Prodigy DXA scanners, within NHS 
Grampian. The Aluminium Phantom must be performed; a minimum of 3 x 
/week or everyday a patient/volunteer is scanned. The Aluminium Phantom, as 
with the Quality Assurance (QA), should be carried out at least 3 x per week 
even when the scanner is not in clinical use. The Aluminium Phantom is unique 
to a particular DXA machine, the original BMD value being found within the 
technical specifications of the DXA machine. The BMD value (L2 – L4) is 
recorded on a paper graph in a folder marked ‘Aluminium Phantom Folder’, 
found in each DXA scanner Location. The Aluminium Phantom is used to 
monitor the long –term precision of the scanner over time. Values are obtained 
from an encapsulated spine phantom, set in resin, from L2-L4, similar to figure 1 










                        
                        GE Lunar Prodigy (Prod3)  303532 
              GE Lunar Prodigy (Prod4)  304002 
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It is the responsibility of the radiography staff to ensure Aluminium Phantom is 
performed each day, before a patient is scanned, or at least 3 times per week if 
no daily list,  as per Grampian Osteoporosis Service (GOS) Protocols  
All electronic data to be archived and backed up on the secure hospital 






Scan acquisition  
 
All Databases i.e. select – SQL Prod4 Phantoms 
Database – Ari-sql-prodigy\SQL_Prod4_Phantoms 
Working folder - \\Ari-sql-prodigy\Lunar 
Databases\db_prod4\Prod4_DB_phantoms\ 
Highlight – last name:  al phantom 
 
The biography does not need to be checked for daily phantom procedures   and 
should remain constant as below  
 
First name – 19741 ( specific to each scanner) 
Last name – al phantom                                                                                                                                                                        
Ht. – 170 
 
 
Wt. – 70 
DOB –28.06.1965 
Gender  male 
Ethnicity  white 
Physician – L2 – L4 BMD 1.247 (manufacturers est. mean) 
 
Method 
Place encapsulated aluminium phantom on mid line on table top  
 
Position the phantom so T12 is toward head of scanner table and lunar 
phantom number to the foot of the table 
Acquisition as for AP spine measurement 
 
Measure – common tool bar 
 
Exam – highlight AP spine 
 
Position – common tool bar 
Position laser light in middle of L5 – move phantom to laser light so always 
scanned in the same part of scanner table 
Check the phantom is straight by running the laser light up one side of the 
phantom – always return to the start position. 
 
 
Start measurement – monitor the first few lines to make sure the detector 
position is correct.   Allow the measurement to continue into T12.  The detector 
must not measure air during acquisition. 
Analyse 
Copy to the first acquired scan 
Remove the phantom from the table    
The BMD value region of L2 – L4 must be within 2% of the expected BMD 
value.   
If BMD values repeatedly vary by more than 2% call Lunar.  Do not scan 
patient.  (Manufacturers recommendation is 3%.  Most research studies require 
that the BMD value be within 1.5% of the expected range). 
Plot BMD value on scatter graph in file folder labelled Al Phantom. 
 
 
Cross calibration of DXA scanners (n.4). 
 
All scanners were cross calibrated by taking 50 measurements using the same 
Hologic spine phantom on each by the same operator across 2 consecutive 
days.  All results were collated, one way ANOVA testing (IBM SPSS Version 26 
software , NY USA), was utilised to offer BMD comparison between scanners 
following cross calibration with Hologic phantom.  Agreement and 95% 
confidence interval was calculated for the cross calibration of four DXA 
scanners across the region, and a Bland-Altman plot was used to display the 
results, demonstrating the level of agreement between scanners.  Of note, this 
is a spine phantom cross calibration, so provides evidence of stability of the 


















              
 
 
              
 
 
              
 
Instructions for completion of spreadsheet 
Ethnicity –  C = Caucasian 
  A = Asian 
  H = Hispanic 
  B = Black 
Bisphosphonates (ever had)  – Y or N 
 
 
HRT (ever had) – Y or N 
Alcohol (regularly >14 units per week) - Y or N 
Smoking (no, past, current) N, P, C 
PPI, thyroxine, SSRI, Steroids, Anti-oestrogen or androgen, groin pain - Y or N 
Peak ≥1mm, Y and size. 
 
 


















           




Assessment of extended femur scan 
 
Technical analysis: 
Is there adequate separation of the neck of femur and pelvis? 
Is the acetabulum included in the scan field? 
Is there sufficient space proximal to greater trochanter? 
Is the lesser trochanter minimised? 
Is the femur straight and vertical in the field of view? 
Is there any inclusion of supracondylar flare or patella in the scan field? 
Regions of interest analysis: 
Are all the regions of interest correctly placed in accordance with the GE Lunar scan manual and NHS Grampian SOP – is all bone point 
typed correctly, is the hip axis line running from greater trochanter to fovea capita then pelvic brim? 
 
 
Is the neck of femur box perpendicular to the neck of femur? 
Are all four corners of this box in soft tissue – no ischium or greater trochanter should be included in the measurement area? 




9.11 Training record template 
 
Document Number: TR/DXA/05/20 
 




Scanner make GE Lunar 
Scanner ID 303532, 304002, 302308, 130139 
Trainee name  
HCPC registration number  




 Date completed Trainer signature 





Log in to scan PC   
Emergency stop 









Handover forms   
Online radiation safety 
training  
  
Read all SOPs and 
protocol document 
  
Understands the input 
requirements of the 
comments box  
  
General functions     
 Date completed Trainer signature 
Justification of DXA 
scans 
  
Patient ID checks   





Measurement of height    
Measurement of weight   
Cleaning of dxa room   
Casefinding FLS 





Scanning areas Date completed Trainer signature 
Lumbar spine scan 
acquisition and analysis 
  
Extended femur scan 
acquisition and analysis 
  
Lateral vertebral 
assessment scan and 
analysis 
  
Whole body scan 
acquisition and analysis 
  
Forearm scan 
acquisition and analysis 
  
Evaluation and reporting 


























9.12 Acquisition, analysis and assessment of extended femur scans with 
GE Lunar scanner 
Document Number: SOP/DXA/03/20 
 
Title: Acquisition, analysis and assessment of extended femur scan 




Effective from: 26/03/2020 
Valid to: 26/03/2025  
Superseded Version Number & Date (if applicable) 






Reviewed by:  
Date:  





2.0 Purpose/Background  
This SOP describes the process of acquisition, assessment and analysis of 
extended femur DXA scans obtained from GE Lunar prodigy DXA scanners 
within NHS Grampian.    
 
3.0 Equipment 
                        




It is the responsibility of the clinic co-ordinators to ensure co-ordination of 
appointments within the DXA scanning  departments. 
It is the responsibility of the radiographer to check the referral for DXA in a 
timely manner.     
It is the responsibility of the radiography staff to ensure correct data entry, into 
patient biography, prior to appointment. 
It is the responsibility of the radiographer to ensure completion of the 
Osteoporosis Questionnaire at time of appointment. 
It is the responsibility of the radiography staff to ensure daily calibration, 
phantom measurement, archive and backup of phantom databases as per 
Grampian Osteoporosis Service (GOS) Protocols  
All electronic data to be archived and backed up on the secure hospital SQL 
server.                      
 
 
 5.0  Procedure  
 
Scan acquisition  
Biography entry on the GE Lunar Prodigy scan database. 
Ionising Radiation Medical Exposure Regulation (IR(ME)R2017) check patients 
details in conjunction with scan referral on Trak Care/paper referral as per GOS 
protocol. 
An avoidance of irradiation in pregnancy (LMP) form must be completed by all 
female patients aged 12-55.  This should be completed in private, and should 
be completed in the absence of parents/carers as per document RA4: Making 
enquiries of pregnancy status found on NHS Grampian Radiology site, radiation 
protection documents. 
Height and weight as per departmental SOP. 
The patient should be adequately prepared for the scan having confirmed 
patient identity, completed biography questions and measurements and the 
removal of external/clothing artefacts such as jeans, belts and pocket contents. 
Other artefacts which may appear and interfere in scan should also be 
removed, such as underwired bra, clasp and zip at front of trousers, zip in dress 
and any adornments on clothing such as glitter, sequins or beads. Body 
piercings should be removed where possible.  
 
The patient should be central on the scan table, with arms on chest away from 




The femur should be straight, and the femur positioning aid supplied with the 
scanner.  The legs will be abducted and rotated, and the feet (in shoes) should 
be strapped securely to the positioner with the Velcro provided.   
 
The positioning aid supplied with the scanner determines the leg position and 
the rotation of the lesser trochanter, ensuring reproducibility in subsequent 
scans.  Consistent use of the supplied positioning aid has the ability to improve 
precision on follow up scans[17, 260]. Correct and reproducible positioning of 
patients, as demonstrated in figure 1, is necessary to ensure continuity and 
accurate comparison of all measurements, including beaking measurements, as 
incorrect positioning can result in beaking measurement differences quoted as 









The patella is used as initial centring point, where the laser cross should be 
central on the patella.   
The image acquired should display the acetabulum, greater trochanter, ischium 
and minimized lesser trochanter at the proximal femur.  No patella or 
supracondylar flare should be evident at the distal femur.  
The positioning aid supplied with the scanner determines the leg position and 
the rotation of the lesser trochanter, ensuring reproducibility in subsequent 
scans, as the beak size is determined by its position on a two dimensional 
image.  Consistent use of the supplied positioning aid has the ability to improve 
precision on follow up scans[17, 260]. Correct and reproducible positioning of 
patients, as demonstrated in figure 2.1, is necessary to ensure continuity and 
accurate comparison of all measurements, including beaking measurements, as 
incorrect positioning can result in beaking measurement differences quoted as 
+/- 0.5mm by GE Lunar.  
 
Analysis and assessment of extended femur scan 
 
If the patient has been scanned previously, the mask is superimposed from the 
original scan over the new scan, using the copy function.     
Scans should be assessed on the accuracy of the bone mapping, positioning 
and inclusion of relevant areas. 
Scan should begin with shaft of femur, no supracondylar flare or patella should 




The femoral neck region of interest box has all four corners in soft tissue and no 
ischium or greater trochanter mapped as bone in the measurement of the 
femoral neck, as shown by box labelled 2 in figure 2.   
The mid femur axis line bisects the femoral head correctly, allowing the femur 
neck box to lie perpendicular to the femoral neck, as indicated by line 3 in figure 
2.   
 
Figure 2 
The shaft of femur should be straight in the scan field. 
The acetabulum should be fully visualised. 
The lesser trochanter should be minimsed as far as patient habitus allows. 
There should be 2-3 sweeps above greater trochanter. 
There should be adequate separation of the neck of femur and the pelvis. 
If the neck of femur box is moved or adjusted by the operator, use the search 
function (looks like binoculars) to return the box to the area of lowest density. 
Any irregularity of the femoral cortex should be highlighted to the reporting 
clinician.  Do not highlight any false positive peaks created by the scan 













Figure 4 An example of false positive peak created by software 
 
6.0 Related Documents   
 GOS Protocols and SOPs  held on v/rheumatology/GOS 
 Local Rules held electronically on Radiology intranet NHS Grampian  
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